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Abstract 
This Ph.D. thesis focuses on two main topics: 
Part A. Resorc[4]arene ω-Undecenyl Ester in the Chair Form as 
Macrocyclic Synthon for Olefin Metathesis 
Olefin metathesis has become a powerful tool for the formation of 
carbon-carbon bonds and, therefore, for the synthesis of a number 
of molecules. This progress was recognized in 2005 with the award 
of NOBEL Prize in Chemistry to Yves Chauvin, Robert Grubbs and 
Richard Schrock for their work in this area. While the series of 
[2+2]cycloadditions and retro[2+2]cycloadditions that make up the 
pathways of ruthenium-catalysed metathesis reactions is well-
established, the exploration of mechanistic aspects of alkene 
metathesis is going on. At first, we reported the tetramerization of 
(E)-2,4-dimethoxycinnamic acid ω-undecenyl ester with ethereal 
BF3. The reaction gave three stereoisomers 1a, 1b, and 1c, which 
were assigned as the chair, cone, and 1,2-alternate conformations, 
respectively. Undecenyl resorc[4]arene 1a, which featured the 
simplest pattern of substituent, was submitted to olefin metathesis 
using the second generation Grubbs complex as the catalyst. 
Depending on the reaction conditions, different products were 
isolated: a bicyclic alkene 2a, a linear dimer 3a, and a cross-linked 
homopolymer P1a. Moreover, we detected for the first time the 
formation of a ruthenium-carbene-resorc[4]arene complex during 
the metathesis reaction of resorc[4]arene olefin 2a with the first 
generation Grubbs catalyst in CDCl3. We developed an NMR 
analytical protocol which proved capable of yielding both qualitative 
and quantitative information. In the first case, we were able to 
identify the complex 3a[Ru] as a key intermediate in the ROM-CM 
sequence of reactions, giving us a definitive proof of the previously 
hypothesized mechanism. As a further feedback of the pathway, we 
performed a quantitative analysis using benzene in the place of 
CDCl3, due to the poor stability of the catalyst in such a solvent. The 
reaction allowed the isolation of decomposition products of the 
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ruthenium-carbene-resorc[4]arene complex 2a[Ru] such as 
compound 4a, which, due to the presence of still reactive alkene 
functions, proved to behave as propagating alkylidene species 
leading to further decomposition products.  
Part B. Metabolomics Studies by NMR Spectroscopy 
Metabolomics provides a direct measure of the state of the cell or 
biological system, where changes in the metabolome capture how 
the system responds to environmental or genetic stress. Specifically, 
a drug or an active chemical lead would be expected to perturb the 
metabolome of a cell or tissue upon treatment. The two leading 
analytical approaches to metabolomics are mass spectrometry (MS) 
and nuclear magnetic resonance (NMR) spectroscopy. In particular, 
NMR technique accounts for high reproducibility, quantitative 
determination of a wide dynamic range, and the capability to 
determine the structure of unknown metabolites.  
Cells of high-grade tumors, including medulloblastoma (MB) and 
glioblastoma (GBM), must similarly balance energy metabolism with 
the need to synthesize the macromolecules essential for tumor 
growth. Cells with large ATP requirements are likely to be 
disadvantaged by aerobic glycolysis because glycolysis generates 
less ATP per molecule of glucose than oxidative phosphorylation. 
Proliferating cells, however, may use aerobic glycolysis to satisfy the 
competing needs for both energy generation and the accumulation 
of biomass. Recently, it has been demonstrated that Sonic 
Hedgehog (SHH) pathway activation in granule cell progenitors 
(GCPs), responsible of MB development, induces transcription of 
hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2), two key 
gatekeepers of glycolysis. The process is mediated by the canonical 
activation of the GLI transcription factors and causes a robust 
increase of extracellular lactate concentration.  
Glabrescione B (GlaB), an isoflavone naturally found in the seeds of 
Derris glabrescens (Leguminosae), turned out to be an efficient 
inhibitor of the growth of HH/GLI-dependent tumors and cancer 
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stem cells in vitro and in vivo. Here, we reported the GlaB activity on 
both human MB DAOY and murine glioma GL261 cell models in vitro 
and in vivo. In order to evaluate how the GlaB-treatment affects cell 
metabolism as a consequence of GLI1 inhibition, untargeted NMR 
metabolomics analyses of cellular lysates and conditioned media 
were performed in both cell lines. For this purpose, a simple, fast, 
and reproducible sample preparation protocol was developed. To 
reduce bias in the interpretation of the experiments, it was decided 
to produce from five to seven biological replicates for each treated 
and untreated group. The 1D 1H NMR spectra were acquired to 
determine the metabolic fingerprints of the treated and untreated 
cancer cells. Notably, the NMR metabolomics approach revealed a 
typical endo-metabolic phenotype of the cells under investigation. 
Both the exo- and endo-metabolome of the DAOY and GL261 cell 
lines resulted to be completely changed after 24 h and 48 h of GlaB 
administration, respectively. The levels of most metabolites 
decreased after treatment, consistently with possible apoptosis 
phenomenon.  
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Part A 
Resorc[4]arene ω-Undecenyl Ester in the 
Chair Form as Macrocyclic Synthon for Olefin 
Metathesis 
The present part of the thesis deals with a research activity carried 
out at the Dipartimento di Chimica e Tecnologie del Farmaco at 
Sapienza Università di Roma, under the supervision of Prof. Bruno 
Botta. 
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A1.1 Emerging class of macrocyclic receptors 
A1.1.1 Calixarenes 
Calixarenes are macrocyclic molecules containing phenolic rings 
bridged by methylene groups and are among the most ubiquitous 
host molecules in supramolecular chemistry (Arduini et al., 2001; 
Casnati et al., 2003; Gutsche, 1998; Katsuhiko and Toyoki, 2006; 
Ludwig, 2005; Mandolini and Ungaro, 2000). The basic molecular 
scaffolds are, in general, simple to prepare in high yields from cheap 
starting compounds: they derive from the condensation of phenols 
and formaldehyde. These compounds are characterized by an 
hydrophobic cavity which allows the interactions with neutral 
molecules (Arduini et al., 2001), but they can also be derivatized in 
the lower rim or in para positions on the aromatic nuclei (upper rim) 
with catalytic centers or other functional groups which favor 
interactions with ions (Figure 1.1) (Dalla Cort and Mandolini, 2000).  
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Figure 1.1. Anatomy of a calix[4]arene in the cone conformation. 
The parent calixarenes are flexible during their high temperature 
synthesis, the rotation of the phenolic moieties about the bridging 
CH2 groups possible, but the smallest members of the class “freeze 
out” upon cooling to ambient temperatures (Steed and Atwood, 
2009). This is an important consideration when working with 
calix[4]arenes, macrocyclic molecules consisting of four phenol units 
connected via methylene bridges in the ortho position with respect 
to the hydroxyl group. They exist in different conformers that are 
hard to interconvert and become immobilized in a particular case if 
substituents are bound in the lower rim, even if re-heated to 
relatively high temperatures. Four principal conformers are 
observed at room temperature (Figure 1.2). If all four upper rim 
substituents are in the same orientation, then a cone conformer 
results, which is the average C4v symmetry structure resulting from a 
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fast equilibrium between two equivalent C2v flattened cone 
conformers (Abis et al., 1988). If one phenolic group is inverted with 
respect to the others, a partial cone conformer is found. Finally, two 
possibilities exist when two phenol rings are inverted: 1,3-alternate 
and 1,2-alternate. Similar descriptions exist also for larger 
calixarenes, although these compounds are often conformationally 
dynamic and only frozen out in the solid state or in low temperature 
experiments. 
Figure 1.2. Calix[4]arene conformers. 
A1.1.2 Resorcarenes 
Condensation products obtained from the reaction between 
aliphatic aldehyde and resorcinol were first reported in the XIX 
century (Baeyer, 1872a; Baeyer, 1872b), but only in 1968 their 
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structure was finally proved by Erdtman and co-workers by a single 
crystal X-ray analysis (Erdtman et al., 1968). A suitable trivial name 
for these molecules was not found earlier, but recently the term 
resorc[4]arene (or resorcarene, in a shorter version) seems to be 
generally accepted to indicate cyclic tetramers made by resorcinol 
units connected with methylene bridges. A simplified general 
structure of a resorcarene is shown in Figure 1.3 with typical atoms 
(Botta et al., 2005). 
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Figure 1.3. General structure of resorcarenes. 
 Conformations of resorcarenes
The stereochemistry of resorcarenes may be defined as the 
combination of three elements (Timmerman et al., 1996): 
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1. The conformation of the macrocyclic ring, which can adopt five
extreme symmetrical arrangements: crown or cone (C4v
symmetry), boat or flattened cone (C2v), diamond or 1,2-
alternate (Cs), saddle or 1,3-alternate (D2d), and chair (C2h). The
five architectures are presented both in 3D (Figure 1.4) and in
sketched representations (Figure 1.5). The most common
conformation of resorc[4]arenes (cone) is very close in solution
to the one of calixarenes, but it is, in reality, the result of the
equilibrium between two equivalent forms (Högberg, 1980a,
Högberg, 1980b). Only one form (namely, flattened cone)
characterizes the structure of the macrocycle in solid (Erdtman
et al., 1968) and gas (Botta et al., 1994) phases.
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Figure 1.4. Principal conformations (and symmetry) for the resorc[4]arene. 
Figure 1.5. Sketched conformations. 
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Octamethoxyresorcarenes have also been found in two different 
chair-like forms, named flattened partial cone 1 (f) (Botta et al., 
1994) and flattened partial cone 2 (Botta et al., 1997), coincident 
with the previously reported “chair” (e) (Abis et al., 1988).  
2. The relative configurations of the side chains at the methylene
bridges: the arrangements of the substituents were ruled by 
Högberg (Figure 1.6), who took as a reference the side chain on the 
C-2 methine (r) and considered the relative positions (cis or trans, 
i.e. c or t) of the other CH in the sequence (C-8, C-14, C-20). The 
substituents of the cone and 1,3-alternate forms are all cis (or rccc). 
The substitution pattern of 1,2-alternate is rctc, where it is 
evidenced the anomalous position of the C-14 substituent. The 
substitutions found for flattened partial cone 1 and chair were rccc  
and rctt, respectively, but other arrangements cannot be excluded. 
Figure 1.6. Substituents distribution pattern.
3. The individual configuration of the substituents at the methylene
bridge, which, in conformations of the macrocycle with C symmetry, 
may be axial or equatorial. In the sketched structures of Figure 1.5, 
axial substituents are represented with a dotted line. 
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 Synthesis of resorcarenes
Condensation of resorcinol with aldehydes 
The acid-catalyzed condensation reaction between resorcinol and 
an aliphatic or aromatic aldehyde (Scheme 1.1) is generally carried 
out by heating the constituents to reflux in a mixture of ethanol and 
concentrated HCl for several hours (Egberink et al., 1992; Tunstad et 
al., 1989; Thoden van Velzen et al., 1994). Each aldehyde, in an 
almost unlimited range of R options, requires different optimal 
conditions, while unsubstituted resorcinol (1,3-dihydroxybenzene, 
X=H) is the mostly used counterpart. 2-Methylresorcinol (X=Me) 
(Konishi et al., 1990) or pyrogallol (1,2,3-trihydroxy benzene, X=OH) 
(Cometti et al., 1992) have been preferentially used in the reaction 
with formaldehyde to obtain better yields. A number of different 
5,11,17,23-tetrahydroxyresorc[4]arenes (pyrogallo[4]arenes) have 
been obtained via acidic condensation of 2-hydroxyresorcinol with 
the appropriate aldehyde in mixtures of HCl, ethanol, and water. 
Tetra-n-nonyl-, tetra-n-octyl-, tetra-isobutyl-, tetraethyl-, 
tetramethyl-, and tetrakis(biphenylyl)-hydroxyresorcarenes has 
been prepared in this way (Gerkensmeier et al., 2001). The 
substituents, with some exceptions, presented an axial all-cis 
configuration, which forced the cyclic tetramer to assume a bowl-
like shape and form polarity-induced double layers (Gerkensmeier 
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et al., 2001), in the solid state. Resorcinol derivatives carrying 
electron-withdrawing substituents, like NO2 or Br at C-2 or featuring 
partially alkylated hydroxyl groups do not give cyclization. The 
resorcarenes synthesized throughout the years till the end of 1994 
are listed in a review by Reinhoudt and co-workers (Timmerman et 
al., 1996). 
Scheme 1.1. Classical synthesis of resorcarenes X=H, Me,OH. 
Tetramerization of resorcinol dimethyl ether derivatives by Lewis 
acid 
It has been seen that treatment of (E)-2,4-dimethoxycinnamic acid 
esters (R = COOMe, COOEt, COOiP) with BF3·Et2O in CHCl3 at reflux 
(Scheme 1.2) gives after 15 min the corresponding octamethylated 
resorcarene (R=COOMe, COOEt, COOiP) in 75% overall yield, as a 
mixture of cone, 1,2-alternate and 1,3-alternate forms (Botta et al., 
1992). 
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Scheme 1.2. Tetramerization of cinnamic acid derivatives. 
Indeed, this simple reaction allows the design of several new 
structures: the versatility of the reaction does not depend only on 
the variability of R group in the monomer, but also on the possible 
modifications of the side chains, CH2R. Each new structure is a 
potential owner of features that may introduce into a novel 
research avenue. 
As an example Botta et al. synthesized double-spanned resorc 
[4]arenes treating octamethylated resorc[4]arenes with glutaroyl, 
adipoyl and pimeloyl dichlorides in the presence of triethylamine 
(Botta et al., 1997). The insertion of two polymethylene bridges led 
to the formation of a cavity-shaped architecture resembling a 
basket which gave the name to these molecules (Fig 1.7). NMR 
characterization showed a C2v symmetry with two parallel  bridges: 
the formation of the bridge froze one of the two flattened cone 
conformations, which are normally in fast equilibrium to get the 
cone conformation as average (Figure 1.7). 
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Figure 1.7. Chemical structure of a basket resorc[4]arene with two polymethylene 
bridges. 
Analogously, when 2,4-dimethoxybenzyl alcohol was treated with 
trifluoroacetic acid (5% in CHCl3), the unsubstituted resorcarene a 
was obtained in 95% yield (Scheme 1.3) (Falana et al., 1994). 
Notably, compound a cannot be synthesized by the acid-catalyzed 
condensation of resorcinol and formaldehyde, since this reaction 
gives only polymeric products (Gutsche, 1983; Gutsche, 1989; 
Gutsche, 1995; Böhmer, 1995; Mandolini and Ungaro, 2000; Asfari 
et al., 2001). Lewis acid catalyzed also the condensation (Scheme 
1.3) of 1,3-dimethoxybenzene with isovaleraldehyde, to give b; in 
particular, SnCl4 led to selective formation in high yield of the rccc 
isomer. 
Scheme 1.3. Octamethoxyresorcarenes by Lewis acid catalyzed reaction. 
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A1.2 The metathesis reactions: from a historical perspective 
to recent developments 
Metathesis, with its multiple aspects, has become one of the most 
important chemical reactions and is now extremely useful. This area 
has gone beyond the research stage in inorganic and organometallic 
chemistry to develop in organic, medicinal, polymer and materials 
chemistry to such an extent that it has now become a familiar tool 
for the specialists of these fields (Astruc, 2005). 
A1.2.1 Metathesis: fragments changing place 
The etymology of the word metathesis comes from the Greek 
 (metathesis) that means transposition. Thus, metathesis 
is invoked when, for instance, ions are exchanged in a solution 
containing two ion pairs in order to produce the most stable ion 
pairs [eqn. (1)] (Loupy et al., 1992). In the same way, two carbenes 
of an olefin can be exchanged to give, if they are different, another 
recombination leading to the two symmetrical olefins [eqn. (2)] or 
the two carbynes of an alkyne to give the two symmetrical alkynes 
[eqn. (3)]. 
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Although the name metathesis was given for the first time to this 
reaction by  Calderon in the seventies (Calderon, 1967; Calderon, 
1972) the first observation of the metathesis of propene at high 
temperature was reported in 1931. Twenty years later, industrial 
chemists at Du Pont, Standard Oil and Phillips Petroleum reported 
that propene led to ethylene and 2-butenes when it was heated 
with molybdenum (in the form of the metal, oxide or [Mo(CO)6] on 
alumina) (Banks and Bailey, 1964; Rouhi, 2002). The first 
polymerization of norbornene by the system WCl6/AlEt2Cl was 
independently reported in 1960 by Eleuterio (Eleuterio, 1960; 
Eleuterio, 1991) and by Truett (Truett et al., 1960), but it was 
recognized only in 1967 that ROMP (ring opening metathesis 
polymerization) and the disproportionation of acyclic olefins were 
the same reaction. A detailed historic account was reported by 
Eleuterio (Eleuterio, 1991). The metathesis reactions are in principle 
under thermodynamic control, that is they are equilibrated, which 
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clearly is an inconvenience. In fine chemical synthesis, this problem 
can be circumvented by choosing to carry out metathesis of a 
terminal alkene or alkyne. The formation of ethylene (or 
respectively, acetylene) displaces the reaction towards the product. 
This strategy also applies to olefins terminated by an ethylidene 
group, because metathesis then produces 2-butenes whose 
volatility also displaces the reaction towards the products. 
Operating under reduced pressure insures elimination of the 
volatile olefin in order to displace the metathesis reaction [eqns. (4) 
and (5)]. In fact, many metathesis reactions are under kinetic 
control. Notably alkene metathesis is most often complicated by the 
formation of both Z and E isomers [eqn. (4)], whereas this problem 
does not exist in alkyne metathesis [eqn. (5)], disclosed for the first 
time by Blanchard, Mortreux and coworkers (Blanchard and 
Mortreux, 1972; Blanchard and Mortreux, 1975; Mortreux et al., 
1977; Mortreux et al. 1978; Mortreux et al., 1995; Bunz, 2002; Bunz, 
2003; Grela and Ignatowska, 2002; Zhang et al., 2003; Zhang et al., 
2004; Zhang and Moore 2004).  
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A1.2.2 The Chauvin mechanism 
At the end of the 1960’s, the metathesis reaction was very 
mysterious. Catalytic systems were either oxides such as WO3/ SiO2 
used in industry for the transformation of propene to ethylene and 
butenes or Ziegler–Natta derived systems such as WCl6 (or MoCl5) + 
AlXnR3-n or (SnR4). Mechanistic ideas had appeared, but they did not 
match the results of some metathesis experiments. In the process of 
thinking about the metathesis mechanism, Yves Chauvin from the 
Institut Français du Pètrole, had taken into account the report of 
Fischer on the synthesis of a tungsten-carbene complex (Fischer, 
1964), that of Natta on the polymerization of cyclopentene by ring 
opening catalyzed by a mixture of WCl6 and AlEt3 (Natta, 1964) and 
that of Banks and Bailey on the formation of ethylene and 2-butene 
from propene catalyzed by [W(CO)6] on alumina (Banks and Bailey, 
1964). Consequently, Chauvin and his student Jean-Louis Hérisson 
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published their proposition of metathesis mechanism in 1971 
(Scheme 1.4) (Hérisson and Chauvin, 1971). The latter involves a 
metal-carbene species (or more precisely metal-alkylidene), the 
coordination of the olefin onto the metal atom of this species, 
followed by the shift of the coordinated olefin to form the 
metallocyclobutane intermediate, and finally the topologically 
identical shift of the new coordinated olefin in the 
metallocyclobutane in a direction perpendicular to the initial olefin 
shift. This forms a metal-alkylidene to which the new olefin is 
coordinated, then liberated. This new olefin contains a carbene 
from the catalyst and the other carbene from the starting olefin. 
The new metalalkylidene contains one of the two carbenes of the 
starting olefin and it can re-enter into a catalytic cycle of the same 
type as the first one. In fact, depending on the orientation of the 
coordinated olefin, the new catalytic cycle can give two different 
metallacyclobutenes, one leading to the symmetrical olefin and the 
other one leading the starting olefin. This latter cycle is said to be 
degenerate olefin metathesis. Thus, the catalytic cycles alternatively 
involves both metal-alkylidene species resulting from the 
combination of the metal with each of the two carbenes of the 
starting olefin. Hérisson and Chauvin not only suggested the 
metallacyclobutane mechanism, but also published several 
experiments to confirm it. 
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Scheme 1.4. Chauvin’s mechanism, proposed in 1971, for the catalyzed olefin 
metathesis involving metal alkylidene and metallacyclobutane intermediates. 
Chauvin’s mechanism introduced several new ideas. First, it 
proposed the implication of a metal-carbene complex to initiate the 
catalysis of the metathesis reaction. This idea first suggested that 
one could just synthesize metal-alkylidene complexes and let them 
react as catalysts with olefins to carry out the metathesis reaction.  
Chapter A1 
22 
It was in 1980 that Dick Schrock’s group at MIT reported a tantalum-
alkylidene complex, [Ta(=CH–t-Bu)Cl(PMe3)(O–t-Bu)2], which 
catalyzed the metathesis of cis-2-pentene (Schrock et al., 1980). This 
provided the very first proof for Chauvin’s mechanism of olefin 
metathesis with a well-defined high oxidation state alkylidene 
complex, almost a decade after Chauvin’s proposal. Molybdenum 
and tungsten, however, were obviously the most active metals in 
alkene metathesis and, around 1980, Schrock and his group 
considerably increased their efforts in the search for stable 
molecular alkylidene and alkylidyne complexes of these metals that 
would catalyze the metathesis of unsaturated hydrocarbons. This 
search was successful (Wengrovius et al., 1980) and eventually 
produced a whole family of molybdenum- and tungsten-alkylidene 
complexes of the general formula [M(=CHCMe2Ph)(=N–Ar)(OR2], R 
being bulky groups. These compounds presently are the most active 
alkene metathesis catalysts (Figure 1.8) (Schrock et al., 1990; Bazan 
et al., 1990; Bazan et al., 1991).  
The advantage of Schrock’s catalysts, whose most efficient 
members were reported in 1990, was that even though they are 
extremely active, they are molecular (without additives) and also 
provided a commercial catalyst and chiral versions for the first 
examples of asymmetric metathesis catalysis (Aeilts et al., 2001; 
Teng et al., 2002; Tsang et al., 2003a; Tsang et.al., 2003b).  
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Schrock’s closely related Mo-alkylidyne complexes do not react with 
olefins, but they selectively and efficiently metathesize alkynes 
without the need for a co-catalyst. 
Figure 1.8. Main families of molecular Mo and W metathesis catalysts. 
A1.2.3 Transition metal catalysts 
Two classes of metal-alkylidene complexes are usually 
distinguished: those containing a nucleophilic carbene of the  
Schrock type and those with an electrophilic carbene of the Pettit 
type (Guerchais and Astruc, 1985). A related Fischer-type ruthenium 
complex, [RuCp{=C(Me)OMe}(CO)(PCy3)][PF6], stabilized by a 
methoxy group on the carbene carbon, was synthesized by Malcolm 
Green’s group at Oxford in 1971. This was the first reported 
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ruthenium-carbene complex (Green et al., 1971). The reactivity of 
this type ruthenium complexes towards olefins is again 
cyclopropanation, because of the strongly electrophilic character of 
the carbene ligand due to the positive charge, further increased by 
the electron-withdrawing carbonyl ligands (Figure 1.9). Grubbs had 
been interested for a long time in the metathesis reaction, as 
indicated by his mechanistic proposal of a metallocyclopentane 
intermediate (Grubbs, 1972). He had noticed Natta’s publication on 
the catalysis by RuCl3 of the polymerization of cyclobutene and 3-
methylcyclobutene by ring opening (Natta et al., 1965; Grubbs and 
Tumas, 1989). This process (in butanol) had been developed by 
Norsorex. In this context, the Ziegler–Natta polymerization of 
olefins under mild conditions obviously had a considerable impact 
on polymer chemistry. The delineation of a new polymerization 
mechanism, however, was not a simple task. Wellinspired by this 
approach, Grubbs published in 1988 the polymerization of 7-
oxanorbornene into a high molecular weight monodisperse polymer 
(Mw = 1.3 x106 g mol1; Mw/ Mn = 1.2) by RuCl3 or [Ru(H2O)6] 
(OTs)2 (OTs = toluene sulfonate). This catalysis was all the more 
remarkable as it was conducted in water (Novak and Grubbs, 1988). 
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Figure 1.9. Grubbs-type (or derived) ruthenium metathesis catalysts, air-stable and 
compatible with most functional groups. 
Shortly afterwards, he could show, in the course of the same 
reaction, the formation of a Ru-alkylidene intermediate, then the 
polymerization of cyclooctene, an olefin with little constraints, 
when the alkylidene ligand source was ethyl diazoacetate added to 
the aqueous solution of [Ru(H2O)6](OTs)2 (France, 1993; Nguyen, 
1992; Schwab et al., 1998). Consecutively and according to the same 
logic, a great step forward was accomplished by Grubbs in 1992. He 
reported the first molecularly well-defined ruthenium-carbene 
complex that promoted the ROMP of low-strain olefins as well as 
the catalytic ring-closing metathesis (RCM) of functionalized dienes. 
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Grubbs showed that these vinylidene complexes, [RuCl2(PR3)(=CH–
CH=CPh2)] (R = Ph or Cy), were efficient molecular catalysts for 
these polymerization reactions (Scheme 1.5) and other metathesis 
reactions such as those involving ring closing of terminal diolefins.  
Scheme 1.5. Metathesis mechanism for the ring-opening metathesis 
polymerization (ROMP) of a cyclic olefin. 
In 1995, the new molecularly well-defined catalysts 
[Ru(=CHPh)Cl2(PR3)2], R = Ph or Cy, whose structures are closely 
related to the vinylidene ones published three years earlier, 
appeared and were commercialized with R = Cy (Figure 1.9). 
[Ru(=CHPh)Cl2(PCy3)2] is now known as the first generation Grubbs 
catalyst (G1ST)  and is still today the most used metathesis catalyst 
by organic chemists, because of its stability to air and compatibility 
with a large variety of functional groups (except for amines and 
nitriles and basic media). 
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Fine mechanistic studies with this catalyst led Grubbs’ group to 
conclude that the mechanism first involved the dissociation of one 
phosphine to generate the reactive 14-electron ruthenium 
intermediate. In order to accelerate this dissociative step, Grubbs 
introduced, in place of one phosphine, one of Arduengo’s cyclic bis-
amino carbene ligands that are relatively stable, even in the free 
forms obtained by deprotonation of the corresponding imidazolium 
cation (Arduengo, 1999; Herrmann and Köcher, 1997; Bourissou et 
al., 2000; Wetskamp et al., 1998). It is Herrmann’s group that first 
synthesized ruthenium complexes with two such carbene ligands in 
the context of the catalysis of olefin metathesis, but their catalytic 
activity was shown to be modest. In G1STs containing only one such 
ligand, they increase the electron density at the ruthenium center, 
however, and their trans effect labilizes the ruthenium-phosphine 
bond, favoring phosphine dissociation. Thus, the second generation 
Grubbs catalysts (G2ND) [RuCl2{C(N(mesityl)CH2)2}(PCy3)(=CHPh)] 
and its catalytic activity in metathesis were successively proposed 
within a few months by the groups of Nolan (Ackermann et al., 
1999), Grubbs (Scholl et al., 1999a; Scholl et al., 1999b; Trnka et al., 
2003; Love et al., 2003; Chatterjee et al., 2003; Morril and Grubbs, 
2003), and Fϋrstner and Herrmann (Ackermann et al., 1999). It is 
presently the most used catalyst for efficient cross-metathesis 
reactions, although it is not tolerant to amines and nitriles (for 
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instance, with acrylonitrile, Schrock’s catalyst is efficient, in contrast 
to the ruthenium catalysts). On the contrary, this new, commercially 
available, catalyst is even more active although it is also more 
thermally stable than the first one. Along this line, Hoveyda 
(Kingsbury et al., 1999; Grela et al., 2002), Hofmann (Hansen et al., 
1999; Volland et al., 2004), Grela and Blechert (Connon et al., 2002; 
Wakamatsu and Blechert, 2002a; Wakamatsu and Blechert, 2002b; 
Dunne et al., 2003) reported other related, very active, stable and 
functional- group tolerant ruthenium metathesis catalysts. The first 
Hoveyda metathesis catalyst is derived from Grubbs’ first 
generation catalysts. It bears only one phosphine and a chelating 
carbene ligand. The second one bears, in addition, Arduengo’s 
carbene instead of the phosphine. Both catalysts are now 
commercially available, although expensive. Grela recently reported 
variations of the Hoveyda catalyst with increased efficiency (active 
even at 0 °C) when the aryl group of the benzylidene ligand bears a 
nitro group in the meta or para positions or two methoxy 
substituents (Figure 1.9). Grela’s successful idea was to destabilize 
the Ru–O(ether) bond in order to favor the ether decoordination 
that generates the catalytically active 14-electron species (Grela et 
al., 2002). The family of Hoveyda catalysts, whose activity compares 
with that of the second generation Grubbs catalyst, are especially 
useful for difficult cases of metathesis of polysubstituted olefins and 
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selective cross metathesis (CM) in which homo-coupling needs be 
avoided (Kingsbury et al., 1999; Honda et al., 2004). The most 
successful variation of these Ru-benzylidene catalysts so far was 
reported by Blechert whose strategy to sterically destabilize the Ru–
O(ether) bond was to introduce an aryl (phenyl or naphthyl) 
substituent on the benzylidene aryl in the ortho position relative to 
the O(ether) (Connon et al., 2002; Wakamatsu and Blechert, 2002a; 
Wakamatsu and Blechert, 2002b; Dunne et al.,  2003). The catalytic 
efficiency and stability of Blechert complexes surpasses those of all 
the other Ru catalysts, although it has been shown several times 
that the catalytic efficiency depends on the type of metathesis 
reaction examined and the tolerance towards the required 
functional group. 
A1.2.4 Intra- and intermolecular olefin metathesis 
Olefin metathesis is a metal-catalyzed transformation, which acts on 
carbon-carbon double bonds and rearranges them via cleavage and 
reassembly. According to the mechanism, first introduced by 
Chauvin, the coordination of an olefin to a metal carbene catalytic 
species leads to the reversible formation of a metallacyclobutane 
(Scheme 1.6). This intermediate then proceeds by cycloreversion via 
either of the two possible paths: 1) non-productive—resulting in the 
re-formation of the starting materials or 2) product-forming—
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yielding an olefin that has exchanged a carbon with the catalyst’s 
alkylidene. Since all of these processes are fully reversible (Scheme 
1.6), only statistical mixtures of starting materials as well as all of 
possible rearrangement products are produced in the absence of 
thermodynamic driving forces. 
Scheme 1.6. General mechanism of olefin metathesis. 
The most important olefin metathesis subtypes are presented in 
Scheme 1.7. They are currently employed in the synthesis of a large 
varierty of small, medium and polymeric molecules, as well as novel 
materials. 
Scheme 1.7. Different types of olefin metathesis, all proceeding according to the 
Chauvin mechanism and catalyzed by Schrock-type or Grubbs-type catalysts. 
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Ring-Closing Metathesis (RCM) 
Construction of rings is one of the fundamental processes in organic 
synthesis. Of the various strategies available, cyclization is the most 
straightforward way of obtaining rings. Commonly employed 
cyclization methods involve reactions of cationic, anionic or radical 
species. Common rings such as 5–7 membered ones are easily 
available by these methods. However, formation of medium or large 
rings by these methods either proceeds with low yields or does not 
proceed at all due to unfavourable enthalpic and entropic factors. In 
recent years, olefin metathesis has emerged as a powerful tool for 
carbon–carbon bond formation and has enabled the synthesis of 
rings of different sizes (Ghosh et al., 2006). The construction of 
macrocycles by ring-closing metathesis (RCM) is often used as the 
key step in the synthesis of natural products containing large rings 
(Conrad and Fogg, 2006). The Chauvin mechanism for olefin 
metathesis (Hérisson and Chauvin, 1971) involves a sequence of 
[2+2] cycloadditions and retroadditions, in which the key 
intermediate is a metallacyclobutane species. Each step of the 
catalytic cycle is in principle reversible, resulting in an equilibrium 
mixture of olefins unless a bias can be exerted to drive the reaction 
in a chosen direction. Ring-closing metathesis of dienes is 
entropically favoured by the formation of two olefinic products 
from a single diene precursor (Scheme 1.8). When both olefinic 
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groups in the diene are terminal, one equivalent of ethylene is 
formed for each cycloalkene, and ring-closing is driven by the loss of 
volatile ethylene.  
 
Scheme 1.8. Intramolecular RCM metathesis of a diene to form a cyclic olefin. 
 
Steric parameters favour metathesis of α,ω-olefins over internal 
olefins, as does the decreased volatility and increased solubility 
(Atiqullah et al., 1998) of olefinic coproducts heavier than ethylene. 
The rate, products, and selectivity of RCM processes are determined 
by a subtle interplay of substrate and catalyst parameters. Substrate 
parameters, of course, determine whether a target reaction is 
thermodynamically feasible. Reaction rates and product selectivity 
are determined by the interaction of catalyst and substrate 
properties: the structure-activity relationships are very complex and 
remain poorly understood.  
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Cross-metathesis (CM) and Ring-Opening Cross-Metathesis 
(ROM-CM) 
Olefin cross-metathesis (CM) can be formally described as the 
intermolecular mutual exchange of alkylidene (or carbene) 
fragments between two olefins promoted by metal-carbene 
complexes (Grubbs and Chang, 1998; Randall and Snapper, 1998). 
There are two main variations on this theme (Scheme 1.9): a) “pure” 
cross-metathesis (CM) and b) ring-opening cross-metathesis (ROM-
CM).  
CM is not yet in such widespread laboratory use as the more 
entropically favorable RCM reaction. However, the development of 
a second generation of active and robust ruthenium catalysts (see 
Section A1.2.3), which combine the high activity previously only 
associated with molybdenum-based catalysts with an impressive 
functional-group tolerance, has recently allowed many groups to 
breathe new life into what were previously in many cases little more 
than unselective mechanistic curiosities (Hérisson and Chauvin, 
1971). 
Scheme 1.9. Variations of cross-metathesis (CM). 
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A general mechanistic scheme for the CM of two symmetrically 
substituted olefins (in the practice, this is quite difficult) is 
presented in Scheme 1.10. The first step in the catalytic cycle (after 
the first catalyst turnover to produce A) is a [2+2] cycloaddition 
reaction between olefin B and a transition metal carbene A to give a 
metallacyclobutane C. The latter undergoes subsequent collapse in 
a productive fashion to afford a new olefin product D and a new 
metal carbine (alkylidene) E, which carries the alkylidene fragment 
R1. Similarly, E can react with a molecule of F via G to yield D and A, 
which then re-enters the catalytic cycle. The net result is that D is 
formed from B and F with A and E as catalytic intermediates. 
Scheme 1.10. General mechanistic scheme for the CM of the two symmetrically 
substituted olefins B and F. 
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The highly efficient and atom-economic ROM–CM reaction has been 
the subject of much recent investigation. The presumed catalytic 
cycle for this reaction is shown in Scheme 1.11.  
Scheme 1.11. ROM–CM catalytic cycle. 
The reaction of ruthenium methylidene A and olefin substrate B 
furnishes metallacyclobutane intermediate C, which on collapse 
gives ring-opened alkylidene D. This step is most efficient for highly 
strained cyclic olefin substrates, in which relief from ring strain 
provides an energetic counterweight to the entropically favored 
reverse ring-closing reaction (D→A). It is hardly surprising, 
therefore, that norbornenes, oxanorbornenes, (Schneider and 
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Blechert, 1996; Schneider et al., 1997) and cyclobutenes (Randallet 
al., 1995; Tallarico et al., 1997; Snapper et al., 1997) are generally 
excellent substrates for ROM–CM reactions. CM between D and 
terminal olefin E (internal olefins may also serve as CM partners) 
then affords ROM–CM product G via intermediate F with loss of the 
ruthenium methylidene, which then reenters the catalytic cycle. An 
important condition for ROM–CM to be efficient is that CM 
between D and E must be faster than the reaction between D and B 
(a competing ROMP pathway), a factor which very much depends 
on the nature of the cyclic olefin B and the CM partner E used. 
However, in the majority of cases, ROM–CM competes effectively 
with ROMP, particularly under high dilution conditions.  
Acyclic diene metathesis polymerization (ADMET) 
Traditionally, acyclic diene metathesis (ADMET) is considered to be 
a step-growth polycondensation-type polymerization, which makes 
strictly linear chains from unconjugated dienes (Allcock et al., 2001; 
Wagener et al., 1997).  
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As such, ADMET requires very high monomer conversion rates to 
produce polymer chains of considerable size. Therefore, the more 
active second generation catalysts are usually better suited for 
ADMET than bisphosphine ones. Since the loss of ethylene is the 
main driving force behind the cross metathesis of terminal olefins, 
the efficient removal of this volatile gas from the reaction vessel is 
also crucial. Consequently, although olefin metathesis with 
ruthenium catalysts is, in general, very mild and does not require 
stringent air removal, ADMET greatly benefits from conditions 
which promote the diffusion and expulsion of ethylene (i.e., higher 
reaction temperatures, application of vacuum, and rigorous 
stirring). In addition, the use of concentrated or even neat solutions 
of monomers is usually helpful to polycondensation reactions but, in 
the case of ADMET, a  very viscous solution might be detrimental to 
efficient stirring and ethylene removal. Furthermore, as a 
consequence of the poor molecular weight control of stepgrowth 
reactions, the polydispersity index (PDI) of polymers obtained by 
this method is usually quite large. However, an important advantage 
of ADMET is that it allows a large variety of monomers to be 
polymerized since terminal olefins are quite easy to install. Many 
functional groups and moieties of interest can be incorporated into 
such polymers directly through monomer design, due to the 
excellent tolerance of ruthenium catalysts. 
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Ring-Opening Metathesis Polymerization (ROMP) 
Ring opening metathesis polymerization (ROMP) exhibits very 
different reaction kinetics from the ADMET approach to polymeric 
materials. ROMP is a chain-growth type polymerization which relies 
on monomer ring strain and, thus, it can be efficiently controlled by 
catalyst loading.  
The equilibrium molecular weight of the resulting polymer chains is, 
therefore, essentially independent of the extent of conversion. 
Moreover, a variety of olefin metathesis catalysts effect ROMP and 
sufficiently fast initiating ones can even lead to a living 
polymerization of appropriately chosen monomers. For example, 
the polymerization of norbornenes with the fast initiating 
bispyridine species produces well-defined polymers with PDIs close 
to 1.0 (Choi and Grubbs, 2003). The employment of these strained, 
bi-cyclic alkenes as monomers ensures that both depolymerization 
via competing RCM and chain fragmentation via “back-biting” of the 
catalyst into the growing chain are significantly suppressed. 
However, the limited availability of suitable monomers is the main 
disadvantage of this method. Although a variety of backbones can 
be created through monomer functionalization, such alterations 
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sometimes negatively affect the ring strain and, thus, success of 
ROMP. 
A1.3 Key processes in ruthenium-catalysed olefin metathesis 
The elucidation of the mechanism of metathesis reaction catalyzed 
by Grubbs catalysts has been the subject of intense experimental 
(Dias et al., 1997; Ulman and Grubbs, 1998; Hinderling et al., 1998; 
Adlhart et al., 2000a; Adlhart and Chen, 2000; Adlhart et al., 2000b; 
Sanford et al., 2001; Conrad et al., 2007) and theoretical (Cavallo, 
2002; Adlhart and Chen, 2004; Occhipinti et al., 2006; Urbina-Blanco 
et al., 2013) investigations. Key processes (Scheme 1.12) in the 
ruthenium-catalysed homogeneous alkene metathesis reaction 
include: the study of pre-catalyst initiation, during which a stable 
precatalyst (typically 16-electron RuII) becomes an active 14-
electron species; the study of how the ancillary ligand affects 
reactivity; the partitioning between intra- and inter-molecular 
metathesis pathways; the study and understanding of the key steps 
that occur during metathesis reactions, the development of Z-
selective metathesis pre-catalysts; and the study of catalyst 
decomposition.  
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Scheme 1.12. Key stages of alkene metathesis reactions. (Reproduced from Nelson 
et al., 2014) 
In the specific case of olefin metathesis, it has been proposed that 
carbenes and metallocyclobutanes (MCBs) are the key 
intermediates of the reaction (Hérisson and Chauvin, 1971). The 
first step to clarify the mechanism of the metathesis reaction has 
been the direct identification of the two above-mentioned 
ruthenium complexes by NMR technique. In 1992, Grubbs reported 
the first NMR spectroscopic evidence of a carbene intermediate 
produced during the reaction of a strained olefin with a well-defined 
Ru(II)-complex (Nguyen et al., 1992). Notably, Ru(II)-complex was 
able to polymerize norbornene in a 1:8 mixture of CH2Cl2/C6H6 at 
room temperature to yield polynorbornene. A new signal, 
attributed to Hα of the propagating carbene, was observed by 1H 
NMR spectroscopy at 17.79 ppm. Its identity and stability were 
confirmed by Grubbs and collaborators by preparing a block 
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polymer with 2,3-dideuterionorbornene and perprotionorbornene 
(Scheme 1.13).  
Scheme 1.13. The block copolymerization of 2,3-dideuterionorbornene and 
perprotionorbornene by a well-defined Ru alkylidene complex. 
Later on, the selectivity and reactivity in ROM reactions was 
investigated by another research group by means of 1H and 31P NMR 
studies of the ruthenium alkylidenes formed during the reaction of 
cyclobutene-containing substrates (Randall et al., 1995; Tallarico et 
al., 1997a; Tallarico et al., 1997b). The factors behind the chemo-, 
regio- and stereoselectivities of ROM were examined and the 
mechanistic models suggested were supported by stoichiometric 
studies of the ruthenium alkylidenes formed during the ROM of 
various cyclobutene-containing substrates. The utility and 
limitations of 1H NMR methods for monitoring the progress of ring-
Chapter A1 
42 
closing metathesis (RCM) reactions were also examined (Monfette 
et al., 2010). 
A significant advance in MCBs intermediate detection was made 
when Piers and co-workers developed rapidly-initiating 14-electron 
ruthenium carbene complexes such as Piers1 and Piers2 (Romero et 
al., 2004; Dubberley et al., 2006; Leitao et al., 2010). This class of 
compounds has enabled the preparation, observation and study of 
MCB species using modern low-temperature NMR spectroscopic 
techniques (Romero and Piers, 2005). In the first report of this 
reactivity, Piers demonstrated that the reaction of Piers2 with 2.2 
equiv. of ethene yielded quantitative conversion to MCB b (Scheme 
1.14). 
Scheme 1.14. Formation of MCBs using Piers-type complexes. (Adapted from 
Nelson et al., 2014) 
The NMR data suggested a bottom-bound MCB geometry, while Hα 
exhibited a resonance at 6.6 ppm and Hᵦ at -2.6 ppm. 
a 
b 
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1JCH Coupling constants suggested a ‘kite-shaped’ MCB. First 
generation analogue Piers1 yielded no observable MCB, consistent 
with DFT calculations that suggest that first generation MCBs are 
less stable than their second generation analogues (Cavallo, 2002). 
As an extension of their work, the same authors have shown the 
formation of ruthenacyclobutane and ruthenium carbene 
intermediates in RCM reaction (van der Eide et al., 2008), and 
provided a direct spectroscopic characterization of them. 
Recently, we submitted to olefin metathesis reaction undecenyl 
resorc[4]arene macrocycles, with the aim to synthesize macrocyclic 
compounds capable of behaving as pre-organized hosts for the 
supramolecular recognition of appropriate molecular guests. The 
chair stereoisomer proved to be suitable substrate to yield cyclic 
alkenes by both intra- and intermolecular metathesis. In particular, 
the reaction performed on the chair substrate 1a led mainly to the 
formation of the resorc[4]arene bicyclic olefin 2a, along with the 
dimer 3a. The latter proved to develop from two molecules of 2a 
reacting together via a ring opening-cross metathesis (ROM-CM) 
sequence, according to an hypothesized mechanism (Ghirga et al., 
2013). 
The key role played by resorc[4]arene bicyclic olefin 2a as 
monomeric building block for the construction of more complex 
architectures prompted us to investigate more deeply the 
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mechanism of the ROM-CM sequence of reactions. Typically, ROM-
CM reactions are most successful when using highly strained 
substrates that show a good propensity to undergo a ring opening, 
which is the initial step then followed by CM. In the presence of 
reactive metal carbenes, also unstrained olefins proved to be 
suitable substrates for ROM-CM reactions (Ulman et al., 2000; Randl 
et al., 2001) by effecting ring-expansion reactions leading to a 
variety of macrocycles whose ring sizes can be modulated by using 
appropriate cyclic olefins (Lee et al., 2002). We report here the 
direct observation of a ruthenium-carbene-resorc[4]arene complex 
produced during a metathesis reaction of a resorc[4]arene bicyclic 
olefin with the G1ST catalyst. 
 
 
 
 
 
 
 
 
 
 
Chapter A2 
45 
Chapter A2 
Synthesis of Resorc[4]arene 
 ω-Undecenyl Esters 1a–1c 
A2.1 Results and discussion 47 
A2.1.1 Synthesis of resorc[4]arene ω-undecenyl esters 
1a–1c 47 
A2.1.2 X-Ray diffraction analysis of resorc[4]arene 1a 49 
A2.2 Experimental section 55 
A2.2.1     Synthesis of ω-undecenyl 
(E)-2,4-dimethoxycinnamate      55 
A2.2.2 Synthesis of resorc[4]arene ω-undecenyl esters 
1a–1c 57 
A.2.2.3 Crystallographic data of resorc[4]arene 1a 64 

Chapter A2 
47 
A2.1 Results and discussion 
A2.1.1 Synthesis of resorc[4]arene ω-undecenyl esters 1a–1c 
The preparation of C-alkylated resorc[4]arenes by tetramerization in 
the presence of ethereal BF3 of opportunely substituted 2,4-
dimethoxycinnamates  has prompted our group to study both the 
versatility of the reaction and the chemical and physical properties 
of the new macrocycles obtained, as depending on the variation of 
the side chains (Botta et al., 1992; Botta et al., 1997; Botta et al., 
2005). In this Phd thesis i planned to synthesize resorc[4]arenes 
featuring long aliphatic side chains ending with a vinylidene group 
which provides the possibility for cross-linking reactions.  
(E)-2,4-Dimethoxycinnamic acid was quantitatively converted into 
the corresponding acid chloride (Scheme 2.1) by reaction with 
thionyl chloride in dry dichloromethane (DCM), and then converted 
into the corresponding ester by reaction with ω-undecenyl alcohol 
in dry THF, in the presence of diisopropylethylamine (DIPEA). 
Purification by silica gel column chromatography (chloroform as 
eluent) yielded the ω-undecenyl ester as a yellow oil (yield 81%). 
Treatment of (E)-2,4-dimethoxycinnamic acid ω-undecenyl ester 
with BF3•Et2O (molar ratio 1:2) in chloroform at reflux afforded in 
60% yield three stereoisomeric resorc[4]arene ω-undecenyl esters, 
which were shown to be in the chair (1a), cone (1b), and 1,2-
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alternate (1c) configuration. The structure of stereoisomers 1a–1c 
was confirmed by 1H and 13C NMR spectroscopy and by electrospray 
ionization high-resolution mass spectrometry (ESI-HRMS). 
Scheme 2.1. Synthesis of resorc[4]arene ω-undecenyl esters 1a–1c. Reagents and 
conditions: (i) thionyl chloride, dry DCM, reflux, 2 h and 40 min; (ii) 10-undecen-1-
ol, DIPEA, dry THF, reflux, 3 h. (iii) BF3•Et2O (molar ratio 1:2), CHCl3 (stabilized with 
amylene), reflux, 20 min. 
Conformation in solution of resorc[4]arenes 1b (cone with a C4v 
symmetry) and 1c (1,2-alternate with a Cs symmetry) could easily be 
assigned by the distribution pattern of NMR spectral data (Abis et 
al., 1988). On the contrary, the NMR spectral data of resorc[4]arene 
1a were in agreement with both the D2d symmetry of the 1,3-
alternate conformation (Botta et al., 2005) and the C2h symmetry of 
a chair conformer (Högberg, 1980a; Högberg, 1980b). This 
ambiguity was solved by X-ray diffraction analysis of a crystal of 
OCH3
H3CO
OH
O OCH3
H3CO
O
(CH2)8
O
H3CO OCH3
OCH3
OCH3
H3CO
H3CO
H3CO OCH3
O
O
O
O
O
O
O
O
i, ii
iii
8
88
8
(E)-2,4-dimethoxycinnamic acid (E)-undec-10-enyl 2,4-dimethoxycinnamate
1a 
1b 
1c
conformation
chair
cone
1,2-alternate
A
2
B
C
D
814
20 25
26
27
28
Chapter A2 
49 
resorc[4]arene 1a (solvent, ethyl acetate): the results obtained fit 
very likely with a chair conformation (vide infra). 
In the three forms, the side chains have different arrangements, i.e., 
two cis and two trans (rctt) in the chair 1a, all-cis (rccc) in the cone 
1b, three cis and one trans (rctc) in the 1,2-alternate 1c (Figure 2.1). 
Figure 2.1. Chemical structures of resorc[4]arene ω-undecenyl esters 1a (chair), 1b 
(cone), and 1c (1,2-alternate). 
A2.1.2 X-Ray diffraction analysis of resorc[4]arene 1a 
The molecular structure of resorc[4]arene 1a is illustrated in Figure 
2.2. Taking as a reference the weighed least squares plane, namely 
R, passing through the four bridging carbon atoms of the 
macrocycle, the calculated dihedral angles  values (Perrin and 
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Oehler, 1991) (collected in Table 2.1) show that the B and D 
aromatic rings are almost coplanar with the plane R, whereas A and 
C are almost orthogonal to it, but on opposite sides.  
Figure 2.2. X-Ray structure of undecenyl resorc[4]arene 1a showing the chair 
conformation adopted by the macrocycle. Colors are as follows: C, grey; O, red. 
Hydrogen atoms are omitted for clarity. 
Following a procedure already adopted, (Botta et al., 2007) the 
molecular conformation of the macrocycle was given by the 
conformational parameters and , which account without 
ambiguities for the reciprocal orientations between adjacent 
aromatic rings (see Table 2.1).  
Chapter A2 
51 
Table 2.1. Dihedral angles ) and conformational parameters ( and) for 
resorc[4]arene 1a. 
Rings  [°]a Rings  [°]a  [°]a 
R^A 90.23 (3) 
AB 76.8 (4) 
-151.4 
(2) 
R^B 178.02 
(4) 
BC 
-147.9 
(2) 
78.3 (1) 
R^C 270.48 
(4) 
CD -70.3 (1) 
152.2 
(2) 
R^D 177.13 
(4) 
DA 
145.9 
(1) 
-75.5 (1) 
a Estimated standard deviations (ESD) are reported in parentheses. R is the weighed least 
squares plane passing through the four bridging carbon atoms of the macrocycle. 
The sequence of signs (+-,+-,-+,-+) of the calculated values of and 
fits very likely with a chair conformation. The four ester chains 
attached to the bridging methine groups of the aromatic pocket 
point towards the exterior of the macrocycle and are segregated in 
pairs on opposite sides of the R plane. Such arrangement in the solid 
state makes resorc[4]arene 1a a preorganized synthon undergoing a 
peculiar type of self-assembly which produces zigzag one-
dimensional ribbons as those depicted in Figure 2.3. 
Figure 2.3. Perspective view of a zigzag one-dimensional ribbon in resorc[4]arene 
1a showing CH/ interactions (green lines) occurring between the terminal 
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methylene hydrogen atoms of one molecule and the  systems of two adjacent 
molecules. 
In the novel “secondary structure”, two pairs of aliphatic arms from 
two neighbouring resorcarenes are inserted as in a sandwich by two 
pairs of aromatic methoxyl groups. The driving force for such self-
assembly seems to be CH/ interactions between the terminal 
methylene hydrogen atoms of one molecule and thesystems of 
two adjacent molecules (evidenced by green lines in Figure 2.3). In 
such a way, resorc[4]arene 1a can behave at the same time as 
donor and acceptor of CH/ interactions, whose geometrical 
parameters are collected in Table 2.2. 
Table 2.2. Geometrical parameters for the CH/ interactions in resorc[4]arene 1a. 
Carbon number C•••C(Ǻ)a H•••C(Ǻ)a CH•••C (°)a 
  C21A-H···C3A’ 3.509 (3) 2.716 (2) 136.6 (2) 
  C21A-H···C4A’ 3.248 (3) 2.797 (2) 108.4 (2) 
  C21B-H···C5B’’ 3.197 (3) 2.955 (3) 94.7 (2) 
  C21B-H···C4B’’ 3.199 (3) 2.619 (2) 117.0 (2) 
a Estimated standard deviations (ESD) are reported in parentheses. 
As it can be seen, strong CH/ interactions could be expected, as 
judged by three intermolecular distances (i.e., 2.619 (2), 2.716, (2) 
and 2.797 (2) Å) significantly shorter than the corresponding value 
of 3.6 Å found by high-level ab initio calculations on a benzene-
ethylene complex (Tsuzuki et al., 2000). Drawing inspiration from 
these findings, we envisaged to carry out high-level ab initio 
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calculations when resorcinol replaced benzene in the complex with 
ethylene. To this purpose, interaction energies were calculated 
using 6-311++G**, aug-cc-pVDZ, and aug-cc-pVTZ basis sets, for 
each of the two model complexes shown in Figure 2.4, namely (A) 
and (B), where resorcinol and ethylene are in the same two 
reciprocal orientations observed in the crystal structure, i.e., at the 
same intermolecular distances [2.797 and 2.716 Å in complex (A), 
and 2.619 and 2.955 Å in complex (B)].  
Figure 2.4. Resorcinol-ethylene complexes (A) and (B) considered for high-level ab 
initio calculations of CH/ interactions. The intermolecular distances are the same 
as those found in the crystal structure of resorc[4]arene 1a. 
The calculated interaction energies of (A) and (B) complexes 
(summarized in Table 2.3) proved to be dependent on the basis set 
used, becoming more negative (the mutual attraction increases) as 
the set is enriched with correlation-consistent polarized basis sets. 
Moreover, reciprocal resorcinol-ethylene attraction is always larger 
(the interaction energy is more negative) in complex (A) than in 
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complex (B), where ethylene is tilted with respect to the resorcinol 
plane. In any case, the calculations were in agreement with the 
experimentally observed short contacts in the crystal of 
resorc[4]arene 1a and support the hypothesis of a pivotal role 
exerted by the CH/interactions in the detected self-assembly. 
Notably, along each ribbon, polar surfaces (due to the resorcarene 
core, the calculated dipole moment being 3.046 D) are alternated to 
apolar surfaces (due to the aliphatic chains). A peculiar “tertiary 
structure” was indeed detected in the crystal lattice for 
resorc[4]arene 1a, where a lamellar-type crystalline organization is 
built-up by the face-to-face exposition of polar-with-polar and 
apolar-with-apolar surfaces. The result is a multilayer structure 
containing hydrophilic (ca 7 Å thick) and hydrophobic (ca 6 Å thick) 
layers intercalated. Such structure might give a chance of 
intercalating resorc[4]arene 1a inside biological membranes. 
Table 2.3. Calculated interaction energies (kJ mol–1) of the resorcinol-ethylene 
complexes (A) and (B). 
Basis set (A)a (B)a 
MP2/6-311++G** (290)b –4.52 –0.72 
MP2/aug-cc-pVDZ (320)b –7.14 –4.60 
MP2/aug-cc-pVTZ (690)b –8.41 –6.48 
a The geometry of complexes (A) and (B) is shown in Fig. 3. b Basis functions are 
given in parentheses. 
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A2.2 Experimental section 
NMR measurements 
NMR spectra were recorded at 300 K on a Bruker AVANCE AQS600 
spectrometer operating at the proton frequency of 600.13 MHz and 
equipped with Bruker a multinuclear z-gradient inverse probe head 
capable of producing gradients in the z-direction with a strength of 
55.4 G cm−1. 1H and 13C NMR spectra were always referenced to 
residual CHCl3 signal (1H, δ = 7.26 ppm; 13C, δ = 77.20 ppm). The 1H 
NMR spectra were acquired using the following experimental 
conditions: number of scans 16–32, recycle delay 5 s, π/2 pulse 9.0 
μs, and 32K data points. 1H diffusion filter-edited NMR spectra were 
obtained using a double stimulated echo pulse sequence 
incorporating a longitudinal eddy current delay (Jerschow and 
Mueller, 1997) with a Δ of 160 ms, a δ of 2.6 ms, and a longitudinal 
eddy current delay of 25 ms. A gradient pulse recovery time of 0.1 
ms, 2% and 60% of the maximum gradient intensity were used. 
Sixty-four scans were accumulated in time domain with 32768 
points.  
A2.2.1 Synthesis of ω-undecenyl (E)-2,4-dimethoxycinnamate 
A solution of (E)-2,4-dimethoxycinnamic acid (6.0 g, 28.8 mmol) in 
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dry DCM (60 mL) was treated with SOCl2 (3.1 mL, 42.6 mmol) and 
the mixture was held at reflux for 2 h and 40 min. After removing 
the solvent under vacuum, the residue was dissolved in dry THF (32 
mL) and diisopropylethylamine (DIPEA; 5.4 mL, 31.2 mmol) was 
added under nitrogen. After 20 min stirring at room temperature, 
10-undecen-1-ol (7.0 mL, 34.1 mmol) was added to the solution and 
the mixture was heated under reflux for 3 h. Purification of the 
crude residue by silica gel chromatography with chloroform as 
eluent afforded the title compound (8.4 g, 81%, yellow oil). 1H NMR 
(600 MHz, CDCl3, 300 K):  (ppm) = 7.89 (d, J = 16 Hz, 1H, H-), 7.43 
(d, J = 8.6 Hz, 1H, H-6), 6.49 (dd, J = 8.6, 2.4 Hz, 1H, H-5), 6.44 (d, J = 
2.4 Hz, 1H, H-3), 6.42 (d, J = 16 Hz, 1H, H-), 5.80 (m, 1H, =CH), 4.98 
(br d, J = 17 Hz, 1H, =CHAHB), 4.91 (br d, J = 10 Hz, 1H, =CHAHB), 4.16 
(t, J = 6.7 Hz, 2H, -CH2), 3.86, 3.83 (s, 3H each, 2  OCH3), 2.03 (q, J 
= 7.5 Hz, 2H, -CH2), 1.68 (m, J = 7 Hz, 2H, -CH2), 1.36 (m, 2H, -
CH2), 1.28 (m, 8H, 4  CH2); 13C NMR (100 MHz, CDCl3, 300 K):  
(ppm) = 168.0 (s, C=O), 162.6, 159.8 (s each, C-4, C-2), 139.9 (d, CH-
), 139.2 (d, =CH), 130.4 (d, CH-6), 116.7 (s, C-1), 116.2 (d, CH-), 
114.1 (t, =CH2), 105.2 (d, CH-5), 98.4 (d, CH-3), 64.4 (t, -CH2), 55.5 
(q, OCH3), 33.8 (t, -CH2), 29.5–29.1 (t, 4  CH2), 28.9 (t, -CH2), 
28.8 (t, -CH2), 26.0 (t, -CH2). HRMS (ESI): m/z calcd for C22H32O4 + 
Na+: 383.21928 [M + Na]+ (monoisotopic mass); found: 383.21910. 
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A2.2.2  Synthesis of resorc[4]arene ω-undecenyl esters 1a–1c 
BF3•Et2O (1.5 mL; 11.25 mmol) was added to a solution of ω-
undecenyl (E)-2,4-dimethoxycinnamate (2.0 g, 5.55 mmol) in CHCl3 
(stabilized with amylene, 5 mL) under stirring and the mixture was 
held under reflux for 20 min. After addition of ice-water, the stirring 
was continued until the chloroform phase turned to fuchsia. The 
chloroform layer was dried over Na2SO4 and the solvent was 
removed under vacuum. The residue was purified by silica gel 
column chromatography (DCM and DCM-ethyl acetate, 97:3) to 
yield resorc[4]arene ω-undecenyl esters, in the order of elution, 1b 
(130 mg, 26%), 1a (120 mg, 24%), and 1c (45 mg, 9%). 
Resorc[4]arene ω-undecenyl ester 1a (chair) 
White solid, 24% overall yield. Mp: 137  0.3 °C. 1H and 13C NMR 
signals are reported in Table 2.4. HRMS (ESI): m/z calcd for 
C88H128O16 + Na+: 1463.90946 [M + Na]+ (monoisotopic mass); found: 
1463.91035. FT-IR (KBr): 2918, 2852, 1734, 1612, 1585, 1468, 1299, 
1201 cm–1. In Fig. 2.5 is reported a rapresentative 1H NMR spectrum 
of resorc[4]arene 1a. 
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Table 2.4. 1H NMR and 13C NMR signals* of undecenyl resorc[4]arene 1a (chair). 
Carbon 13C 1H 
C=O 172.4 - 
CAr–O 156.6 
155.8 
- 
=CH 139.2 5.82 ddt (17.2, 10.2, 6) 
CHi (26,28) 
CHi (25,27) 
126.6 
125.7 
6.19 s 
6.82 s 
CAr–C 125.3 
122.6 
- 
=CH2 114.3 4.99 br d (17.2) 
4.92 br d (10.2) 
CHe (5,17) 
CHe (11,23) 
97.1 
95.3 
6.47 s 
6.39 s 
OCH2 64.3 3.98 br t 
3.92 t 
OMe 56.0 
56.0 
3.88 s 
3.64 s 
CH2-(CO) 39.6 2.73 dd (14.5, 10.5) 
2.65 dd (14.5, 6.5) 
CH2-(CH=) 34.0 2.05 q (6) 
CH 33.0 5.04 dd (10.5, 6.5) 
CH2-(CH2-CH=) 29.1 1.46 m 
CH2-(CH2O) 28.7 1.38 m 
CH2  5 29.6 
29.6 
29.5 
29.3 
26.0 
1.24 br m 
* 600 MHz (1H) and 100 MHz (13C), CDCl3, T = 300 K; coupling constants J (Hz) are 
given in parentheses. 
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Figure 2.5. 1H NMR spectrum of undecenyl resorc[4]arene 1a (chair). 600 MHz, 
CDCl3, 300 K. 
Resorc[4]arene ω-undecenyl ester 1b (cone) 
Yellow solid, 26% overall yield. Mp: 101  0.9 °C. 1H and 13C NMR 
signals are reported in Table 2.5. HRMS (ESI): m/z calcd for 
C88H128O16 + Na+: 1463.90946 [M + Na]+ (monoisotopic mass); found: 
1463.91035. FT-IR (KBr): 2918, 2852, 1734, 1612, 1585, 1468, 1299, 
1201 cm–1. In Fig. 2.6 is reported a rapresentative 1H-NMR spectrum 
of resorc[4]arene 1b. 
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Table 2.5. 1H NMR and 13C NMR signals* of undecenyl resorc[4]arene 1b (cone). 
Carbon 13C 1H 
C=O 172.5 - 
CAr–O 156.2 - 
=CH 139.3 5.82 ddt (17.2, 10.2, 6.5) 
CHi (25,26,27,28) 126.0 6.51 s 
CAr–C 124.2 - 
=CH2  114.3 4.99 br d (17.2) 
4.93 br d (10.2) 
CHe (5,11,17,23) 96.4 6.30 s 
OCH2 64.4 3.95 t (6.8) 
OMe 56.0 3.63 s 
CH2-(CO) 39.2 2.83 d (7.6) 
CH2-(CH=) 34.0 2.03 m (6.5) 
CH 33.2 4.96 t (7.6) 
CH2-(CH2-CH=) 29.1 1.35 br m 
CH2-(CH2O) 28.8 1.49 br m 
CH2  5 29.7 
29.6 
29.5 
29.3 
26.0 
1.27 br m 
* 600 MHz (1H) and 100 MHz (13C), CDCl3, T = 300 K; coupling
constants J (Hz) are given in parentheses. 
Chapter A2 
61 
Figure 2.6. 1H NMR spectrum of undecenyl resorc[4]arene 1b (cone). 600 MHz, 
CDCl3, 300 K. 
Resorc[4]arene ω-undecenyl ester 1c (1,2-alternate) 
Yellow solid, 9% overall yield. Mp: 86  0.9 °C. 1H and 13C NMR 
signals are reported in Table 2.6. HRMS (ESI): m/z calcd for 
C88H128O16 + Na+: 1463.90946 [M + Na]+ (monoisotopic mass); found: 
1463.91035. FT-IR (KBr): 2918, 2852, 1734, 1612, 1585, 1468, 1299, 
1201 cm–1. In Figure 2.7 is reported a rapresentative 1H-NMR 
spectrum of resorc[4]arene 1c. 
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Table 2.6. 1H NMR and 13C NMR signals* of undecenyl resorc[4]arene 1c (1,2-
alternate). 
Carbon 13C 1H 
C=O 172.7  2 
172.3 
172.2 
- 
CAr–O (6,22) 
CAr–O (4,24) 
CAr–O (10,18) 
CAr–O (12,16) 
156.4 
156.3 
156.1 
156.1 
- 
=CH 139.2 5.79 ddt (17.2, 10.2, 6.5) 
CHi (25,28) 
CHi (26,27) 
127.6 
126.5 
7.25 s 
6.36 s 
CAr–C (7,21) 
CAr–C (1,3) 
CAr–C (13,15) 
CAr–C (9,19) 
124.7 
124.4 
124.0 
123.4 
- 
=CH2  114.4 4.97 br d (17.2); 4.91 br d (10.2) 
CHe (11,17) 
CHe (5,23) 
96.7 
96.0 
6.38 s 
6.40 s 
OCH2 (2) 
OCH2 (14) 
OCH2 (8,20) 
64.4 
63.1 
64.4  2 
4.00 t (7.0) 
3.97 t (7.0) 
3.91 t (7.0) 
OMe 56.4; 56.1; 55.9; 55.9 3.83 s; 3.82 s; 3.75 s; 3.64 s 
CH2-(CO) (2) 
CH2-(CO) (14) 
CH2-(CO) 
(8,20) 
41.2 
40.3 
39.4  2 
2.87 d (8.0) 
2.33 d (8.0) 
2.88 dd (15.1) 
CH2-(CH=) 34.0 2.03 
CH (2) 
CH (14) 
CH (8,20) 
34.0 
33.6 
34.0  2 
5.46 t (8.0) 
5.10 t (8.0) 
5.06 dd (9.6, 6.5) 
CH2-(CH2-
CH=) 
29.1 1.38 br m 
CH2-(CH2O) 28.8 1.45 br m 
CH2  5 29.7; 29.7; 29.7; 29.6; 26.0      1.27 br m 
* 600 MHz (1H) and 100 MHz (13C), CDCl3, T = 300 K; coupling constants J (Hz) are 
given in parentheses. 
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Figure 2.7. 1H NMR spectrum of undecenyl resorc[4]arene 1c (1,2-alternate). 600 
MHz, CDCl3, 300 K. 
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A.2.2.3 Crystallographic data of resorc[4]arene 1a 
Chemical formula C88H128O16 
Formula weight 1441.97 
crystal system triclinic 
space group P1 
a (Å)  12.297(5) 
b (Å)  17.946(5) 
c (Å) 10.559(5) 
 (°) 100.610(5)
 (°)  102.440(5)
(°)  105.110(5)
V (Å3) 2124(1) 
Z 1 
calcd (g  cm–3) 1.127
 (mm–1) 0.6 (Cu-K)
Data Collection and Refinement 
max for data collection (°) 139.98
Temperature (K) 293 
Data collected (h, k, l)  (-14, -21, -12) to (14, 21, 12) 
Total reflections 8039 
Unique reflections 7989 (Rint = 0.0) 
Observed reflections 2598 [Fo>4.0( Fo)] 
Goodness-of-fit S on F2 [a] 1.040 
Final R indices (obs. data)[b] R1 = 0.0639, wR2 = 0.143 
Largest diff. peak and hole (e/Å–3) 0.16/-0.12 
[a] Goodness-of-fit S = [w(Fo2-Fc2)2/(n-p)]1/2, where n is the number of reflections 
and p the number of parameters. [b]R1 =  Fo-Fc/Fo, wR2 = [w(Fo2-
Fc2)2/wFo4]1/2. 
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A3.1 Results and discussion 
A3.1.1 Olefin metathesis reaction on resorc[4]arene 1a 
The field of olefin metathesis is currently in a period of renaissance, 
largely because of the development in the early 1990s of well-
defined ruthenium catalysts (Scholl et al., 1999). When we started 
our investigation on olefin metathesis, we faced with the problem 
of the selection of the appropriate catalyst. Second-generation 
Grubbs and Grubbs-Hoveyda complexes were tested, with a starting 
catalyst loading of 10 mol% (Figure 3.1).  
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Figure 3.1. The structure of the second-generation Grubbs (left) and Grubbs-
Hoveyda (right) complexes. 
To ascertain the optimal reaction conditions, several experiments 
(summarized in Table 3.1) were run with resorc[4]arene 1a as the 
substrate, in which a variation in the substrate concentration and 
the catalyst loading was performed. After some trials under TLC 
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plate checking, we observed that when the reaction was performed 
under high substrate concentration (i.e., 1.0  10–2 M in DCM), a 
large quantity of undesired products (polymers, presumably) was 
obtained, as revealed by the thickness of the baseline in the TLC 
plate system. Under high dilution conditions (i.e., 3.0  10–4 M), a 
less complicated TLC pattern was obtained, but the starting material 
did not completely disappear (except in the case of second-
generation Grubbs catalyst at 10 mol%). An intermediate 
concentration (3.0  10–3 M) was afterward chosen, since it allowed 
the formation of a series of interesting compounds to be isolated 
and characterized (vide infra). The two catalysts proved to be 
almost equally effective, but the second left a 10% of starting 
material at a lower catalyst loading (i.e., 1 mol%). Finally, a 
combination of temperature (reflux) and reaction time (20 min) was 
evaluated as the best for the complete disappearance of 1a on the 
TLC plate, as compared with room temperature and longer times. 
On the other hand, as we previously showed, thermal-induced 
conformational changes from the chair to other stereoisomers do 
not occur, unless ethereal BF3 is involved (Botta et al.,1994).  
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Table 3.1. Summary of results obtained for olefin metathesis reactions of 
resorc[4]arene 1a.a
Catalyst (loading) Yield (%) 
2a 3a P1a 
3  10–3 M 
Grubbs 2nd (10%) 46 5 44 
Grubbs-Hoveyda 
(10%) 
30 trace 50 
Grubbs 2nd (1%) 43 trace n.f. 
Grubbs-Hoveyda (1%) 30b trace n.f 
3  10–4 M 
Grubbs 2nd (10%) 60 n.f n.f 
Grubbs-Hoveyda 
(10%) 
40b n.f n.f 
Grubbs 2nd (1%) 30b n.f n.f 
Grubbs-Hoveyda (1%) 10b n.f n.f 
a Reactions in DCM at reflux temperature and 20 min reaction time. b Starting 
material 1a was present. n.f. = not formed. 
The crude reaction mixture obtained under the optimal conditions 
(see first row of Table 3.1) was treated with a QuadraSil AP metal 
scavenger (amine-modified silica gel) to remove residual ruthenium 
by filtration (McEleney et al., 2006). The soluble (DCM) part of the 
filtrate was purified by silica gel chromatography eluting with 
DCM/ethyl acetate mixtures of increasing polarity (see A3.2.1 
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Section). The following products (Scheme 3.1) were isolated: 2a 
(white powder, 46% yield) and 3a (white powder, 5% yield). The 
insoluble (in most organic solvents, including DMSO) fraction P1a 
(85 mg, 44%) was obtained in two fractions: the first, as a 
precipitate (40 mg) and the second, as the material (45 mg) 
recovered by the top of the chromatographic column.  The structure 
of compounds 2a and 3a was assigned by NMR spectroscopy and by 
electrospray ionization high-resolution mass spectrometry (ESI-
HRMS). With regard to 2a, the comparison of its NMR spectral data 
with those of the parent resorc[4]arene 1a evidenced the following 
points. Proton and carbon signals (AB part of an ABM system) for 
the terminal methylene group of 1a are absent, while the signal for 
an olefinic double bond (M part in 1a) is still present (slightly shifted 
upfield) in 2a and linked with a methylene group of the chain, as 
shown by TOCSY spectra. These evidences support the formation of 
a new double bond between two chains with the elimination of one 
molecule of ethylene, as required by a ring-closing metathesis. As a 
confirmation, the sodium adduct [M + Na]+ in the ESI mass spectrum 
of 2a was found at m/z 1407.84543, that is 56 m/z (2  C2H4) less 
than the corresponding [M + Na]+ peak of 1a (m/z 1463.91035). As 
expected for a long hydrocarbon chain derivative, both the peaks 
originated a series of ions decreasing in intensity by losses of a 
methylene unit (14 m/z). Moreover, the resonance at  5.34 (br t, J 
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= 3 Hz) for the =CH methine is flanked by a minor signal (br t, J = 4 
Hz) at  5.32. The two peaks, in approximate integrated ratio of 3:1, 
were correlated (by TOCSY data) to methylene signals at 2.01 and 
2.03, as well as to the corresponding carbon resonances (by HSQC) 
at  32.0 and 26.8, respectively. The two peaks were thus assigned 
to trans and cis olefinic protons, respectively, in agreement with the 
expected highfield carbon value of the -CH2 in the cis 
configuration. Furthermore, whereas the signal at  5.34 showed a 
strong spatial correlation (by NOESY data) with the protons of both 
- and-methylene groups, the minor signal at 5.32 ppm was 
NOE-correlated only to the protons of the geminal methylene 
nucleus, as required for trans and cis olefinic protons, respectively. 
Two predictable RCM thus occurred independently between two 
neighbour chains (e.g. C-2/C-20 or C-8/C-14) on opposite faces of 
the planar aromatic rings. As a result, two bridges, featuring an 
inner double bond, were formed, leading to a bicyclic alkene 
structure for 2a. The geometrical isomerism of the double bond did 
not apparently influence the NMR resonances of the remaining 
methylene groups. Only two small satellite peaks at δ 6.85 and 6.18 
appeared in the 1H NMR spectrum of 2a and were attributed to the 
H-25/27 and H-26/28 protons of the cis form, respectively. Though 
formally the whole molecule may have a tt (55%), tc (35%) or cc 
(10%) double bonds distribution pattern, actually the compound can 
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be described as a E/Z (3:1) mixture of two independent moieties (for 
the sake of clarity, we reported in Scheme 3.1 just the Z 
stereoisomer of 2a). 
Scheme 3.1. Olefin metathesis reaction on undecenyl resorc[4]arene 1a. 
Catalytic hydrogenation (10% Pd/C) of 2a led to the unique 
reduction compound 2ar, which showed the expected [M + Na]+ 
peak at 1411.87772 m/z and clean signals without satellite peaks in 
the 1H and 13C NMR spectra.  
With regard to the minor product 3a, the 1H NMR spectral data (see 
Table 3.3 of Section A3.2) are almost coincident with those of 2a, 
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except for the signals of a new =CH-CH2-CH2 sequence, belonging to 
a second disubstituted trans double bond, again with a minor 1:3 cis 
partner. Two diagnostic peaks at 2792.69337 and 1407.84371 m/z 
in the ESI mass spectrum, which were attributed to [M + Na]+ and 
[M + 2Na]2+ sodium adducts, respectively, revealed a molecular 
weight of 2769.7 Da and a molecular formula C168H240O32. The two 
ions were flanked by the expected peaks corresponding to serial 
losses of CH2 (14 and 7 m/z, respectively). These findings suggested 
the presence of two new intermolecular eleven carbon chains, while 
two intramolecular bridges as in 2a were still remaining: in 
summary, the formation of a linear dimer 3a, as depicted in Scheme 
3.1. The novel chain could have been originated by a double cross-
metathesis (CM) intermolecular closure of the neighbour chains of 
two different molecules of 1a, but, more likely, it derives from the 
reaction between two molecules of 2a. The role of bicyclic alkene 2a 
as a key intermediate in the pathway leading to the linear dimer 3a 
was stressed by submitting an aliquot of pure 2a to the same olefin 
metathesis conditions (time, temperature and catalyst) as those 
used for 1a (see A3.2.2 Section). As a result, derivative 3a was 
obtained in a comparable 10% yield as the main product, among a 
series of more polar compounds which were not isolated. Around 
34% of unreacted starting bicycle 2a was recovered, but only traces 
of polymeric products were noticed on the TLC baseline. 
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A3.1.2 ADMET-like polymerization 
Besides bicycle 2a and dimer 3a, olefin metathesis of undecenyl 
resorc[4]arene 1a afforded the insoluble (in most organic solvents, 
including DMSO) fraction P1a (85 mg, 44%) as an amorphous solid, 
which was characterized by solid state 13C CPMAS NMR 
spectroscopy. Solid state NMR, in fact, is a powerful method to 
understand macrostructure and morphology of synthetic polymers 
(Yu and Guo, 1990). The 13C CPMAS NMR spectrum of P1a is shown 
in Fig. 3.2. The signals obtained, although typically broadened, 
perfectly match the corresponding signals of 2a recorded in solution 
(see Table 3.2 of section A3.2.1), including the disappearance of the 
terminal methylene signal, which confirmed that a metathesis 
reaction had occurred. However, the quality of the double bond 
(whether intra or intermolecular) could not be established. 
Figure 3.2. Solid state 13C CPMAS NMR spectrum of P1a measured at 100.63 MHz 
with the contact time 6 ms (room temperature).  
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Fourier-Transform IR spectrum of P1a showed a broad absorption 
band at 3444 cm–1 and identical sharp peaks as those obtained for 
the parent undecenyl resorc[4]arene 1a, as well as for bicycle 2a 
and dimer 3a. This means that, in the polymer, the typical functional 
groups are still present. The huge band around 3444 cm–1 is 
indicative of intermolecular hydrogen bonding interactions 
occurring into the labyrinthic framework of the polymer. 
Unfortunately, the insolubility of P1a in most organic solvents 
prevented the resort to both gel permeation chromatography (GPC) 
and MALDI-TOF mass spectrometry to obtain molecular weight 
distribution; however, elemental analysis of the sample was in 
satisfactory agreement with the molecular formula (C84H120O16)n, 
where C84H120O16 is the monomer (with n =1), if we assume that P1a 
is a homogeneous polymer. We afterwards hypothesized that P1a is 
a cross-linked polymer formed by an ADMET-like reaction, even 
though in different conditions. The ADMET polymerization is the 
result of the reversible condensation of highly pure dienes into 
linear polymers (Wagener et al., 1991a; Wagener et al., 1991b; 
Tindall et al., 1998). The presence of two isolated undecenoxy 
groups with active sites quite far from the bulky constituent in the 
core of the molecule (Allcock et al., 2001) and from any “negative 
neighboring group” effect (Wagener et al., 1997) makes 
resorc[4]arene 1a particularly suitable for such reaction. The ring 
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closure between two vicinal chains is competitive in the CM 
conditions and, possibly, will complicate the inner structure of the 
polymer. When the ADMET reaction is carried out under solvent-
free conditions with constant (or intermittent) vacuum (Wagener 
and Smith, 1991; Smith and Wagener, 1993), the competitive 
intramolecular CM reaction does not work and the conditions are 
thus favorable for linear polymers to be formed. Therefore, we 
submitted resorc[4]arene 1a to a previously reported ADMET 
polymerization procedure; again, an insoluble polymer was 
obtained with a solid state 13C CPMAS NMR spectrum coincident 
with that of P1a, resulting from the olefin metathesis of the same 
precursor. The insolubility of both the products obtained by classical 
olefin metathesis and ADMET polymerization of resorc[4]arene 1a 
suggests the formation of a complex polymeric architecture with 
ramifications due to the competitive intramolecular CM reaction 
and/or the intermolecular link between two distant molecules. We 
can reasonably expect that a polymeric line will be formed from a 
chain reaction of two side chains of different molecules A, B, C and 
so on, but the two free terminal methylene groups of any unit (e.g., 
A) will react not necessarily with one of the neighbour molecule
(e.g., B), rather with any other mobile member of the polymeric 
line. The structure represented in Figure 3.3 is only a possible 
formal representation of the constitutional repeating unit of the 
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polymer, that is (C84H120O16)n, and the presence of chains with 
terminal alkene can be considered negligible. In such a way, bicycle 
alkene 2a can be considered as the monomer (n = 1, molecular 
weight 1385 Da) and compound 3a the corresponding dimer (n = 2, 
molecular weight 2770 Da).   
Figure 3.3. Formal representation of the constitutional repeating unit, i.e., 
(C84H120O16)n of polymer P1a. 
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A3.2 Experimental section 
General procedures and materials 
All manipulations were performed using a combination of glovebox 
and high vacuum under a nitrogen atmosphere. HPLC grade solvents 
were dried and degassed by standard procedures. Second-
generation Grubbs and Grubbs-Hoveyda catalysts were purchased 
from Sigma Aldrich, together with QuadraSil AP silica gel. 
NMR measurements 
NMR spectra were recorded at 300 K on a Bruker AVANCE AQS600 
spectrometer operating at the proton frequency of 600.13 MHz and 
equipped with Bruker a z-gradient inverse probe head capable of 
producing gradients in the z-direction with a strength of 55.4 G 
cm−1. 1H and 13C NMR spectra were always referenced to residual 
CHCl3 signal (1H, δ = 7.26 ppm; 13C, δ = 77.20 ppm). The 1H NMR 
spectra were acquired using the following experimental conditions: 
number of scans 16–32, recycle delay 5 s, π/2 pulse 9.0 μs, and 32K 
data points. 1H diffusion filter-edited NMR spectra were obtained 
using a double stimulated echo pulse sequence incorporating a 
longitudinal eddy current delay with a Δ of 160 ms, a δ of 2.6 ms, 
and a longitudinal eddy current delay of 25 ms. A gradient pulse 
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recovery time of 0.1 ms, 2% and 60% of the maximum gradient 
intensity were used. Sixty-four scans were accumulated in time 
domain with 32768 points. 2D NMR experiments, namely 1H–1H 
TOCSY, 1H–1H NOESY, 1H–13C HSQC and 1H–13C HMBC,35 were 
performed using the following experimental conditions: 1H–1H 
TOCSY and 1H–1H NOESY were acquired in phase sensitive mode 
using TPPI selection, a 6 kHz spectral width in both dimensions, a 
1.8 s relaxation delay, a 80 ms contact time for TOCSY and a 400 ms 
mixing time for NOESY, 2048 data points in f2 and 512 increments in 
f1. Zero filling in f1 to 1024 real data points and unshifted sinusoidal 
window functions in both dimensions were applied before Fourier 
transformation. The 1H–13C gradient-selected HSQC experiment was 
acquired in phase-selective mode with the following parameters: 
13.8 μs π/2 13C hard pulse and 73 μs for composite pulse GARP 13C 
decoupling sequence (GARP, Globally optimized Alternating-phase 
Rectangular Pulses), 6 and 30 kHz spectral widths in the proton and 
carbon dimensions, respectively, 2.5 s relaxation delay, 1024 data 
points in f2 and 512 increments in f1. Linear prediction up to 1024 
point and unshifted squared cosine window functions were applied 
in the f1 dimension before Fourier transformation. The 1H–13C 
HMBC spectrum was obtained with a 2 s relaxation delay, π/2 pulse 
of 13.8 μs for 13C, 6 and 30 kHz spectral widths in the proton and 
carbon dimensions, respectively, 1024 data points in f2, 512 
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increments in f1, linear prediction up to 1024 points in f1, processed 
with the use of unshifted sinusoidal window functions in both 
dimensions. 
A3.2.1 Olefin metathesis reaction on undecenyl 
resorc[4]arene 1a 
Resorc[4]arene ω-undecenyl ester 1a (0.2 g, 0.14 mmol) was 
dissolved in dry DCM (46 mL) to reach a final substrate 
concentration of 3.0  10-3 M. The solution was heated at reflux 
temperature and then exposed to a solution of the 
[(H2IMes)(PCy3)(Cl)2Ru=CHPh)] catalyst (0.012 g, 0.014 mmol, 10 
mol%) in dry DCM (4 mL), previously prepared into the glovebox. 
The reaction mixture was kept at reflux under stirring and nitrogen 
atmosphere for 20 min and afterwards treated with QuadraSil AP 
metal scavenger (aminopropyl silica gel, 4 g). After 5 min, the 
mixture was cooled to room temperature and left under stirring 
overnight. After filtration and evaporation, the residue was 
suspended in DCM and the soluble part was applied onto a silica gel 
column to give compound 2a (88 mg, 46%, with DCM/ethyl acetate, 
97:3) and product 3a (10 mg, 5%, with DCM/ethyl acetate, 93:7). 
The yield of the insoluble portion P1a (85 mg in total, of which 45 
mg recovered from the top of the column) was 44%. 
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Bicyclic alkene 2a 
White powder, 46% yield. Mp: 190.9 0.5 °C. 1H and 13C NMR 
signals are reported in Table 3.2. HRMS (ESI): m/z calcd for 
C84H120O16 + Na+: 1407.84686 [M + Na]+ (monoisotopic mass); found: 
1407.84543. FT-IR (KBr): 2921, 2850, 1728, 1583, 1506, 1301, 1201 
cm–1. In Figure 3.5 is reported a representative 1H-NMR spectrum of 
bycyclic alkene 2a. 
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Table 3.2. 1H NMR and 13C NMR signals* of bicyclic alkene 2a 
Carbon 13C 1H 
C=O 172.5 - 
CAr–O 156.5 
155.6 
- 
CH= (trans) 
CH= (cis) 
130.8 
[130.1] 
5.34 br t (3) 
[5.32 br t (4)] 
CHi (26,28) 
CHi (25,27) 
126.3 
125.3 
6.17 br s 
[6.18 br s] 
6.84 br s 
[6.85 br s] 
CAr–C 125.3 
122.6 
- 
CHe (5,17) 
CHe (11,23) 
97.4 
95.5 
6.48 s 
6.40 s 
OCH2 64.3 3.95 dd (11.5, 7) 
3.89 m 
OMe 56.1 
55.9 
3.64 s 
3.90 s 
CH2-(CO) 39.7 2.69 dd (14.5, 7) 
2.64 dd (14.5, 7) 
CH2-(CH=) 32.0 
[26.8] 
2.01 m 
[2.03 m] 
CH 32.8 5.05 t (7) 
CH2-(CH2-CH=) 28.9 1.35 m 
CH2-(CH2O) 28.6 1.50 m 
CH2  5 29.5 
29.3 
29.1 
28.1 
25.9 
1.24 br m 
* 600 MHz (1H) and 100 MHz (13C), CDCl3, T = 300 K; coupling constants J (Hz) are 
given in parentheses. Proton and carbon resonances for the cis form, not 
coincident or overlapped by those of the trans form, are indicated by square 
brackets. 
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Figure 3.5. 1H NMR spectrum of bicyclic alkene 2a. 600 MHz, CDCl3, 300 K. 
Dimer 3a 
White powder, 5% yield. Mp: 166.9 0.5 °C. 1H and 13C NMR signals 
are reported in Table 3.3. HRMS (ESI): m/z calcd for C168H240O32 + 
Na+: 2792.70450 [M + Na]+ (monoisotopic mass) and for C168H240O32 
+ Na2+: 1407.84686 [M + 2Na]2+ (monoisotopic mass); found: 
2792.69337 and 1407.84371. FT-IR (KBr): 2923, 2852, 1736, 1508, 
1458, 1300, 1203 cm–1. In Fig. 3.6 is reported a representative 1H 
NMR spectrum of dimer 3a. 
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Table 3.3. 1H NMR and 13C NMR signals* of linear dimer 3a 
Carbon 13C 1H 
C=O 172.5 - 
CAr–O 156.5 
155.6 
- 
CH= (trans) 
CH= (cis) 
130.8 
130.3 
[130.1] 
[129.8] 
5.33 tt (3,1) 
5.38 tt (3,1) 
[5.35 m] 
[5.36 m] 
CHi (26,28) 
 
CHi (25,27) 
126.3 
 
125.3 
6.18 br s 
 
6.87 br s   
CAr–C 125.3 
122.6 
- 
CHe (5,17) 
CHe (11,23) 
97.4 
95.5 
6.49 s 
6.41 s 
OCH2 64.3 3.92 m 
3.87 m 
OMe 56.1  
55.9 
3.60 s   
3.88 s 
CH2-(CO) 39.7 2.67 m  
CH2-(CH=) 32.6 
32.0 
[26.7] 
[26.8] 
1.96 m 
2.02 m 
[2.03 m] 
[2.03 m] 
CH 32.8 5.04 t (7.5) 
CH2-(CH2-CH=) 29.4 
28.9 
1.32 m 
1.35 m 
CH2-(CH2O) 28.6 1.50 m 
CH2  5 29.5; 29.3; 29.1; 28.1;  25.9  1.24 br m 
 
* 600 MHz (1H) and 100 MHz (13C), CDCl3, T = 300 K; coupling constants J (Hz) are 
given in parentheses. Proton and carbon resonances for the cis form, not 
coincident or overlapped by those of the trans form, are indicated by square 
brackets. 
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Figure 3.6. 1H NMR spectrum of linear dimer 3a. 600 MHz, CDCl3, 300 K. 
Polymer P1a 
White amorphous solid, 44% yield, which did not melt, nor soften 
(visually) under 300 °C. Solid state 13C CPMAS NMR:  172.4 (C=O), 
157.7 (CAr-O), 131.4 (CH=CH-), 126.4 (CHi), 124.3 (CAr-C), 96.4 (CHe), 
65.0 (OCH2), 56.3 (OCH3), 41.9 (CH2-C=O), 30.7 (CH and CH2-CH=), 
30.6 (CH2). FT-IR (KBr): 3444 (broad), 2925, 2848, 1729, 1614, 1504, 
1466, 1301, 1202 cm–1. Elemental analysis (%): found: C 73.9  0.69, 
H 8.79  0.05. If we assume that P1a is a homogeneous polymer and 
C84H120O16 is the molecular formula of the monomer, it requires C 
72.8, H 8.73. 
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A3.2.2 Olefin metathesis reaction on compound 2a 
Compound 2a (0.070 g, 0.05 mmol) was dissolved in dry DCM (17 
mL) to reach a final substrate concentration of 3.0  10–3 M. The 
solution was heated at reflux temperature and then exposed to a 
solution of the [(H2IMes)(PCy3)(Cl)2Ru=CHPh)] catalyst (0.0045 g, 
0.005 mmol, 10 mol%) in dry DCM (3 mL), previously prepared into 
the glovebox. The reaction mixture was kept at reflux under stirring 
and nitrogen atmosphere for 60 min and afterwards treated with 
QuadraSil AP metal scavenger (aminopropyl silica gel, 1.5 g). After 5 
min, the mixture was cooled to room temperature and left under 
stirring overnight. After filtration and evaporation, the residue was 
purified by silica gel chromatography with DCM/ethyl acetate, 93:7 
(v/v) as eluent, to give compound 3a (7 mg, 10%) and more polar 
compounds which were not isolated. The starting bicyclic alkene 2a 
was recovered unreacted from the column eluting with DCM/ethyl 
acetate, 97:3 (46 mg, 34% by weight).   
A3.2.3 Catalytic hydrogenation of 2a 
After two vacuum/nitrogen cycles to replace the air inside the 
reaction tube, compound 2a (42 mg, 0.030 mmol) and 10% Pd/C (10 
mg) in dry THF (5 mL) were vigorously stirred at room temperature 
under 1 atm of hydrogen for 24 h. The reaction mixture was filtered 
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through a membrane filter (Millipore, Millex-LH, 0.45 mm) and the 
filtrate was concentrated. Purification of the residue by silica gel 
chromatography (DCM : ethyl acetate = 99 : 1 → 97 : 3) gave 
compound 2ar (white solid, 42 mg, 0.030 mmol, quantitative yield). 
Mp: 184.3 0.5 °C. 1H NMR (400 MHz, CDCl3, 300 K):  (ppm) 6.81 
(br s, CHi-25,27), 6.45 (s, CHe-5,17), 6.39 (s, CHe-11,23), 6.21 (br s, 
CHi-26,28), 5.03 (t, J = 7 Hz, 4H, CH), 3.92 (dd, J = 11.5 Hz, J = 7 Hz, 
4H, OCH2), 3.87 (s, 12H, OMe), 3.91 (m, 4H, OCH2), 3.64 (s, 12H, 
OMe), 2.69 (dd, J = 14.5 Hz, J = 7 Hz, 4H, CH2–CO), 2.66 (dd, J = 14.5 
Hz, J = 7 Hz, 4H, CH2–CO), 1.49 (m, 8H, CH2– CH2O), 1.26 (br m, 16H, 
8 6 CH2); 13C NMR (100 MHz, CDCl3, 300 K):  (ppm) 172.4 (s, C=O), 
156.5, 155.8 (s each, CAr–O), 126.6 (d, CHi 26,28), 125.8 (d, CHi 
25,27), 125.1, 122.8 (s each, CAr–C), 97.3 (d, CHe 5,17), 95.6 (d, CHe 
11,23), 64.2 (t, OCH2), 56.1, 55.9 (q each, OMe), 39.6 (t, CH2–CO), 
32.8 (d, CH), 29.7, 29.3, 29.0, 28.9, 28.8, 28.5, 28.3, 28.2, 25.7 (t 
each, 9 x CH2). HRMS (ESI): m/z calcd for C84H124O16 + Na+: 
1411.87816 [M + Na]+ (monoisotopic mass); found: 1411.87772. 
A3.2.4 ADMET reaction on undecenyl resorc[4]arene 1a 
According to a literature method (Allcock et al., 2001), 
resorc[4]arene ω-undecenyl ester 1a (0.5 g, 0.35 mmol) was added 
under a dry, nitrogen atmosphere to a previously evacuated and 
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flame dried, high-vacuum valve equipped flask. The 
[(H2IMes)(PCy3)(Cl)2Ru=CHPh)] catalyst (7.5 mg, 8.8  10–3 mmol, 2.5 
mol%) was dissolved in dry DCM (0.5 mL) into the glovebox under a 
nitrogen atmosphere. Such solution was vacuum transferred to the 
flask and the resulting mixture heated at 60 °C under full vacuum 
and magnetic stirring. After 1 h and evaporation of all the solvent, 
the temperature was gradually increased to 80 °C to maintain 
fluidity and facilitate stirring. Immobilization of the stirrer bar and 
discoloration of the catalyst occurred within an additional half an 
hour. The reaction mixture was filtered on paper and washed with 
DCM to give AD-1 fraction (223 mg). The washings were 
concentrated and the residue was suspended in a small volume of 
DCM. The insoluble gelly fraction was separated, washed with n-
hexane/DCM mixtures to give a second AD-2 fraction (12 mg) for an 
overall 49% yield. Both AD-1 and AD-2 fractions were insoluble in 
most organic solvents (including DMSO), as well as in 1 N or 12 N 
HCl. Solid state 13C CPMAS NMR of fraction AD-1:  172.8 (C=O), 
157.9 (CAr-O), 131.8 (CH=CH-), 126.7 (CHi), 124.5 (CAr-C), 96.6 (CHe), 
65.4 (OCH2), 56.6 (OCH3), 42.2 (CH2-C=O), 31.1 (CH and CH2-CH30.8 
(CH2). Solid state 13C CPMAS NMR of fraction AD-2:  172.2 (C=O), 
157.4 (CAr-O), 131.2 (CH=CH-), 126.3 (CHi), 124.0 (CAr-C), 96.1 (CHe), 
64.9 (OCH2), 56.1 (OCH3), 41.7 (CH2-C=O), 31.5 (CH and CH2-CH=), 
Chapter A3 
89 
30.5 (CH2). Elemental analysis of AD-1 fraction: calcd (%) for 
(C84H120O16)n: C 72.8, H 8.73; found: C 73.5 0.69, H 8.94 0.16 
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A4.1 Results and discussion 
Chapter A3 reported that undecenyl resorc[4]arene 1a (in the chair 
conformation), due to the relatively simple arrangement of its 
chains, may give different metathesis products by exposure to 
Grubbs catalysts. Under optimized reaction conditions, two major 
products were isolated, namely, the bicyclic alkene 2a (46%) and the 
dimer 3a (5%) (See A3.1.1 Section). The synthesis of compound 2a 
occurs by two almost contemporary RCM reactions, driven by the 
elimination of two molecules of ethylene (Scheme 4.1), which 
proved to be a powerful driving force for intra- and intermolecular 
metathesis (Monfette and Fogg, 2009). The reaction was also 
reported for p-tert-butylcalix[4]arenes, characterized by two similar 
but shorter chains ending with a terminal alkene, which gives the 
corresponding cyclic alkenes (Yang et al., 2007).  
RCM RCM
1a [4a]
2a
Scheme 4.1. Proposed reaction mechanism for the formation of bicyclic alkene 2a 
starting from undecenyl resorc[4]arene 1a.  
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Furthermore, we clearly demonstrated that the dimer 3a is formed 
by reaction of two molecules of 2a (Scheme 4.2) by submitting 2a to 
the same reaction conditions (namely, time, temperature and 
catalyst) as those used for the starting terminal olefin 1a. 
Accordingly, the mechanism was supposed to imply the two 
following steps: (i) the ROM of 2a, and (ii) the concerted double CM 
between the ruthenium-carbene-resorc[4]arene complex 2a[Ru] 
and a second molecule of 2a, passing through the carbene complex 
3a[Ru]. 
Scheme 4.2. Proposed mechanism for the dimerization of resorc[4]arene bicyclic 
olefin 2a. 
A4.1.1 Detection of a ruthenium-carbene-resorc[4]arene 
complex during the progress of a metathesis reaction 
In the current study, we have decided to monitor the formation of 
such ruthenium-carbene-resorc[4]arene complexes by high-
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resolution (600 MHz) 1H and 31P NMR spectroscopy, in order to get 
an exhaustive picture of the mechanism involved. For this purpose, 
resorc[4]arene bicyclic olefin 2a was supposed to react with the 
metathesis catalyst directly into the NMR tube, using a proper 
deuterated solvent. 
The first problem we faced was the choice of the suitable catalyst 
generation: Grubbs and co-workers proposed a general mechanism 
for ruthenium-catalyzed olefin metathesis where dissociation of an 
organophosphine ligand is a critical step in forming a 14-electron 
ruthenacarbene intermediate, which reacts with the olefin to 
generate a four-coordinate intermediate (Sanford et al., 2001). We 
needed a catalyst that had a reduced catalytic activity towards our 
substrate, in order to be able to monitor the reaction step by step. It 
is widely accepted that exists an inverse relationship between 
organophosphine dissociation (i.e., catalyst production) and 
catalytic activity for the two Grubbs catalyst generations: in the bis-
phosphine systems (namely, G1ST), the 14-electron intermediate is 
formed faster than in the second-generation catalysts (G2ND), but 
they show a much lower catalytic activity. The different rates of 
catalyst production in G1ST and G2ND precatalysts have been 
quantitatively attributed to the different energy barriers for the 
rotation of carbene, which also play a key role in the olefin binding 
step (Yang et al., 2011). We therefore decided to use G1ST as the 
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catalyst for the metathesis reaction of resorc[4]arene bicyclic olefin 
2a, since we expected a plausible scenario where the inactive 
rotamer would have been more favored. 
A first experiment was done using a 1:1 resorc[4]arene 2a/G1ST 
ratio, in CDCl3. The 1H NMR spectrum of the catalyst shows a sharp 
singlet centered at 19.98 ppm (see Figure S1 of Section A4.2.7), 
which can be ascribed to the alkylidene proton. The corresponding 
31P NMR spectrum shows the expected signal at 53.37 ppm.  
With regard to the kinetic analysis, the 1H NMR spectrum of the 
freshly prepared reaction mixture shows two well-separated signals 
centered at 19.98 and 19.26 ppm (see Figure S2 of Section A4.2.7), 
due to the native form of the catalyst and the supposed 
intermediate ruthenium complex 3a[Ru], respectively. In the 1D 
TOCSY spectrum, the signal centered at 19.26 ppm gave scalar 
correlations to the methylene protons directly bound to the oxygen 
of the resorc[4]arene bridges (Figure 4.1). In addition, a correlation 
with a signal at 2.75 ppm is detected, attributed to the allylic 
methylene protons. These results indicate that a ruthenium species 
containing phosphorous ligands has been linked to the 
resorc[4]arene core. 
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Figure 4.1. 1D TOCSY (600 MHz, CDCl3, 25 °C, mixing time 150 ms) spectrum of the 
proton at 19.26 ppm; the arrows point to the methylene protons bound to the 
oxygen atom of the resorc[4]arene. 
In the 31P NMR spectrum of the mixture, two distinct resonances at 
53.37 and 52.68 ppm are detected, whose integrated areas are in 
agreement with those detected in the 1H NMR spectrum for the two 
signals centered at 19.98 ppm and 19.26 ppm, respectively (see 
Figure S2 of Section A4.2.7). 
The increase of the 1H resonance at 19.26 ppm during the reacting 
time is followed by a congruent increase of signals (partially 
superimposed to the aromatic resorc[4]arene signals), and centered 
at 6.35 and 6.20 ppm. They were attributed to the two protons of 
the -HC=CHPh system installed on the resorc[4]arene, as clearly 
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demonstrated by the reciprocal scalar correlation and the dipole-
dipole interactions detected between such protons and the phenyl 
(ortho protons) resonance at 7.31 ppm in the 2D ROESY spectrum 
(see Figure S3 of Section A4.2.7). These olefin resonances are J-
coupled to the allylic methylene protons at 2.17 ppm (CH2 at 33.0 
ppm, gHSQC). Their connection to the resorc[4]arene core unit was 
confirmed by TOCSY correlations produced by the signal centered at 
2.17 ppm and the methylene protons directly bound to the oxygen 
of the resorc[4]arene pendants (see Figure S4 of Section A4.2.7).  
In the double bonds region ranging from 5.45 to 5.20 ppm, a new 
resonance at 5.38 ppm appears, which is not present in the 1H NMR 
spectrum of 2a (Figure 4.2a). Moreover, the signals in this spectral 
region have a minor integrated area than that generated by the 
methine protons on the resorc[4]arene bridges (5.02 ppm). 
Interestingly, the lack of integrated area to achieve a 1 to 1 ratio (as 
in 2a) between these two regions (olefin/methine bridge protons) is 
correlated to the integrated area of olefin protons at 6.35 ppm and 
6.20 ppm bound to the phenyl moiety. Such new kinds of double 
bond signals (5.38 ppm and 6.35/6.20 ppm) are formed during the 
reaction at the expense of the internal vinyl protons of the 
resorc[4]arene core (5.31 ppm and 5.33 ppm, Figure 4.2b-c).  
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Figure 4.2. Expansion of the 5.45–4.70 ppm region in the 
1
H NMR (600 MHz, CDCl
3
, 
25 °C) spectra of 2a (a), freshly prepared 1:1 resorc[4]arene 2a/G1ST reaction 
mixture (b) and after 6.5 h reaction time (c). 
As far as the proton(s) resonating at 5.38 ppm, they gave the 1H-13C 
correlation at 130.3 ppm, which is typical of olefin protons, and in 
the 1D TOCSY experiment correlations are detected with the allylic 
methylene at 1.93 ppm (36.3 ppm in the 13C NMR spectrum) to 
methylene protons directly bound to the oxygens of the 
resorc[4]arene pendants (see Figure S5 of Section A4.2.7). This new 
signal corresponds to the internal double bond formed during an 
intermolecular reaction leading to dimer or trimer aggregates. 
We found that the species linked to the metal (both the catalyst and 
the Ru-resorc[4]arene complexes) were subjected to degradation: in 
the 1H NMR spectrum recorded after 22 h from the beginning of the 
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reaction, the singlets at 19.98 and 19.26 ppm disappeared, as well 
as the corresponding 31P NMR resonances (namely, 53.37 and 52.68 
ppm), and several new phosphorous signals were detected (see 
Figure S6 of Section A4.2.7). After degradation, an average diffusion 
coefficient of 1.7  10–10 m2s–1 was measured in the DOSY map (see 
Figure S7-S8 of Section A4.2.7), to be compared to the value of 4.5  
10–10 m2s–1 measured for the starting resorc[4]arene olefin 2a. This 
value confirmed the formation of dimer-to-trimer aggregates. 
The experimental conditions reported up to now allowed us to carry 
out a qualitative characterization of the ruthenium-carbene-
resorc[4]arene 3a[Ru] complex, but the instability of the G1ST 
catalyst in CDCl3 prevented a quantitative characterization of the 
reaction outcome. Therefore, we performed several experiments in 
different solvents and C6D6 was selected as the optimum for the 
more stability of the G1ST catalyst (Bielawski and Grubbs, 2007).  
A4.1.2 Quantitative characterization of the reaction outcome 
The metathesis reaction of resorc[4]arene bicyclic olefin 2a was 
carried out in benzene in static conditions. Two different ratios were 
selected, involving an excess of olefin substrate relative to the 
catalyst (namely, 2a/G1ST 4:1 ratio) or the reverse (2a/G1ST 1:4 
ratio). Extensive purifications of the reaction mixtures by silica gel 
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column chromatography (DCM/ethyl acetate mixtures as eluents) 
led to isolate, among the reaction products, some pure compounds 
and some partially enriched mixtures. In both conditions, unreacted 
starting 2a was recovered (35–40%), along with oligomeric products
which were not isolated. 
The reaction carried out in a 4:1 ratio (2a/G1ST) led to the isolation, 
beside the known dimer 3a (6%), of a new compound 4a (2% yield, 
Figure 4.3), whereas the opposite condition (namely, 1:4 ratio 
2a/G1ST) yielded again product 4a (12.5%), a new compound 5a 
(6%), and two enriched mixtures named I and II (vide infra). The 
characterization of both pure and enriched mixture products 
allowed us to develop an accurate NMR analytical protocol for the 
direct analysis of the crude reaction in a non-invasive fashion. 
3a
CHPhPhHC
4a
PhHC CHPh
CHPhPhHC
5a
Figure 4.3. Schematic representation of the products isolated in the metathesis 
reaction of 2a in benzene with G1ST catalyst (2a/G1ST = 4:1 and 1:4 ratio). For the 
chemical structures of compounds 3a-5a, see A4.2.6 Section. 
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Compounds 4a and 5a proved to be monomers on the basis of their 
diffusion coefficients (D = 3.6  10–10 m2s–1 and 3.8  10–10 m2s–1, 
respectively), which were quite similar to that measured for the 
starting olefin 2a (D = 4.0  10–10 m2s–1 in C6D6). For compound 3a, a 
value of 2.6  10–10 m2s–1 was obtained, according to a dimeric 
assembly.  
Compound 4a (for the structure, see Figure 4.4) shows a loss of the 
symmetry typical of 2a, as well highlighted by inspection of the 
signals due to the resorc[4]arene core protons, the methine bridge 
protons, the O-bound and the C=C-bound methylene protons 
(Figure 4.4a-b). Two typical olefin signals centered at 6.38 ppm and 
6.14 ppm and their integrated areas pointed out the presence of 
two CH=CHPh groups inserted on the resorc[4]arene skeleton. 
Furthermore, only one of the two intramolecular bridges initially 
present in 2a was detected (5.37 and 5.45 ppm). Notably, the 
aromatic protons of A/A’ rings, which are not involved in the 
formation of the intramolecular double bond between two side 
chains, are little affected, producing signals at 6.30 (H11/H23) and 
6.85 (H25/H27) ppm. A strong perturbation was detected, instead, 
for the corresponding protons of B/B’ rings. In particular, the signal 
for the H5/H17 protons centered at 6.08 ppm in the parent 2a 
(Figure 4.4a) is splitted into two signals (1:1 ratio) at 6.07 (for H5) 
and 6.15 (for H17) ppm. In fact, proton H5 is in the same 
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environment as in 2a, whereas H17 is surrounded by the two 
phenyl-bearing chains (see structure in Figure 4.4). The loss of 
symmetry for 4a was confirmed by inspection of the methylene 
protons directly bound to the oxygen, which showed the original 
triplet (at 4.02 ppm), together with two strongly differentiated 
diastereotopic signals at 4.11 and 4.03 ppm (64.3 ppm in the 13C 
NMR spectrum). The quartet at 2.12 ppm was diagnostic of the 
allylic methylene protons directly bound to the CH=CHPh terminal 
portion. The full NMR characterization of compound 4a is given in 
Section A4.2.6. 
Figure 4.4. 1H NMR (600 MHz, C6D6, 25 °C) spectra of compounds 2a (a), 4a (b), 5a 
(c) and 3a (d). 
• = Signals belonging to B ring and its chains; ◦ = signals belonging to B’ ring and its
chains. 
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Compound 5a showed the original symmetry featured by the 
starting bicyclic olefin 2a, and the following patterns (Figure 4.4c): 
the lack of the signals for intramolecular double bonds; the 
aromatic protons H5/H17 of B/B’ rings at the same chemical shift as 
observed for 4a; a 2:1 olefin/methine bridge protons ratio, which 
suggests the presence of four open chains ending with CH=CHPh 
groups (Figure 4.3). The methylene protons directly bound to the 
oxygen and to the CH=CHPh moiety have the same spectral pattern 
found in 4a (Figure 4.4b-c). 
Compound 3a, previously characterized, was identified for the signal 
at 5.53 ppm (130.4 ppm in the 13C NMR spectrum), which confirmed 
the presence of an intermolecular double bond (Figure 4.4d). Any 
CH=CHPh moieties as in 4a or 5a were not detected. All the signals 
were in agreement with the structure already described (See 
Section A3.2.1). 
Purification of the crude mixture obtained from the reaction carried 
out in a 1:4 ratio (2a/G1ST) gave, beside compound 5a, two 
additional reaction mixtures named I and II. To get a picture of the 
plausible structures of such mixtures we used the following two 
parameters (see Table 4.1): (i) the ratio between the integrated 
NMR areas of intermolecular double bonds (5.52 ppm) and olefin 
protons at 6.39 ppm (namely, inter/CH=CHPh ratio); (ii) the ratio 
between the intermolecular (5.52 ppm) and intramolecular (5.45 
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ppm and 5.37 ppm) double bonds (namely, inter/intra ratio). The 
combination of such parameters, which yielded the average number 
of CH=CHPh, intermolecular and intramolecular CH=CH groups, 
allowed the identification of three plausible dimers (namely, 6a-8a) 
whose schematic structures are given in Figure 4.5. The average 
diffusion coefficient measured on the methine bridge protons of 
mixture I was 2.2  10–10 m2s–1, which suggests the prevalence of 
dimers in the mixture. In fact, the ratio between the integrated 
areas of the aromatic protons at 6.08 ppm, due to H5 proton of B 
ring included between intramolecularly bound chains, and the 
aromatic protons H11/H23 of A/A’ rings at 6.32 ppm was 1:4. For 
mixture II, an average diffusion coefficient of 1.5  10–10 m2s–1 was 
obtained, which suggests the presence of trimeric architectures 
built in a similar way as 6a-8a.  
Table 4.1. Ratios between the integrated NMR areas of the different types of 
double bonds expected for 2a, 3a, 6a-8a and NMR experimental values found in 
mixtures I and II and in the reaction mixture with a 4:1 (2a/G1ST) ratio. 
Double bonds 2a 3a 6a 7a 8a    I    II 2a/G1ST = 4:1 
inter/CH=CHPh 0:0 2:0 1:2 1:1 1:4 1:1.8 1:1.1 1.7:1 
inter/intra 0:2 1:1 1:2 2:1 1:1 1.5:1 3.2:1 1:3.6 
Chapter A4 
106 
CHPh
CHPh
PhHC CHPh
CHPh
CHPh
CHPhPhHC
6a 8a7a
Figure 4.5. Schematic representation of the plausible dimers formed in the 
metathesis reaction of 2a in benzene with G1ST catalyst (2a/G1ST = 1:4 ratio). 
The isolation of compounds 4a and 5a from the reaction mixture 
has been taken as an indirect proof of the formation of the 
ruthenium-carbene-resorc[4]arene complex 2a[Ru] (Scheme 4.2), 
the first complex to be formed by ROM of the starting olefin 2a, 
which rapidly evolves to 3a[Ru], by reaction with a second 
molecule. Indeed, when a 4-fold excess of the resorc[4]arene olefin 
2a is used, the ruthenium-carbene-resorc[4]arene complex 2a[Ru] 
leads mainly to the self-metathesis product 3a through a double CM 
with a second molecule of 2a (see Scheme 4.3). When a 4-fold 
excess of catalyst is used, instead, the two carbene complexes 
2a[Ru] and 3a[Ru] undergo a decomposition pathway typical of the 
G1ST catalyst itself (Ulman and Grubbs, 1999), as outlined in Scheme 
4.3. 
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Scheme 4.3. General pathway for the decomposition of ruthenium-carbene-
resorc[4]arene 2a[Ru] and 3a[Ru] complexes. 
As a final refinement of our analytical NMR protocol, we decided to 
reproduce the same metathesis reaction carried out in benzene into 
the NMR tube, and selected, as probe reaction conditions, the 4:1 
(2a/G1ST) ratio. 
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The reaction proceeds with an increase of the species featuring an 
intermolecular double bond (Table 4.2), but the inter/CH=CHPh 
ratio was in favor of species like 3a and 7a (namely, 2:0 and 1:1, 
respectively, see Table 4.1).  
Table 4.2. Integrated NMR areas of the double bonds at different reaction times 
(2a/G1ST = 4:1). 
Time      CH=CH intra       CH=CHPh     CH=CH inter 
1 h 94.2 3.3 2.5 
2.5 h 90.2 4.5 5.3 
23 h 69.7 10.9 19.4 
The decomposition of the catalyst was assessed to occur after 23 h 
of reaction time, on the basis of the complete disappearance of the 
1H NMR signals at 20.60 ppm and 19.80 ppm. As a consequence, the 
intra/inter ratio proved to be > 1 (see Table 4.1), indicating a high 
percentage of the starting olefin 2a. Accordingly, the diffusion 
coefficient, measured on the intermolecular double bond (5.52 
ppm), remains almost constant at 2.5  10–10 m2s–1, which is 
consistent with a dimeric structure, but the diffusion coefficient, 
measured on the protons of the resorc[4]arene bridges is higher (D 
= 3.8  10–10 m2s–1), in agreement with a high percentage of 
unreacted monomer. Moreover, an intermediate diffusion 
coefficient (D = 3.0  10–10 m2s–1), measured on the CH=CHPh 
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double bond, indicates the presence of monomer and dimer species 
containing CH=CHPh moieties. 
These results proved to be in good agreement with those previously 
described for the reaction carried out in the same experimental 
conditions after work-up and purification. 
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A4.2 Experimental section 
A4.2.1 General information 
All manipulations were performed using a combination of glovebox 
and high vacuum under a nitrogen atmosphere. HPLC grade solvents 
were dried and degassed by standard procedures. First-generation 
Grubbs catalyst was purchased from Sigma Aldrich, together with 
QuadraSil AP silica gel and deuterated chloroform (CDCl3, containing 
silver wire as stabilizer). Deuterated benzene (C6D6) was purchased 
from Deutero GmbH. Both solvents were employed without further 
purification.  
A4.2.2 NMR and High-Resolution (HR) MS measurements 
 NMR measurements were performed on a spectrometer
operating at 600 MHz, 243 MHz and 150 MHz for 1H, 31P and 13C
nuclei, respectively. The temperature was controlled to ± 0.1 °C.
The 2D NMR spectra were obtained by using standard sequences
with the minimum spectral width required. Proton 2D gCOSY
(gradient COrrelated SpectroscopY) spectra were recorded with
128-200 increments of 4-16 scans and 2K data points. The
relaxation delay was 1 s. 2D TOCSY (TOtal Correlation
SpectroscopY) spectra were recorded by employing a mixing
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time of 80-120 ms. The pulse delay was 1 s; 256-512 increments 
of 16-32 scans and 2K data points each were collected. 1D TOCSY 
spectra were acquired with 1024-4096 scans in 32K data points 
with a 1 s relaxation delay and a mixing time ranging from 120 to 
150 ms. The 2D ROESY (Rotating-frame Overhauser 
Enhancement SpectroscopY) experiments were performed by 
employing a mixing time ranging from 200 to 600 ms. The pulse 
delay was 1 s; 128-200 increments of 16-32 scans and 2K data 
points each were collected. 1D ROESY spectra were recorded 
using the selective pulse SEDUCE generated by means of the 
Agilent Pandora Software. The selective 1D ROESY spectra were 
acquired with 2048-8192 scans in 32K data points with a 1-5 s 
relaxation delay and a mixing time ranging from 300 to 600 ms. 
gHSQC (gradient Heteronuclear Single Quantum Coherence) and 
HMBC (Heteronuclear Multiple Bond Correlation) spectra were 
recorded by employing a pulse delay of 1 s and 128 or 200 
increments of 32-128 scans. HMBC experiments were optimized 
for a long-range 1H-13C coupling constant of 8 Hz. DOSY (Diffusion 
Ordered SpectroscopY) experiments were carried out by using a 
stimulated echo sequence with self-compensating gradient 
schemes and 64K data points. Typically, g was varied in 20 steps 
(2-32 transients each) and  and were optimized in order to 
obtain an approximately 90-95% decrease in the resonance 
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intensity at the largest gradient amplitude. The baselines of all 
arrayed spectra were corrected prior to processing the data. 
After data acquisition, each FID was apodized with 1.0 Hz line 
broadening and Fourier transformed. The data were processed 
with the DOSY macro (involving the determination of the 
resonance heights of all the signals above a pre-established 
threshold and the fitting of the decay curve for each resonance 
to a Gaussian function) to obtain pseudo two-dimensional 
spectra with NMR chemical shifts along one axis and calculated 
diffusion coefficients along the other. Gradient amplitudes in 
DOSY experiments have been calibrated by using a standard 
sample of D2O 99%. 
 HR mass spectra were obtained using a Fourier-Transform Ion
Cyclotron Resonance Mass Spectrometer (FT-ICR-MS), fitted with
an electrospray ionization (ESI) source.
A4.2.3 Metathesis reaction into the NMR tube 
Resorc[4]arene bicyclic olefin 2a (20 mg, 0.014 mmol) was dissolved 
in CDCl3 (0.35 mL) into a glovebox under a nitrogen atmosphere, 
and the solution was transferred into a NMR tube with a syringe. A 
solution of G1ST [Ru(=CHPh)Cl2(PCy3)2] catalyst (12 mg, 0.014 mmol) 
in CDCl3 (0.35 mL) was then introduced, and the reaction course was 
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monitored, during the time, by 1H NMR, 31P NMR and DOSY 
spectroscopy. 
 
A4.2.4 Metathesis reaction in benzene (2a/G1ST = 4:1) 
 
Resorc[4]arene bicyclic olefin 2a (120 mg, 0.087 mmol) was 
dissolved in benzene (1.5 mL). The solution was exposed to a 
solution of the G1ST [Ru(=CHPh)Cl2(PCy3)2] catalyst (18 mg, 0.0218 
mmol) in benzene (1.5 mL), previously prepared into the glovebox, 
to reach a 3  10–2 M substrate concentration. After stirring for 4 
days at room temperature under a nitrogen atmosphere, the 
reaction mixture was kept heated to 50 °C for 6 h. Afterwards, it 
was cooled to room temperature, treated with QuadraSil AP metal 
scavenger (aminopropyl silica gel, 6 g) and left under stirring 
overnight. After filtration and evaporation, the residue was 
suspended in DCM and purified by silica gel column 
chromatography to give compounds 4a (2.7 mg, 2%, with DCM-ethyl 
acetate, 97 : 3), 2a (48.2 mg, 40%, with DCM-ethyl acetate, 97 : 3) 
and 3a (7.3 mg, 6%, with DCM-ethyl acetate, 95 : 5). 
This reaction was also reproduced into the NMR tube using C6D6 as 
the solvent and monitored, during the time, by 1H NMR, 31P NMR 
and DOSY spectroscopy. 
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A4.2.5 Metathesis reaction in benzene (2a/G1ST = 1:4) 
Resorc[4]arene bicyclic olefin 2a (100 mg, 0.072 mmol) was 
dissolved in benzene (1.2 mL) and exposed to a solution of the G1ST 
[Ru(=CHPh)Cl2(PCy3)2] catalyst (237 mg, 0.288 mmol) in benzene (1.2 
mL), previously prepared into the glovebox, to reach a 3  10–2 M 
substrate concentration. After four days stirring at room 
temperature under nitrogen atmosphere, the reaction mixture was 
heated at 50 °C for 6 h. After stirring for 4 days at room 
temperature under a nitrogen atmosphere, the reaction mixture 
was kept heated to 50 °C for 6 h. Afterwards, it was cooled to room 
temperature, treated with QuadraSil AP metal scavenger 
(aminopropyl silica gel, 6 g) and left under stirring overnight. After 
filtration and evaporation, the residue was suspended in DCM and 
purified by silica gel column chromatography to give compounds 5a 
(7.7 mg, 6%, with DCM-ethyl acetate, 97 : 3), 4a (14.2 mg, 12.5%, 
with DCM-ethyl acetate, 97 : 3), 2a (35 mg, 35%, with DCM-ethyl 
acetate, 97 : 3) and two enriched mixtures products named I and II 
(with DCM-ethyl acetate, 90 : 10). 
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A4.2.6 NMR characterization of metathesis reaction products 
2a–5a 
Compound 2a. White powder. Mp: 191.4–190.4 °C. 1H NMR (600 
MHz, C6D6, 10 mM, 25 °C),  (ppm) = 7.45 (2H, H26/H28, s), 6.87 
(2H, H25/H27, s), 6.31 (2H, H11/H23, s), 6.08 (2H, H5/H17, s), 5.76 
(4H, H2/H8/H14/H20, dd, JCH-29 = 10.1 Hz, JCH-29’ = 5.7 Hz), 5.45 
(0.96H, CH=CH cis, t, 3J = 5.1 Hz), 5.38 (3.04H, CH=CH trans, t, 3J = 
3.8 Hz), 4.01 (8H, O-CH2, t, 3J = 7.1 Hz), 3.52 (12H, 
OMe10’/OMe12’/OMe22’/OMe24’, s), 3.21  
(12H,OMe4’/OMe6’/OMe16’/OMe18’, s), 3.13 (4H, H29’, dd, J29’-29 = 
15.4, J29’-CH = 5.7), 3.06 (4H, H29, dd, J29-29’ = 15.4, J29-CH = 10.1), 2.04 
(8H, CH2-C=C, m), 1.54-1.00 (56H, lateral chains, m). 13C NMR (150 
MHz, C6D6, 10 mM, 25 °C),  (ppm) = 171.9 (CO), 157.2 
(C4/C6/C16/C18), 156.1 (C10/C12/C22/C24), 131.1 (C=C cis), 130.4 
(C=C trans), 128.3 (C3/C7/C15/C19), 127.0 (C25/C27), 126.2 
(C26/C28), 122.6 (CC1/C9/C13/C21), 97.0 (C5/C17), 95.6 (C11/C23), 
64.4 (O-CH2), 55.4 (C10’/C12’/C22’/C24’), 55.3 (C4’/C6’/C16’/C18’), 
40.1 (C29), 33.6 (C2/C8/C14/C20), 32.5 (CH2 allylic), 30.2-26.3 (CH2, 
lateral chains). 
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Compound 3a. White powder. Mp: 167.4−166.4 °C. 1H NMR (600 
MHz, C6D6, 25 °C),  (ppm) = 7.44 (4H, H26/H28, s), 6.86 (4H, 
H25/H27, s), 6.32 (4H, H11/H23, s), 6.11 (2H, H17, s), 6.08 (2H, H5, 
s), 5.75 (4H, H2/H8/H14/H20, dd, JCH-29 = 6.2 Hz, JCH-29’ = 2.4 Hz), 5.73 
(4H, H2/H8/H14/H20, dd, JCH-29 = 5.5 Hz, JCH-29’ = 2.4 Hz), 5.53 (4H, 
CH=CH inter, m), 5.45 (1.08H, CH=CH cis, t, 3J = 5.1 Hz), 5.37 (2.92H, 
CH=CH trans, t, 3J = 3.7 Hz), 4.05 (8H, O-CH2 of B’ rings, m), 4.01 (8H, 
O-CH2 of B rings, m), 3.53 (12H, OMe10’/OMe24’ or 
OMe12’/OMe22’, s), 3.52 (12H, OMe10’/OMe24’ or 
OMe12’/OMe22’, s), 3.23 (12H, OMe16’/OMe18’, s), 3.21 (12H, 
OMe4’/OMe6’, s), 3.13-2.99 (16H, H29/29’ of B and B’, m), 2.07 (8H, 
CH2-C=C inter, m) 2.04 (8H, CH2-C=C intra, m), 1.84-0.70 (112H, 
lateral chains, m). 13C NMR (150 MHz, C6D6, 25 °C),  (ppm) = 171.9 
(CO), 171.8 (CO), 157.2 (C4/C6 or C16/C18), 157.1 (C4/C6 or 
C16/C18), 156.1 (C10/C24 or C12/C22), 156.0 (C10/C24 or C12/C22), 
131.0 (C=C trans), 130.6 (C=C intermolecular), 130.7 (C=C cis), 126.2 
(C26/C28), 127.0 (C25/C27), 122.6 (C3/C7 or C15/C19), 122.5 (C3/C7 
Chapter A4 
117 
or C15/C19), 96.9 (C5/C17), 95.6 (C11/C23), 64.3 (O-CH2), 55.3 
(C10’/C12’/C22’/C24’), 55.2 (C4’/C6’/C16’/C18’), 40.1 (C29), 33.1 
(CH2 allylic), 32.4 (CH2 allylic), 40.3-19.9 (CH2, lateral chains). 
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Compound 4a. Yellow oil. 1H NMR (600 MHz, C6D6, 25 °C), (ppm) = 
7.43 and 7.42 (2H, H26/H28, s), 7.29 (4H, Ho, dd, Jo-m = 8.0 Hz), 7.15 
(4H, Hm, t, Jm-o = Jm-p = 8.0 Hz), 7.06 (2H, Hp, t, Jp-m = 8.0 Hz), 6.85 
(2H, H25/H27, s), 6.38 (2H, C=CH-Ph, d, JCH-CH = 15.9 Hz), 6.30 (2H, 
H11/H23, s), 6.17 (2H, -CH=C-Ph, dt, 2J = 15.9 Hz, 3J = 6.7 Hz), 6.15 
(1H, H17, s), 6.06 (1H, H5, s), 5.75 (2H, H2/H8, m), 5.74 (2H, 
H14/H20, m), 5.45 (0.54H, CH=CH cis, t, 3J = 5.2 Hz), 5.37 (1.46H, 
CH=CH trans, t, 3J = 3.7 Hz), 4.11 (2H, O-CHH, dt, 2J = 10.7 Hz, 3J = 6.9 
Hz), 4.04 (2H, O-CHH, dt, 2J = 10.7 Hz, 3J = 6.4 Hz), 4.02 (4H, O-CH2, t, 
3J = 7.1 Hz), 3.52 (6H, OMe10’/OMe24’ or OMe12’/OMe22’, s), 3.50 
(6H, OMe10’/OMe24’ or OMe12’/OMe22’, s), 3.26 (6H, 
OMe16’/OMe18’, s), 3.20 (6H, OMe4’/OMe6’, s), 3.17 (2H, H29 of B’ 
ring, dd, 2J = 15.7 Hz, 3J = 5.3 Hz), 3.13 (4H, H29’ of B ring, dd, 2J = 
15.3 Hz, 3J = 6.1 Hz), 3.08 (2H, H29 of B ring, dd, 2J = 15.3 Hz, 3J = 3.6 
Hz), 3.04 (2H, H29’ of B’ ring, dd, 2J = 15.7 Hz, 3J = 5.0 Hz), 2.12 (2H, 
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CH-C=C, q, 3J = 7.6 Hz), 2.04 (2H, CH-C=C, q, 3J = 6.1 Hz), 1.54-0.84 
(56H, lateral chains, m). 13C NMR (150 MHz, C6D6, 25 °C), 
171.9 (CO), 171.8 (CO), 157.2 (C4/C16, C6/C20), 156.1 (C10/C24, 
C12/C22), 138.4 (Ar quaternary), 131.1 (C=C-Ph, C=C cis), 130.5 
(C=C-Ph), 130.4 (C=C trans), 127.0 (C25/C27, Cp), 126.5 (Cm), 126.3 
(Co), 126.2 (C1/C13, C9/C21, C26/C28), 122.7 (C3/C15, C7/C19), 
96.9 (C5, C17), 95.6 (C11/C23), 64.4 (O-CH2), 64.3 (O-CH2), 55.4 
(C10’/C24’, C12’/C22’), 55.3 (C4’/C6’, C16’/C18’), 40.2 (C29), 39.8 
(C29), 33.6 (C2/C8/C14/C20), 33.5 (CH2 allylic), 32.6 (CH2 allylic), 
37.7-23.0 (CH2 lateral chains). HRMS (ESI- FT-ICR) m/z: [M + Na]+ 
Calcd for C98H132O16Na 1587.94076 (monoisotopic mass), found 
1587.94248. 
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Compound 5a. White oil. 1H NMR (600 MHz, C6D6, 25 °C), (ppm) = 
7.37 (2H, H26/H28, s), 7.25 (8H, Ho, dd, Jo-m = 8.0 Hz, Jo-p = 1.2 Hz), 
7.11 (8H, Hm, t, Jm-o = Jm-p = 8.0 Hz), 7.01 (4H, Hp, tt, Jp-m = 8.0 Hz, Jp-o 
= 1.2 Hz), 6.79 (2H, H25/H27, s), 6.34 (4H, C=CH-Ph, d, JCH-CH = 15.7 
Hz), 6.26 (2H, H11/H23, s), 6.13 (4H, -CH=C-Ph, dt, JCH-CH = 15.7 Hz, 
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JCH-CH2 = 6.9 Hz), 6.10 (2H, H5/H17, s), 5.69 (4H, H2/H8/H14/H20, dd, 
JCH-29 = 5.5 Hz, JCH-29’ = 10.4 Hz), 4.08 (4H, O-CH2, dt, 2J = 10.5 Hz, JCH2-
CH2 = 6.8 Hz), 4.00 (4H, O-CH2, dt, 2J = 10.5 Hz, JCH2-CH2 = 6.8 Hz), 3.47 
(12H, H10’/H22’, H12’/H24’, s), 3.21 (12H, H4’/16’, H6’/H18’, s), 
3.13 (4H, H29, dd, J29-29’ = 15.8 Hz, J29-CH = 5.5 Hz), 3.04 (4H, H29’, dd, 
J29’-29 = 15.8 Hz, J29’-CH = 10.4 Hz), 2.08 (8H, CH-C=C, q, JCH-CH = JCH-CH2 = 
7.10 Hz), 1.50-0.8 (56H, m). 13C NMR (150 MHz, C6D6
= 171.5 (CO), 156.8 (C4/C16, C6/C20), 155.7 (C10/C22, C12/C24), 
138.0 (Ar quaternary), 130.7 (C=C-Ph), 130.1 (C=C-Ph), 126.7 
(C25/C27, Cp), 126.0 (Co), 125.8 (C1/C13, C9/C21, C26/C28, Cm), 
122.3 (C3/C15, C7/C19), 96.5 (C5/C17), 95.3 (C11/C23), 64.0 (O-
CH2), 55.0 (C4’/C16’, C6’/C18’, C10’/C22’, C12’/C24’), 39.5 (C29), 
33.2 (C2/C8/C14/C20), 33.1 (C allylic), 37.2-22.9 (lateral chains). 
HRMS (ESI-FT-ICR) m/z: [M + Na]+ Calcd for C112H144O16Na 
1768.03466 (monoisotopic mass), found 1768.03373 ± 7.02 10–4 u 
(mean value of 7 experiments). 
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A4.2.7 Supplementary figures 
Figure S1. 1H NMR (600 MHz, CDCl3, 25 °C) and 31P NMR (243 MHz, CDCl3, 25 °C) 
spectra of the G1ST catalyst (2 mM). 
Figure S2. Expansion of the high-frequencies regions of 1H NMR (600 MHz, CDCl3, 
25 °C) and 31P NMR (243 MHz, CDCl3, 25 °C) spectra of the reaction mixture of 2a 
with G1ST (a) immediately after preparation and (b) after 40 min. 
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Figure S3. 2D ROESY (600 MHz, CDCl3, 25 °C, mixing time 300 ms) map of the 
reaction mixture; expansion of the aromatic/olefin zone. 
Figure S4. 1D TOCSY (600 MHz, CDCl3, 25 °C, mixing time 150 ms) spectrum of the 
proton at 2.17 ppm. The arrows point the methylene protons bound to the oxygen 
and the olefin protons of the double bond directly bound to the phenyl moiety of 
the side chains. 
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Figure S5. 1D TOCSY (600 MHz, CDCl3, 25 °C, mixing time 150 ms) spectrum of the 
proton at 5.38 ppm. The arrows indicate the methylene protons bound to oxygen 
and the allylic protons at 1.93 ppm. 
Figure S6. 31P NMR (243 MHz, CDCl3, 25 °C) spectrum of the reaction mixture after 
degradation. 
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Figure S7. DOSY map (600 MHz, CDCl3, 25 °C) of resorc[4]arene olefin 2a. 
Figure S8. DOSY maps (600 MHz, CDCl3, 25 °C) after 22 h reaction time. 
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B1.1 Metabolomics overview 
Metabolomics is a natural extension of genomics, transcriptomics, 
and proteomics (Figure 1.1), but instead of monitoring changes in 
the expression of genes or proteins, metabolomics monitors 
changes in the concentration of the low-molecular-weight (<1 kDa) 
compounds (metabolites) present in a cell, tissue, organ, organism, 
or biofluid (urine, plasma, cerebrospinal fluid, etc.) (Oliver et al., 
1998; Nicholson et al., 1999).  
Figure 1.1. The metabolome is tightly connected with other “omes”. The 
metabolome interacts and reflects the activity of the genome, transcriptome, and 
proteome. (Reproduced from Stringer et al., 2016) 
The metabolome is the entire collection of small molecules or 
metabolites within a biological sample that may include amino 
acids, carbohydrates, cofactors, fatty acids, nucleotides, and even 
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xenobiotics that includes drugs and drug-associated metabolites. 
Importantly, changes in the metabolome or in a specific metabolite 
are a direct result of changes in the biological activity of an enzyme 
or protein, as they are down-stream products of gene transcription 
and translation. Correspondingly, metabolomics approaches, 
compared to other “omics” techniques, can provide a clearer 
picture of the phenotype of the cell or biological system: the 
changes in the metabolome capture how the system responds to 
environmental or genetic stress (Fiehn, 2002). Specifically, a drug or 
an active chemical lead would be expected to perturb the 
metabolome of a cell or tissue upon treatment.  Targeted and 
untargeted metabolomics are two distinctly different approaches to 
investigating the metabolome. In particular, a targeted 
metabolomics approach follows changes to a specific metabolite or 
set of metabolites based on some prior information or hypothesis. 
The identified or targeted metabolites are expected to respond to a 
drug treatment, disease state, genetic modification, or some other 
environmental stressor. This approach takes advantage of the 
comprehensive understanding of a vast array of metabolic enzymes, 
their kinetics, end products, and the known biochemical pathways 
to which they contribute. Conversely, untargeted metabolomics is 
discovery based. The main aim of untargeted metabolomics is to 
monitor the entirety of the metabolome in order to identify the 
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affected metabolites and pathways. This approach requires the 
identification of unknown metabolites using either in silico libraries 
or experimental investigation through analytical chemistry. In either 
case, the metabolome extracted from cells or biofluids are 
compared before and after the addition of the stress factor (drug 
treatment, genetic mutation, disease, etc.). A variety of analytical 
technics are used to identify changes in the concentrations and 
fluxes of endogenous metabolites, but the high precision of mass 
spectrometry (MS) and the reproducibility of nuclear magnetic 
resonance (NMR) spectroscopy combined with their ability to 
elucidate chemical structures have resulted in these being the two 
most commonly employed methods.  
B1.1.1 Important issues related to metabolomics 
Metabolomics is a valuable tool of chemical and systems biology, 
and its application has been rapidly expanding. Recent 
developments in the use of metabolomics involve the 
characterization and interpretation of the cell metabolome, starting 
from prokaryotes (especially Escherichia coli) to eukaryotes cell lines 
(yeast or mammalian cells) (Tang, 2011; Cuperlovic-Culf et al., 
2010). Complementary to the classic biofluid analyses, the 
metabolomic profiles of cells represent a powerful tool to 
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understand how the local metabolism and biochemical pathways 
are influenced by pathologies and by external or internal stimuli. In 
particular, the metabolome analysis of cells grown in vitro provides 
important information for the development of models of biological 
pathways and networks. In vitro cell metabolomics analysis offers 
several advantages: experimental variables are easier to control, 
higher reproducibility, less expensive and easier to interpret than 
analysis of animal models and human subjects (Zhang et al., 2013a). 
The use of mammalian cells is emerging in the metabolomics field in 
order to understand the molecular mechanism of disease 
progression, the cellular response to drug treatments (Bai et al., 
2011) and the cell culture monitoring (Panopoulos et al., 2012). In 
particular, the identification and characterization of cancer cell 
metabolomic signature may play an important role in the early 
diagnosis as well as in the following therapeutic response, making it 
possible to map the drug action into metabolic pathways (Serkova 
and Glunde, 2009).  
The ease of use and general utility has contributed to the 
continually increasing number of metabolomics studies, also making 
it easy to apply incorrectly. Untargeted metabolomics consists of 
acquiring one-dimensional (1D) 1H NMR spectra for a set of cell 
lysates or biofluid samples that are then analysed using standard 
multivariate statistical analysis techniques (Worley and Powers, 
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2013). The 1D 1H NMR spectra provides a fingerprint of the state of 
the metabolome, where multivariate analyses, such as principal 
component analysis (PCA), partial-least-squares (PLS), and 
orthogonal projection to latent structures discriminant analysis 
(OPLS-DA), determine if the metabolomes differentiate between the 
multiple classes (e.g., drug treated vs untreated cells). PLS and 
OPLS-DA S-plots and loading plots are then used to identify the 
spectral features (i.e., chemical shifts and associated metabolites) 
that primarily contribute to these observed class differentiations. 
The incorrect pre-analytical procedures, involving sample 
preparation, collection and storage, may lead to biologically 
irrelevant changes to the metabolome (Zhang et al., 2013b). Thus, 
inappropriate data processing and analysis protocols may bias the 
metabolomics data set, causing an erroneous interpretation (van 
den Berg et al., 2006; Craig et al., 2006). The lack of model 
validation may imply a class separation in a scores plot that are not 
statistically justified (Kjeldahl and Bro, 2010; Werth et al., 2010; 
Worley et al., 2013). Therefore, a current challenge in the field of 
metabolomics is optimizing and standardizing protocols (Sansone et 
al., 2007; Salek et al., 2013).  
Unlike genomics or proteomics samples, metabolomics samples are 
not static and will change with time and from the handling and 
processing procedures (Canelas et al., 2008): the proof that the 
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observed changes in a metabolomics sample are biologically 
relevant is critical to a successful metabolomics study. Thus, 
multiple replicates of cell samples are grown, harvested, and lysed 
under identical conditions as is practically possible and as quickly as 
possible. Importantly, processing of samples should be completely 
randomized because, at a minimum, a time-bias will be imprinted 
on the samples if each class was processed sequentially. In the same 
way, each step of the process should be performed by the same 
individual. Despite these efforts, significant within class variability 
will occur because of the intrinsic nature of biological samples. 
Thus, it is also critical to prepare enough replicates per class in order 
to obtain statistical relevance to any observed class discrimination. 
Typically, a minimum of 5−10 replicates of cell lysates is required, 
but the sample size increases significantly for a clinical study (Blaise, 
2013). 
Acquiring and processing the NMR spectra for each cell lysate can 
also induce unintended perturbations in the metabolomics data set. 
Randomizing the NMR data collection, utilizing automation, and 
obtaining efficient solvent (water) suppression minimizes these 
issues. Specifically, high-quality water  suppression is required to 
avoid baseline correcting the NMR spectrum: water suppression 
through presaturation has to be employed to reduce the water 
signal in the NMR spectrum, helping observation of the dynamic 
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range of the metabolite concentrations efficiently. A minimal and 
uniform approach to processing the NMR spectrum (Fourier 
transformation and phase correction) is preferred because baseline 
correction, applying a window function, zero filling, and other 
processing steps will modify the data in a biologically irrelevant 
manner. Proper preprocessing of the metabolomics data set, which 
includes removing noise (Halouska and Powers, 2006), 
normalization, scaling, and aligning (or binning), is also necessary for 
a reliable PCA, PLS, or OPLS-DA model and meaningful 
interpretation of the metabolomics data: 
 Removing noise regions eliminates the possibility that
serendipitous covariant noise peaks may contribute to irrelevant
class separation;
 Normalization corrects for the variability in total metabolite
concentration or NMR sensitivity due to experimental
differences in the total number of cells harvested, in the
efficiency in extracting the metabolomes, and potentially due to
changes in instrument performance;
 Scaling accounts for large differences in metabolite
concentrations within a given sample (dynamic range issue) and
prevents intense peaks from dominating the multivariate
statistical analysis;
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 Binning or aligning the spectra corrects for small variations in
peak position and peak shape due to differences in sample
conditions (pH, ionic strength, concentration, etc.) and
instrument variability between replicates.
B1.1.2 Applying metabolomics to cancer research 
The first suitable metabolomic approach for cancer was developed 
in 2003 (Griffiths and Stubbs, 2003). Since then, different types of 
tumors have been studied using this method either to elucidate 
metabolic mechanism or to identify biomarkers (Bu et al., 2012; 
Claudino et al., 2012; Wei et al., 2014; Brunelli et al., 2016). A 
cancer biomarker can be a metabolite (secreted by tumor, 
metabolic pathway or process) that may be employed to diagnose 
cancer, predict patient response towards therapies and monitor 
recurrence. Markers can be employed for diagnosis (to identify early 
stage), prognosis (assess the lethality) and prediction (of patient’s 
response to treatment) of cancer. Biomarkers have been identified 
for many types of tumors including but not limited to cancers of the 
prostate (Sreekumar et al., 2009; Trock, 2011; Teahan et al., 2011), 
breast (Crooke et al., 2006; Riscuta and Dumitrescu, 2012; Simpson 
et al., 2012), ovary (Zhang et al., 2012), colorectum (Yoshie et al., 
2012; Cheng et al., 2012; Leichtle et al., 2012), colon (Denkert et al., 
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2008), kidney (Clyne, 2012), lung (Hori et al., 2011) and bladder 
(Hyndman et al., 2011) as well as leukemia (Tiziani et al., 2009) and 
head (Wei et al., 2014). Various biological matrices, such as plasma, 
serum, urine, cell lines and cells were analysed in these studies. It is 
well known that cancer metabolism differs from that of normal 
tissue. Cancer cells rely on anaerobic metabolism as the source for 
energy, even under physiological oxygen levels. The best studied 
feature of cancer metabolism is central carbon metabolism (CCM) 
and the relationship between glycolysis, the tricarboxylic acid (TCA) 
cycle and oxidative phosphorylation. The general metabolic 
characteristics observed in cancers are summarized in Table 1.1. 
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Table 1.1. General features related to cancer metabolism. 
Feature References 
High glycolytic enzyme activities Weljie et al., 2010 
Expression of the pyruvate kinase isoenzyme 
type M2 
Vander Heiden et al., 2010 
High phosphometabolite levels Mazurek and Eigenbrodt, 
2003 
High rate of channeling of glucose carbons to 
synthetic processes 
Mazurek, 2007 
High rate of pyrimidine and purine de novo 
synthesis 
Jahns-Streubel et al., 1997 
High rate of fatty acid de novo synthesis Brunet et al., 2008 
Low (ATP+GPT)/(CTP+UTP) ratio Fleming et al., 1983 
Low AMP levels Warrington et al., 2010 
A high glutaminolytic capacity Mazurek et al., 1996 
Release of immunosuppressive metabolites Adams et al., 2012 
High level of methionine dependency Crott et al., 2001 
Cells are used extensively in disease research for understanding the 
molecular mechanism of disease progression, response, and 
resistance to therapeutics. Cultivated cell lines, although 
phenotypically and genetically not identical to the original cancer 
types, are still useful models because of their unlimited availability, 
the broad range of cells available, and the flexibility in the design of 
treatment (experimental setup). Cell metabolomics is an emerging 
field that addresses fundamental biological questions and allows 
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observation of metabolic phenomena in cells. Pan et al. (Pan et al., 
2011) exposed four brain cancer cell lines to cisplatin drug and 
subjected to 1H NMR analysis. The result shed light on relation of 
glycosylated UDP compounds (uridine diphospho-N-
acetylglucosamine and uridine diphospho-N-acetylgalactosamine) 
to cancer cell death following chemotherapeutic treatment. 
Serizawa et al. (Serizawa et al., 2014) employed Capillary 
Electrophoresis Time Of Flight Mass Spectrometer (CE-TOF/MS) to 
screen biomarkers for the early detection of resistance to these 
inhibitors, using PC-9ER cells (drug erlotinib-resistant non-small-cell 
lung cancer cell). Enhanced glutamine metabolism was observed in 
the cancer cells that can be explained by the multiple pathways for 
bioenergetics and biosynthesis in proliferating cells. Lefort et al. 
(Lefort et al., 2014) used 1H NMR experiments to profile the effects 
of drugs and concluded that treatment of breast cancer cells (MDA-
MB-231 and MCF-7) with dichloroacetate (a pyruvate 
dehydrogenase kinase inhibitor) and allopurinol (xanthine 
oxidase/dehydrogenase inhibitor) results in more pronounced 
changes in metabolites found in extracellular medium than 
intracellular pools. An elevation in phosphocholine, total choline 
and phosphocholine/glycerophosphocholine level was observed in 
cancer cells compared to control. Furthermore, cell lines have been 
frequently directed to apoptosis phenomenon. An increased 
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concentration of fructose 1,6-bisphosphate was detected in the 
apoptotic HL-60 human leukaemia cell line by Williams and 
colleagues as early as 1998 (Williams et al., 1998). A decrease in the 
phosphocholine concentration in the hamster cell line CHO-K1 was 
detected after treatment with different pro-apoptotic agents 
including camptothecin, ceramide, chelerythrine and etoposide 
(Williams et al., 1998). The accumulation of mobile lipids, which are 
more mobile than most cell lipids (Luciani et al., 2009), was 
described in 2005 as a characteristic of apoptosis in human prostate 
carcinoma (DU145) cells treated with phenylacetate and 
phenylbutyrate (Milkevitch et al., 2005), and in 2008 after induction 
of apoptosis by ionizing radiation and the administration of the 
antineoplastic drug doxorubicin in HL-60 cells (Rainaldi et al., 2008). 
B1.2 The Hedgehog (HH) signaling pathway 
Tumors  are composed of a heterogeneous group of cells. Some 
tumor cell fractions have the ability to initiate tumors in xenograft 
models, whereas other fractions do not. These cells, capable of 
sphere-like growth  in vitro and tumor formation in vivo, are defined 
as cancer stem cells (CSCs) and share similarities with normal neural 
stem cells (NSCs). It has been hypothesized that these cells are 
involved in radio- and chemo-resistance, as well as tumor 
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recurrence. Several signaling pathways that regulate normal stem 
cells can cause neoplastic proliferation when disregulated by 
mutation. In tumor initiating cells those pathways may be 
constitutively activated or improperly regulated through genetic 
and/or epigenetic changes, leading to uncontrolled growth. 
Nevertheless, targeting CSCs alone may not be sufficient to get 
effect cures or long-term remission for most cancers. A 
combinatorial therapy, using conventional chemotherapeutic drugs 
with an agent that can target CSCs may provide a good approach to 
eradicate both cancer cells and cancer stem cells. 
 Cancer stem cells in tumors
The theory that malignancies arise from a small subset of stem-cell-
like cancer cells has received increasing attention during the past 
decade. These cells, referred to as CSCs or cancer-initiating cells 
(CICs), have been identified in many malignancies and are hypoth-
esized to form the clonogenic core of tumor tissues (Figure 1.2) 
(Vermeulen et al., 2008). The origin of CSCs in human tumors is, 
however, not fully understood. Such cells could potentially originate 
from a more-differentiated cancer cell that acquires self-renewal 
properties, perhaps as a result of epithelial-to-mesenchymal 
transition (EMT) (Espinoza and Miele, 2013). Alternatively, CSCs 
might derive from a normal tissue stem cell that undergoes 
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transformation as a result of oncogenic somatic mutations, under 
the influence of extrinsic microenvironmental factors (Reya et al., 
2001; Krivtsov et al., 2006).  
Figure 1.2. The cancer 
stem cell hypothesis. The 
cancer stem cell (CSC) 
hypothesis posits that 
tumor growth is driven by 
a subpopulation of cancer 
cells that are capable of 
proliferation and self-
renewal. CSCs are also 
multipotent and can give 
rise to the diverse set of 
cells that make up a given 
tumor. Inherent within 
this hypothesis is the 
assumption that current treatments for cancer can considerably diminish tumor 
burden, but have a decreased effect on CSCs, which are later capable of driving 
tumor recurrence and regrowth. To achieve cancer remission or cure, therefore, it 
will be necessary to develop novel therapies that are cytotoxic to CSCs. 
(Reproduced from Das et al., 2008) 
Although the co-occurrence of subpopulations of cancer cells with 
different tumorigenic properties within individual tumors is no 
longer in question (Pattabiraman et al., 2014), the CSC hypothesis 
remains controversial. This controversy arises as a consequence of 
the technical and logistical challenges in isolating and identifying 
CSCs from human solid tumors that contain heterogeneous cell 
populations, and the limited number of validated surrogate assays 
Chapter B1 
155 
currently available to substantively confirm stem-cell-like properties 
(Tirino et al., 2013). These cells tend to comprise a small fraction of 
total tumor mass and are, therefore, difficult to unequivocally 
identify histologically. Nonetheless, numerous researchers 
hypothesize that treatments targeting the CSC population could be 
more effective than existing therapies, and could dramatically 
transform treatment outcomes in oncology. 
CSCs have been shown to have one or more aberrations in various 
signaling pathways; however, abnormal activity of pathways that 
control stem-cell self-renewal, and have important roles in 
embryonic development and differentiation (Notch, HH, and Wnt) 
are probably most crucial to the tumorigenicity of CSCs. Increasing 
evidence demonstrates that these embryonic pathways can interact 
with other cellular signaling pathways, such as those involving 
nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB), mitogen-activated protein kinase (MAPK), phosphoinositide-
3-kinase (PI3K), and epidermal growth factor (EGF). Therefore, these 
developmental pathways might be important therapeutic targets 
for blockade of CSC self‑renewal and proliferation, and tumor 
progression (Figure 1.2) (Merchant and Matsui, 2010).  
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 The pathway
The HH signaling pathway is implicated in tissue-patterning during 
embryonic development and in normal tissues repair, and EMT 
transition (Beachy et al., 2010; Takebe et al., 2015). Binding of HH 
ligands (Sonic hedgehog (SHH), Indian hedgehog (IHH), or Desert 
hedgehog (DHH)) releases the inhibitory effect of their Patched 
(PTCH) transmembrane receptors on Smoothened (SMO), which is 
also located in the cell membrane (Figure 1.3) (Odoux et al., 2008).  
Figure 1.3. The canonical HH-
signaling pathway and 
pharmacological inhibitors 
targeting this pathway that 
are under ongoing 
development as anticancer 
therapies. The HH-processing 
pathway involves HHC 
autocatalysis, and SKN and 
Dispatched proteins, which 
mediate the release of HHN 
ligands (IHH, DHH and SHH). In 
the absence of HHN binding, 
PTCH interacts with and 
inhibits the activity of SMO; 
HHN binding to PTCH releases its inhibitory effects on SMO, resulting in SMO 
accumulation and sequestration of COS and SUFU proteins in cilia, which releases 
the GLI transcription factors to exert their effects in the nucleus. KIF3A and 
β-arrestin are required for localization of SMO to cilia. GLI1/2 promote a gene-
expression pattern relevant to tumorigenesis. Abbreviations: COS, Costal; DHH, 
Desert hedgehog; HH, Hedgehog; HHC, Hedgehog C-terminal domain; HHN, 
Hedgehog N-terminal domain; HIP, Hedgehog interacting protein; IHH, Indian 
hedgehog; Ptch, Patched; SHH, Sonic hedgehog; SKN, Skinny hedgehog; SMO, 
Smoothened; SUFU, suppressor of fused. (Reproduced from Takebe et al., 2015) 
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Progressively, the signaling cascade initiated by SMO leads to 
activation and nuclear localization of GLI transcription factors, which 
drive expression of HH target genes; most of the target genes are 
involved in proliferation, survival, and angiogenesis (Amakye et al., 
2013). This cascade represents a novel target for cancer therapy, as 
aberrations in the HH-pathway contribute to tumorigenesis and 
tumor growth through several mechanisms. These mechanisms 
include mutations in the key members of the pathway, such as loss-
of-function mutations in PTCH1 gene encoding Patched 1 and gain-
of-function mutation in the SMO gene, that result in ligand-
independent activation of the HH-pathway, as well as ligand-
dependent signaling by either autocrine or paracrine routes 
(Amakye et al., 2013). Mutation-driven mechanisms of HH-pathway 
activation have been demonstrated in some tumors, such as basal-
cell carcinoma (BCC) of the skin, medulloblastoma (MB), and rarely 
rhabdomyosarcoma (Ng and Curran, 2011). Indeed, PTCH1 
mutations are associated with HH-pathway hyperactivation in >90% 
of BCCs and 30% of adult MB (Kool et al., 2014). The aetiology of 
rhabdomyosarcomas, although thought to originate by a similar 
mechanism, is controversial (Roma et al., 2012). Moreover, some 
studies have focused their attention to the role of HH-GLI signaling 
in glioma stem cells (GSCs) and found that it regulates self-renewal 
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and tumorigenic potential in GSCs (Clement et al., 2007; Uchida et 
al., 2011; Po et al., 2010; Hsieh et al., 2011; Liu et al., 2014).  
Similarly to the Notch cascade, HH-signaling can involve canonical 
and noncanonical pathways. Canonical signaling follows the PTCH1-
SMO-GLI axis (Figure 1.3), whereas noncanonical pathways can be 
SMO-independent (Amakye et al., 2013). The noncanonical signals 
are largely attributed to various tumor-associated signaling 
pathways integrating with HH-signaling, in part by influencing the 
activity of GLI transcription factors (Amakye et al., 2013).  
 Resistance mechanism
The most clinically advanced agent targeting the HH pathway is 
vismodegib (a direct cyclopamine-competitive SMO antagonist), 
which was approved by the US FDA in 2012 and by the European 
Medicines Agency (EMA) in 2013 for the treatment of metastatic 
BCC, or locally advanced BCC in patients who are not candidates for 
surgery or radiotherapy (Sekulic et al., 2012; Dirix, 2014).  
To date, clinical efficacy has not been demonstrated in trials of SMO 
inhibitors, except in patients with tumors driven by mutations in 
components of the HH-signaling cascade, such as SMO and PTCH1 
(Von Hoff et al., 2012). Primarily, possible reasons for the resistance 
to HH-inhibitor monotherapy and the lack of additional efficacy or 
benefit in combination with chemotherapy, compared with the 
Chapter B1 
159 
outcomes of chemotherapy alone, include insufficient drug 
concentrations in the stroma. This resistance mechanism has been 
discussed by Graham and colleagues (Graham et al., 2011), who 
described an unusual pharmacokinetic profile for vismodegib, owing 
to high-affinity, reversible binding to plasma proteins, solubility-
limited absorption, and slow metabolic elimination. Moreover, a 
mutation in the gene SMO (D473H) was detected in a patient with 
MB after 3 months of treatment with vismodegib who harbored a 
PTCH1 mutation in both primary and metastatic lesion biopsies 
taken before therapy (Yauch et al., 2009). The SMO D473H mutation 
was present only after tumor progression and caused disruption of 
the vismodegib-binding site on SMO, and was, therefore, 
considered as the cause of the acquired resistance (Yauch et al., 
2009). Compensatory upregulation of other signaling represents 
another potential resistance mechanism; for example, primary 
resistance to SMO inhibitors can be due to noncanonical activation 
of GLI transcription factors through pathways that bypass SMO and, 
in turn, the effects of SMO inhibitors (Ramaswamy et al., 2012). 
During the last decade, GLI factors are emerging as attractive 
targets for the development of novel anticancer drugs. A few GLI 
inhibitors have been identified, such as GANT61 (Lauth et al., 2007) 
and arsenic trioxide (ATO) (Kim et al., 2010) (Figure 1.4) and they 
have shown a good inhibitory effect on HH-dependent transcription 
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and MB growth in vitro and in vivo. However, none of these drugs 
have entered into clinical trials to date, mostly due to their potential 
toxicity or lack of specificity is still a major concern.  
Figure 1.4. GANT 61 and ATO chemical structures. 
B1.2.1 The role of HH-pathway in cancer cells metabolism 
Cells of high-grade tumors, including MB and glioblastoma (GBM), 
must similarly balance energy metabolism with the need to 
synthesize the macromolecules essential for tumor growth. In most 
mammalian cells, glycolysis (literally lysis of glucose) is inhibited by 
the presence of oxygen, which allows mitochondria to oxidize 
pyruvate to CO2 and H2O (oxidative phosphorylation). This inhibition 
is termed the “Pasteur effect”, after Louis Pasteur, who first 
demonstrated that glucose flux was reduced by the presence of 
oxygen (Racker, 1974).  Cells with large ATP requirements are likely 
to be disadvantaged by aerobic glycolysis (conversion of glucose to 
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lactic acid in the presence of oxygen) because glycolysis generates 
less ATP per molecule of glucose than oxidative phosphorylation (2 
ATP vs 38 ATP, respectively). Proliferating cells, however, may use 
aerobic glycolysis to satisfy the competing needs for both energy 
generation and the accumulation of biomass. This phenomenon 
(termed “Warburg effect”) was first described by Warburg in the 
1930s (Warburg, 1930), leading him to the hypothesis that cancer 
results from impaired mitochondrial metabolism (Figure 1.5). Unlike 
oxidative phosphorylation, aerobic glycolysis also generates 
metabolic intermediates that can be used for lipid (lypogenesis) and 
nucleic acid biosynthesis.  
Figure 1.5. Cells metabolism. Warburg's theory on the origin of cancer postulates 
that tumor cells have defects in mitochondrial oxidative phosphorylation and 
therefore rely on high levels of aerobic glycolysis as the major source for ATP to 
fuel cellular proliferation. This was in contrast to normal cells, which primarily 
utilize oxidative phosphorylation for growth and survival. 
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In 2014, it has been demonstrated that HH-pathway activation in 
granule cell progenitors (GCPs), the cells from which MB arises, 
induces transcription of hexokinase 2 (HK2) and pyruvate kinase M2 
(PKM2), two key gatekeepers of glycolysis (Di Magno et al., 2014). 
The process is mediated by the canonical activation of the GLI 
transcription factors by upregulanting PKM2 and HK2 mRNA levels 
and causes a robust increase of extracellular lactate concentration. 
These studies have shown by quantitative PCR analysis how both 
HK2 and PKM2 transcripts are significantly upregulated after 
treatment with SHH or the SMO agonist SAG (Figure 1.6), inducing a 
robust increase of the lactate released in the medium, that is 
conversely counteracted by ATO (direct GLI inhibitor). Since in 
metabolic tissues and fibroblasts the activation of SMO promotes 
Warburg-like effect (Teperino et al., 2012), through a rapid GLI-
indipendent and AMPK-mediated activation of key glycolytic 
enzymes, further demonstration of GLI-dependent mechanism 
arises from the incubation of GCPs cells with purmorphamine, a 
SMO agonist that selectively activates the canonical GLI-dependent 
route (Di Magno et al., 2014). Importantly, aerobic glycolysis plays a 
key role also in GBM tumor that, like MB, shows high expression in 
Hk2 enzyme and high glucose uptake. 
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Figure 1.6. The SMO agonist SAG chemical structure. 
In 2015, a joint investigation between our research group featuring 
a large expertise in the synthesis and isolation of natural products 
and experts in the molecular medicine of brain tumors was 
published, aimed at identifying the first naturally occurring small 
molecule capable of  interfere with GLI activity (Infante et al., 2015). 
In particular, we identify the natural isoflavone Glabrescione B 
(GlaB) (Figure 1.7) as the first small molecule binding to GLI1 zinc-
finger and impairing GLI1 activity by interfering with its interaction 
with DNA (Infante et al., 2015). Remarkably, as a consequence of its 
robust inhibitory effect on GLI1 activity, GlaB inhibited the growth 
of HH-dependent MB and BCC tumor cells both in vitro and in 
orthotopic xenograft mice and in allograft mice models, as well as 
the self-renewal ability and clonogenicity of tumor-derived stem 
cells (Infante et al., 2015).  
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Figure 1.7. GlaB chemical structure. 
On the basis of these evidences, targeted and untargeted NMR 
metabolomics analyses of HH-dependent tumor cells and the 
corresponding conditioned media would be able to figure out how 
the GlaB-treatment affects cell metabolism as a consequence of 
GLI1 inhibition. 
Chapter B2 
165 
Chapter B2 
Cell Metabolomics: a Strategy to Study 
Crucial Pathways in Cancer Development 
B2.1  Results and discussion 167 
B2.1.1    Brain cancer cell models 167 
B2.2   Cell metabolomics: protocol optimization and 
experimental design 173 
B2.2.1  Metabolic profile 177 
 DAOY cell line 179 
 GL261 cell line 183 
B2.2.2 Metabolic pathway analysis 187 
B2.3 Experimental Section 194 
B2.3.1 Materials 194 
B2.3.2 Cell culture and NMR sample preparation 195 
B2.3.3 NMR experiments  198 
B2.3.4 Spectral analysis 200 
B2.3.5 Metabolite statistical analysis 201 
B2.3.6 Supplementary figures 202 

Chapter B2 
167 
B2.1 Results and discussion 
The present part of the thesis deals with a research activity carried 
out at the Centro di Risonanza Magnetica (CERM) at the Università 
degli Studi di Firenze, under the supervision of Prof. Paola Turano. 
B2.1.1 Brain cancer cell models 
Human cancer research heavily relies on molecular biology, which, 
among other methods, includes controlled studies in culture cell 
lines. Even though typical commercially available cell lines often 
differ from normal and cancer cells, difficult access to human tumor 
and/or human normal tissue makes them useful and popular 
experimental models. Two standard tumor brain cell lines DAOY, 
human MB cells, and GL261, murine glioma cells, are widely used in 
studies that employ experimental models of brain neoplastic 
disease. 
MB, the most common malignant brain tumor in children, is a 
primitive neuroectodermal tumor arising in the cerebellum. The 
aggressive clinical behavior of the tumor along with the cognitive 
and endocrinological long-term side effects of current therapies 
mean that both the development of prognostic indicators for 
disease stratification and the identification of new therapeutic 
targets represent major goals. Current understanding of the 
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molecular biology of MB is limited. Cytogenetic studies have 
described consistent chromosomal aberrations, but molecular 
genetic studies have identified specific genetic and epigenetic 
abnormalities in only a small proportion of those tumors 
(Giangaspero et al., 2000; Ellison, 2002; Jones and Baylin, 2002). The 
DAOY cell line was established in 1985 by Jacobsen from the Royal 
Perth Hospital in Western Australia (Jacobsen et al., 1985). The line 
was derived from the biopsy material taken from a tumor in the 
posterior fossa of a four-year-old boy. Although the original tumor 
presented characteristics of both neuronal and glial phenotypes, 
these were not retained by the DAOY cell line. In the DAOY model, 
SHH consistently induced GLI1 mRNA, a biomarker of pathway 
activity (Scales and de Sauvage, 2009) and, therefore, these cells are 
useful for the pharmacological examination of the HH-pathway.  
On the basis of the crystallographic structure of the zinc finger 
domain of GLI1 (GLI1ZF) in complex with DNA (Pavletich and Pabo, 
1993), together with NMR studies as well as computational and 
experimental mutagenesis, we clarified the structural requirements 
of GLI1/DNA interaction and identified GlaB as a novel small 
molecule that binds GLI1ZF and interferes with its interaction with 
DNA (See Section B1.2.1). This small molecule turned out to be an 
efficient inhibitor of the growth of HH/GLI-dependent MB cells in 
vitro and in vivo (Infante et al., 2015). In the present study, the HH-
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dependent DAOY tumor cells, belonging to the SHH MB subgroup, 
were taken into account as model to elucidate the direct effect of 
GlaB on GLI, knocking down GLI1 and GLI2 by siRNA. GlaB proved 
unable to repress PTCH1 mRNA levels in siGLI1/GLI2-knocked down 
DAOY cells, indicating that the presence of GLI factors is required for 
GlaB activity (Figure 2.1). 
  
Figure 2.1. PTCH1 mRNA expression levels (left panel) were determined by qRT–
PCR in DAOY cells transfected with siRNA specific for GLI1 and GLI2 (siGLI1/2) or a 
non-specific control siRNA (siCTR) and treated for 24 h with GlaB or DMSO as a 
control. (right panel) The graph shows GLI1 and GLI2 mRNA expression levels 
determined by qRT–PCR in DAOY cells transfected with siGLI1/2 or siCTR. Results 
are expressed as fold repression relative to control, and data were normalized to 
GAPDH and HPRT expression. 
 
Moreover, to confirm the inhibitory effect of GlaB to impair MB 
tumor growth in vivo, the human MB DAOY cell system were 
implanted into the cerebellum of NOD/SCID mice. Tumor volume 
displayed a significant reduction of the tumor mass formed by DAOY 
cells in GlaB-treated mice compared to the control. 
Chapter B2 
170 
Gliomas are the most frequent and lethal cancers originating in the 
central nervous system (CNS) in adults. Despite current treatments 
consisting of surgery followed by adjuvant radiotherapy and 
chemotherapy, GBM patients display a median overall survival of 
only 14.6 months. Even though significant advances in cancer 
molecular targeting have been made, several promising preclinical 
results revealed poor translatability. 
The application of suitable animal models in glioma research is 
necessary for the development of new therapeutic approaches. An 
ideal animal model of human glioma should reproduce the major 
features of this neoplasm: predictable and reproducible in vitro and 
in vivo growth patterns; infiltrative, but non-metastatic, tumor 
growth; and poor immunogenicity. A number of animal brain tumor 
models are being used; however, no model currently available 
simulates human high-grade gliomas exactly. Tumor models vary in 
their immunogenicity, growth patterns and invasiveness. For this 
reason, it is important to choose an appropriate animal model 
depending on the endpoint examined. Most models are derived 
from rat and several xenograft models, based on the intracerebral 
transplantation of human brain tumors into immune-deficient nude 
mice, are also available. Murine models of malignant brain tumors 
are used much less frequently, mainly because the number of 
available models is limited. One of the most frequently used murine 
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brain tumor models is GL261. The GL261 tumor was induced 
originally by intracranial injection of 3-methylcholantrene into 
C57BL/6 mice and maintained by serial intracranial and 
subcutaneous transplantations of small tumor pieces on the 
syngeneic mouse strain (Ausman et al., 1970). Perhaps, because of 
these serial passages, GL261 lacks the most important glial 
differentiation marker, such as the glial fibrillary acidic protein 
(Weiner et al., 1999). During the mid-1990s, in vitro growing cell 
cultures were established from the GL261 tumor, that was used in 
many immune therapeutic and gene therapeutic investigations. A 
subset of GBM tumors display enhanced HH-signaling, and this can 
be recapitulated in vitro, where some GBM cell lines proliferate in 
response to SHH treatment (Morgenroth et al, 2014). In particular, 
the GL261 cell model contains a small subpopulation of CSCs which  
overexpress the HH-pathway. 
Since we observed  that GLI1 is expressed in these cells and that its 
expression is reduced of about 20% if they were treated with GlaB 5 
μM for 48 hours, the MTT assay was performed in order to estimate 
the toxicity of free GlaB on this cell system. As reported in Figure 
2.2, a dose- and time-dependent reduction in cell viability was 
observed: cytofluorimetric cell count after 48 h revealed a reduction 
of total cell number of about 80% in samples seeded in the presence 
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of GlaB 5 µM and 10 µM and, after experimental times 72 h and 96 
h, of about 50% at the same concentrations.   
Figure 2.2. In vitro cytotoxicity of GlaB on GL261 cell line. Cells were incubated 
with GlaB for 48 h, 72 h and 96 h at increasing drug concentrations (1 – 100 μM). 
Cell viability, expressed as a percentage of control untreated cells, was determined 
by MTT assay after 48 h, 72 h and 96 h incubation with GlaB treatments.  
Moreover, the analysis  of early apoptosis in cells treated with GlaB 
5 µM after 48 h, revealed by the double positivity to Annexin V and 
PI, showed a 10% increase of the percentage of apoptosis with 
respect to the untreated cells.  
In vivo studies were also performed to evaluate the GlaB effect on 
tumor volume upon intraperitoneal and  intranasal administrations,  
using murine GL261 glioma cells-bearing mice (8 week-old male 
mice, C57BL/6 strain, 20-25 g). The experimental data have shown 
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that intranasal and intraperitoneal GlaB administration reduced 
tumor volume compared to vehicle treated mice at 4.4 mg/Kg and 
35 mg/Kg concentrations, respectively. Notably, the intranasal 
administration seems as effective as intraperitoneally at 
concentrations about 8 times lower. 
B2.2 Cell metabolomics: protocol optimization and 
experimental design  
Cell metabolomics has emerged as a promising tool with wide 
applications in many research areas (Zhang et al., 2013a). 
Metabolomics represents a very good approach to explore the cell 
phenotype and to have an overall portrait of the biological process 
under investigation. This analytical approach offers advantages with 
respect to animal models or to experiments involving human 
subjects. The advantages include an easier control of the 
experiments, a greater reproducibility and an easier and more direct 
interpretation of the results. 
Many possible applications for cell metabolomics have been 
described, including studies aimed at characterising cellular 
responses to toxicity and environmental factors, as well as to 
expression of oncogenic molecules and treatment with drugs (Bayet-
Robert et al., 2009; West et al., 2010; Kleinstreuer et al., 2011; Bai et 
al., 2011; Paglia et al., 2012; Chong et al., 2012).  
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A key condition for in vitro cell studies is to achieve reliable and 
reproducible models that are representative of the in vivo situation: 
sample preparation and metabolism quenching represent 
fundamental aspects (León et al., 2013). Depending on the 
experimental plan, the metabolomics analysis would be focused on 
the endo-metabolome (all the metabolites present inside the cell), 
the exo-metabolome (all the metabolites in the surrounding 
extracellular medium), or both.  
In the present study, we analysed the effects of GlaB treatment on 
the endo- or/and on the exo-metabolome of two different cancer 
cell lines, the human MB DAOY and the GL261 cells, respectively.  
For this purpose, a simple, fast, and reproducible sample 
preparation protocol was developed, as reported in the Section 
B2.3.2; the analysis of the cellular lysates was performed to detect 
as many metabolites as possible and to avoid extraction procedures. 
Indeed, the metabolomics analysis of cellular extracts suffers from 
accuracy problems coming from differences in solubility of the 
various metabolites, variations in individual metabolite extraction 
efficiencies, and chemical destruction of some metabolites. In order 
to overcome all the inconveniences of the extraction procedures, 
the here developed protocol was performed by analysing the 
cellular cytosolic fraction using high-field profiling of standard 
solution of cell lysates. After an intense washing procedure to 
Chapter B2 
175 
remove the medium residues, the cells were detached from the 
dishes by mechanical scraping and quenching of the cellular activity 
was performed using protease and phosphatase inhibitors, in order 
to assure minimal changes in the metabolome and avoid misleading 
results. Subsequently, the cell lysis was carried out by sonication in 
multiple short bursts, while the sample was put into an ice bath, 
and the removal of all macromolecular waste products (cell 
membrane components and cellular debris) performed by 
centrifugation. The optimized protocol (Figure 2.3A) can be 
summarized in the following main steps: (i) growth of the cell 
culture; (ii) cell washing; (iii) cell scraping; (iv) quenching with 
protease and phosphatase inhibitors; (v) cell lysis by sonication; and 
(vi) centrifugation. Furthermore, the cell culture media are 
characterised by the presence of foetal bovine serum (FBS) thus, 
these samples were considered and analysed according to standard 
procedures for the NMR metabolomics analyses of human plasma 
and serum (Beckonert et al., 2007). 
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Figure 2.3. (A) General scheme describing the whole sample preparation protocol. 
(B) Overview of the experimental design.  
In order to reduce bias in the interpretation of the experiments, it 
was decided to produce various biological replicates for each 
treated cell (from five to seven, namely with GL261_GlaB_1-5 and 
DAOY_GlaB_1-7). Furthermore, the corresponding control samples 
for each cell system (untreated ones) were also collected (from five 
to seven, namely GL261_CTR_1-5 and DAOY_CTR_1-7). Moreover, 
the culture medium of each cell growth was gathered for the exo-
metabolome analysis and the produced samples were then analysed 
by high-resolution 1H NMR spectroscopy. The whole design of 
experiment is summarized in Figure 2.3B. The most efficient dose 
and drug exposure duration time of cell culture were used on the 
basis of previous biological assays (see Section B.2.1.1).  
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B2.2.1 Metabolic profile 
The 1D 1H NMR spectra were acquired to determine the metabolic 
fingerprints of the treated and untreated cancer cells. The two cell 
lines used in this study revealed different metabolic signature. The 
cell lysates and the corresponding conditioned media were 
subjected to NMR analysis. The NMR spectra of cell lysates acquired 
24 hours for the DAOY cell line and 48 hours for GL261 cell system 
after seeding are shown in Figure 2.4. As the 1H NMR spectra from 
different measurements for each cell line displayed almost identical 
spectral profiles, only one of the replicates is shown in Figure 2.4. 
These observations indicated that metabolic profiles of the 
independently grown cell system were highly reproducible under 
the same culture conditions.  
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Figure 2.4. DAOY and GL261 cell lines assignment. (A) Upfield region (0.8  ̶  4.4 
ppm) of the 1H CPMG NMR spectrum along with the assignment of the most 
intense metabolites. (B) Downfield region (DAOY: 5.4 ̶ 9.0 ppm; GL261: 5.2   ̶ 8.6 
ppm) of the 1H CPMG NMR spectrum along with the assignment of the less intense 
metabolites.  
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The resonance assignments of the major metabolites in the spectra 
were performed using a NMR spectra library of pure organic 
compounds (AMIX software), public databases (i.e. Human 
Metabolome Database-HMBD, http://www.hmdb.ca) storing 
reference NMR spectra of metabolites, spiking NMR experiment and 
using data available in literature. As a result, around 30 metabolites 
were identified, which provided information for assessing variations 
in metabolic profiles after drug administration.  
The 1D 1H NMR spectra were processed and studied using a 
completely untargeted and unbiased multivariate data analytical 
approach. The aim was to identify the perturbation in the metabolic 
signatures associated with response to treatment for each tested 
cell. For this purpose, a principal component analysis (PCA) was 
performed on the NMR spectra.  
 DAOY cell line
Our previous studies identified GlaB as an efficient inhibitor of the 
growth of HH/GLI-dependent tumors (in particular MB and BCC) and 
cancer stem cells in vitro and in vivo, indicating that GLI/DNA 
interference is an appealing therapeutic strategy to regulate the 
heterogeneous molecular changes leading to HH/GLI pathway 
activation in cancer (Infante et al., 2015). In this study we wished to 
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investigate whether a metabolomics approach could identify 
signatures associated with HH-pathway inhibition and whether this 
signatures provide new insight into the mechanism of action of this 
new molecule. We evaluated the metabolic changes induced by 
drug treatment after 24 h at the 0.5 μM concentration on MB DAOY 
cell line. Multivariate statistical modeling using PCA (unsupervised 
analysis) was performed on 1H NMR spectra of seven independently 
grown replicates from cell lysates of treated and untreated cells. 
The scores plot, principal component 1 (PC1 72.9%) vs principal 
component 2 (PC2 9.59%), resulting from PCA revealed very clear 
discrimination between the intracellular metabolome before and 
after the drug administration (Figure 2.5A).  
Figure 2.5. endo-Metabolomic phenotyping of DAOY cells. A) PCA score plot: 
endo-metabolomic profiles of native cell (orange dots) and GlaB-treated (purple 
dots) cell lysates. The discrimination accuracy value of the model is reported. Each 
dot represents a different cell lysate sample; B) PCA loading plot: section of the 
loading plot (0.7 – 6 ppm) obtained from the PCA analysis. The color in the plot can 
be used to identify the significant variables in the class separation.  
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It is noteworthy that the treatment with and without GlaB is 
separated along the first principal component. Importantly, even in 
the presence of the drug, reproducibility between replicates (7 for 
each treated and untreated sample) remained very high and the 
sample-to-sample variation within each group was significantly 
smaller (95% confidence interval location) than any variation arising 
from treatment or genetic variability. It must be emphasized that 
these differences were identified using an unsupervised analysis, i.e. 
any prior information about the samples. The discrimination 
accuracy of the model was assessed by the leave-one-out cross-
validation method (LOOCV) and resulted to be about 100%. LOOCV 
method starts to split-sample cross-validation in forming training set 
and a test set. With LOOCV, however, the test set consists of only a 
single sample; the rest of the samples are placed in the training set. 
The sample in the test set is placed aside and not utilized at all in 
the development of the class prediction model.  
The loading plot was used to identify the significant characteristic 
metabolites responsible for the clustering patterns. The plot for the 
first principal component of the comparison between the groups 
(treated vs untreated) identified threonine (3), alanine (4), 
glutamate (5), glutamine (6), glutathione (GSH, 8), and the signals 
arising from mobile lipids and two unknown metabolites (*) as 
major discriminators between the CTR and GlaB samples (Figure 
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2.5B). The metabolites 3, 4, 5, 6, 8 and 13 were lower in the treated 
cells, meanwhile the mobile lipids and unknown metabolites were 
high. The ability to distinguish the two groups so accurately 
represents a significant progress for profiling differing shared and 
non-shared drug responses. 
Additionally, we calculated the relative integrals of the 
characteristic small molecules for the two groups and we focused 
on deregulated metabolites whose abundances changed 
significantly (p<0.05, Wilcoxon test). We found the significant 
alteration of 20 metabolites (see Figure S1 of Section 2.3.6). The 
administration of GlaB lowered the concentrations of the most of 
molecules, characterizing the DAOY endo-metabolic profile, 
including metabolites intimately associated with the TCA cycle, 
some amino acids and other metabolites, and induced a significant 
increase in concentration of two unknown compounds distinguished 
in the 1H NMR spectra by a singlet centered at 2.56 ppm and two 
related doublet centered at 3.10 ppm and 3.15 ppm respectively, 
with a typical geminal proton-proton coupling constant (J= 16 Hz) 
(Figure 2.6). 
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Figure 2.6. Altered metabolite levels in DAOY cells. Fold-change (FC) is calculated 
for each metabolite by dividing the treatment group (GlaB) by the reference 
treatment (CTR); the bars plot show the Log2(FC) (red and black bars refer to 
p<0.05 and p>0.05, respectively; Wilcoxon test was used). Abbreviations: s, singlet; 
d, doublet. 
 
 GL261 cell line 
To characterize the molecular mechanism induced by GlaB in GL261 
cell line, we studied the metabolic changes introduced by the drug 
administration after 48 h at the 5 µM concentration. We analysed 
the effects of GlaB administration both on the endo- and on the exo-
metabolome of this cell line. The separate analysis of the exo- and 
endo-metabolome provided complementary information for a 
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comprehensive picture of the cellular metabolic state and 
phenotype. To determine the differences in the metabolic profiles 
among the treated and untreated cells, respectively, we performed 
PCA to analyze the normalized 1H NMR data. The results showed 
that all samples were located in the ellipse of the 95% confidence 
interval, and both the cell lysates and the conditioned media from 
untreated samples were perfectly separated from those treated 
with GlaB along the first principal component (PC1). The PCA scores 
plot displaying the two main PCs accounting for 87.08% of the 
variance (PC1 64.61%, PC2 22.47%) in the case of the endo-
metabolome and for 99.92% (PC1 99.86%, PC2 0.06%) of the 
variance for the exo-metabolome, respectively (Figure 2.7A-B).  
Figure 2.7. Metabolomic phenotyping of GL261 cells: scores plot of PCA analysis; 
discrimination of A) endo-metabolomic profiles of native cell (green dots) and GlaB-
treated (purple dots) cell lysates; B) exo-metabolomic profiles of native cell (cyan 
dots) and GlaB-treated (red dots) cell lysates. The discrimination accuracy value of 
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each model is reported. Each dot represents a different cell lysate-conditioned 
medium sample. 
The LOOCV method revealed that the two groups can perfectly be 
discriminated to each other with a discrimination accuracy of 100%.  
Figure 2.8. PCA loadings plot of cell lysates (A) and culture media (B) samples. The 
loading profiles correspond to first principal component (PC1). The color in the 
loadings plot can be used to identify the significant variables in the class 
separation. 
The plot for the first principal component of cell lysates shows that 
samples treated with GlaB are characterized by an higher content of 
lactate (2) whereas the concentration of glutamate (8), myo-inositol 
(18), creatine (16) and phosphocreatine (17) are lower with the 
respect to the samples untreated (Figure 2.8A). The corresponding 
loadings plot of conditioned media along the first principal 
component exhibits higher content in lactate concentration in 
treated samples and the reverse lower amount in the glucose 
concentration,  differing from the control samples (Figure 2.8B).     
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However, to better understand the effect of GlaB on the 
metabolism of the murine glioma cell line, a direct comparison of 
the average 1H NMR spectra of the five replicates for both group of 
the intra- and extracellular samples was performed. Compared with 
the untreated group of cell lysates, the treated one showed a 
marked decrease in the relative intensities of the majority of 
metabolites such as alanine, NAA, glutamate, glutamine, aspartate, 
creatinephosphate and creatine, myo-inositol, glucose-6-P, UDP-
glucose and UDP-N-acetylglucosamine and signal related to 
diphosphate nucleotides (XDP), and significantly increase levels of 
other metabolites, including lactate, succinate, citrate and signal 
related to monophosphate nucleotides (XMP) (Figure 2.9). The 
univariate statistical analysis of conditioned media revealed also 
essential differences in the metabolic pattern distribution between 
the two groups under consideration: in particular, the concentration 
of lactate increases after treatment and, on the contrary, the 
glucose and pyruvate concentrations decrease. Moreover, branched 
chain amino acids (BCAA), including isoleucine, leucine and valine 
and alanine were observed to increase upon treatment with GlaB; 
succinate increased and glycine, glutamine and citrate decreased 
significantly; choline and myo-inositol both decrease after 
treatment (see Figure S2 of Section 2.3.6).   
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Figure 2.9. Univariate analysis of the relative integrals of characteristic 
metabolites inside the cells. The box plot shows the comparison of relative 
intensities of characteristic metabolites between the untreated (CTR, turquoise 
box) and treated (GlaB, violet box) samples of GL261 cell line. (p<0.05, Wilcoxon 
test was used).
B2.2.2 Metabolic pathway analysis 
Cancer cell lines are well established models to study specific 
cellular mechanisms characteristic for different types of cancer, 
usually by monitoring specific proteins and their actions. Recent 
advances in “omics” technologies allow for more systematic 
investigations to characterize parameters like gene expression, 
protein and metabolite profiles (Blaise et al., 2006; Bundy et al., 
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2007). The advantage of “omics” technologies lies in their 
multiparametric nature probing a large array of indicators at the 
same time. For the application of “omics” technologies to the 
understanding of drug action, it is essential that effects of drugs 
produce a sensitive response which can be reproduced with 
sufficiently high quality. Here we have shown that metabolic 
profiling of different cancer cells (human MB DAOY and murine 
GL261) can not only identify phenotypic differences between cell 
lines but can also sensitively detect and distinguish changes in 
metabolite concentrations after perturbation. It is important to 
mention that the GlaB administration caused a distinct reproducible 
profile which is observed in unsupervised PCA. 
From the visual inspection of 1H CPMG NMR spectra of DAOY cell 
line, there is a clear increase after 24 h of treatment with GlaB in 
the signals corresponding to the so-called mobile lipids (ML),  
represented mostly by triacylglycerides. These signals are attributed 
primarily to the methylene group (-CH2-) at 1.3 ppm and to the 
methyl group (-CH3) at 0.9 ppm of fatty acyl chains. ML apparently 
come from intracellular lipid bodies or membrane microdomains 
during the ongoing metabolic changes associated with programmed 
cell death (apoptosis phenomenon). Accordingly, in the PCA loading 
profile the signals arising from ML are some of the major 
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discriminators between the treated and untreated groups (see 
Figure 2.10).  
Figure 2.10. Superimposed 1H NMR spectra of DAOY cell line before (orange) and 
after (purple) treatment with GlaB at 0.5 μM concentration. Notice a clear 
increase in the ML peaks intensity (indicative of apoptosis) at 0.9 ppm and 1.3 ppm 
over a 24 h incubation time.
Moreover, the altered amino acids (phenylalanine, tyrosine, leucine 
and valine) in tumor are mostly involved in TCA cycle anaplerosis 
(Tripathi et al., 2012) and protein biosynthesis (Owen et al., 2002) 
by being converted into fumarate and succinyl CoA, respectively 
(Dang, 2010). In our case, the treatment with GlaB induced a 
significant reduction in relative intensities of both phenylalanine 
and tyrosine amino acids and of TCA cycle intermediate fumarate. 
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Additionally, the treatment of DAOY cells for 24 h with GlaB lowered 
the concentration of glutamate and induced glutamine depletion 
resulting in aerobic respiration reduction. It has been known that 
glutamine has a prominent role in promoting oxygen consumption, 
because glucose depletion in the presence of glutamine enhanced 
oxygen consumption while glutamine depletion in the presence of 
glucose diminished oxygen consumption substantially (Alam et al., 
2016). Through glutaminolysis process as a source of energy to fuel 
tumor growth, glutamine metabolite is the dominant respiratory 
substrate in tumor cells. Both glutamate and glutamine are the two 
most important amino acids in maintaining the nitrogen balance in 
the cell, supporting the central role of glutaminolysis and nitrogen 
anabolism to sustain cancer cell growth and proliferation. 
Furthermore, the metabolite GSH is also down-regulated in the 
treated group. As a ubiquitous intra- and extracellular protective 
antioxidant, GSH plays a key role in reducing reactive oxygen 
species (ROS) and combating increased oxidative stress. GSH is 
particularly vital in protecting cells from radiation damage, which 
has generated ROS. Rosi et al. found that a high level of this 
metabolite was correlated with radiation-induced apoptosis by MR 
spectra of cultured tumor cells (Rosi et al., 2007). Since GlaB after 
24 h of treatment strongly diminished oxygen consumption 
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(glutamine depletion) and induced apoptosis, the GSH levels cannot 
supply the excessive ROS production induced by oxidative stress.     
On the other hand, in GL261 cell line GlaB proved to be able to 
perturb the levels of the metabolites that are involved in 
mitochondrial activities, compared to the untreated control 
samples. In fact, among the detected metabolites, the increased 
levels of succinate indicate inhibition of Complex I of respiratory 
chain of mitochondria useful to convert succinate in fumarate. This 
process impairs TCA cycle and production of ATP. Moreover, 
mitochondrion dysfunctions are shown by prevented conversion of 
creatine to phosphocreatine that results in further impairment of 
urea cycle and amino acids synthesis. Furthermore, the level of 
glutamine was slight reduced after treatment: glutamine provides a 
crucial source of cellular energy and building blocks for cancer cells 
(Hensley et al., 2013) through glutaminolysis, which enters the TCA 
cycle by being converted into glutamate initially and then into α-
ketoglutarate (Dang, 2010). In our case, the small reduction in 
glutamine concentration might be imply in down-regulation of 
anaplerotic flux. In addition, the GlaB administration to GL261 cells 
significantly induced a decrement in glutamate and NAA 
metabolites. Notably, N-acetylaspartate is the second most 
abundant amino acid derivative in the brain, second only to 
glutamate, and is the most abundant source of acetate (Mehta and 
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Namboodiri, 1995). NAA is synthesized in neuronal mitochondria 
(Goldstein, 1959) or endoplasmic reticulum (Lu et al., 2004) via 
acetylation of aspartate by the enzyme aspartate N-acetyl 
transferase. NAA may be converted to the dipeptide 
neurotransmitter N-acetylaspartylglutamate (NAAG) by the 
enzymes NAAG synthetase I and II (Becker et al., 2010; Collard et al., 
2010) and it serves as a source of perisynaptic NAA and glutamate 
metabolites. Neverthless, the exact function of glutamate and NAA 
reduction remains unknown and requires further investigation. The 
other metabolites, such as lactate and myo-inositol, are metabolic 
markers frequently reported in cancers. Increased levels of lactate 
were detected in stomach cancer, oral cancer and rectal cancer 
tissues (Wang et al., 2013). Interestingly, the decreased level of 
lactate was observed in cells of head and neck squamous cell 
carcinoma, compared with those of normal human oral 
keratinocytes. It has also been found a decreased lactate level in 
glioma cell lines in the high-grade group. Lactate production, due to 
the high glycolytic rates in cancer cells, enhances intracellular 
acidosis, which in turn leads to apoptosis. Previous works (Baumann 
et al., 1992; Colen et al., 2011) have also demonstrated that glioma 
cells could rapidly discharge lactate into the nearby 
microenvironment through monocarboxylate transporters. Thus, 
the lactate up-regulation observed in both intra- and extracellular 
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metabolic profile might be associated with the capability of GlaB to 
promote the glycolytic rate as clear sign of apoptosis event and cell 
death. Furthermore, myo-inositol is associated with osmo-
regulation and volume regulation (Duarte et al., 2013). In our study, 
the level of myo-inositol in the two groups was significantly 
different both in the intra- and extracellular media, implying that 
these metabolite might be involved in osmoregulation and volume 
regulation of GL261 cells upon treatment with GlaB.  
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B2.3 Experimental section 
B2.3.1 Materials 
 DAOY cell line
DAOY cells were purchased from American Type Culture Collection 
(ATCC–Manassas, VA, USA), and maintained in Eagle's Minimum 
Essential Medium (MEM) purchased from Sigma Aldrich (St. Louis, 
MO, USA), plus L-Glutamine, antibiotics and 10% fetal bovine serum 
(FBS; ThermoFisher Scientific, Waltham, MA, USA). Trypsin-EDTA 1X 
in PBS (w/o Calcium, w/o Magnesium, w/o Phenol Red) was 
purchased from EuroClone S.p.A. (Milan, Italy). Leupeptin, 
Pepstatin, Sodium Orthovanadate, PMSF, Aprotinin were purchased 
from Sigma Aldrich. 
RNA interference 
DAOY cells were transfected with non-targeting siRNA as control or 
with double-stranded siRNAs targeting human GLI1 and GLI2 (On 
target-Plus SMARTpool reagents; Dharmacon, Lafayette,CO). 
Transfections were performed with HiPerFect transfection reagent 
(Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. 
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 GL261 cell line 
GL261 cells were kindly provided by Dr. Serena Pellegatta, 
Neurological Institute “Carlo Besta”, Italy. Cell culture medium 
(Dulbecco’s modified minimum essential medium, DMEM), fetal 
bovine serum (FBS), penicillin G, streptomycin, glutamine, sodium 
pyruvate were from GIBCO Invitrogen (Carlsbad, CA). Phosphate 
buffer saline (PBS) (0.01 M Phosphate buffer, 0.0027 M KCl e 0.14 M 
NaCl, pH 7.4 at 25 °C) was purchased from Sigma-Aldrich (St. Louis, 
MO). 
 
MTT viability assay 
GL261 cells  (5000/well) were seeded into 96 multi-well plates and 
treated with Glab 5 M or vehicle for 4 days. MTT (500 μg/ml) was 
added into each well for 1.5 h. DMSO was then added to stop the 
reaction and the formazan produced was measured at 570 nm. 
Viability of cells was expressed relative to absorbance. 
 
B2.3.2 Cell Culture and NMR sample preparation 
 
 DAOY cell culture 
DAOY cells were grown in MEM, plus 10% FBS at 37 °C in a 
humidified atmosphere of 5% CO2. In order to obtain the final 
desired number of cells (3 x 106) for each treatment (DMSO-d6 0.5 
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μM and GlaB 0.5 μM solubilized in DMSO-d6, respectively), the cell 
growth was carried out in parallel in multiple 100 mm tissue culture 
dishes (Corning). Upon achievement of 90% cellular confluency, the 
culture medium was removed and immediately stored at -80 °C, for 
the exo-metabolome analyses. In brief, the cells were washed with 
ice-cold phosphate-buffered saline (PBS 1X w/o Calcium, w/o 
Magnesium) in order to completely remove any residue of culture 
medium. For GlaB treated dishes, the cells were collected by adding 
4 ml of PBS 1X and scraping with a rubber policeman.  For DMSO-d6 
treated dishes, the cells were harvested by adding 1 ml of Trypsin-
EDTA 1X in PBS (w/o Calcium, w/o Magnesium, w/o Phenol Red), 
then PBS 1X and scraping with a rubber policeman. Finally, the cells 
were counted and aliquoted 3 x 106 for each treatment replicate. 
Each replicate was lysed with 700 µl of Lysis Buffer (10 mM Tris-HCl, 
5 mM EDTA, 120 mM NaCl) plus protease and phosphatase 
inhibitors (1 µg/µl Leupeptin, 0.5 ng/µl Pepstatin, 0.2 mM Sodium 
Orthovanadate, 0.1 mM PMSF, 0.1 mg/ml Aprotinin) and then 
sonicated 5 times (15s on – 15s off; 50% amplitude). The lysates 
were centrifuged two times at 17,000xg for 1 h and the last 
supernatant stored at -80 °C for the endo-metabolomic analysis. 
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 GL261 cell culture
GL261 were cultured in DMEM supplemented with 20% heat-
inactivated FBS, 100 IU/ml penicillin G, 100 μg/ml streptomycin, 2.5 
μg/ml amphotericin B, 2 mM glutamine, and 1 mM sodium 
pyruvate. Cells were grown at 37 °C in a 5% CO2 humidified 
atmosphere. Cells were subcultivated when confluent. 
For metabolome analyses confluent GL261 cells were trypsinized, 
counted and plated (3 x 106) in 6 cm dishes containing 1% FBS 
medium. After 4 h the growth medium was changed and 
supplemented with GlaB 5 μM or vehicle (DMSO) for 48 h.  Then the 
culture medium of each dish was collected, centrifuged (10,000xg 
for 10 minutes) and immediately stored at  -80 °C until used. On the 
other side, cells were extensively washed (4 times) with ice-cold 
phosphate-buffered saline (PBS 1X), in order to completely remove 
any residue of culture medium, trypsinized and centrifuged. 
Afterwards, cells were dispersed in a buffer solution containing 10 
mM Tris (pH 7.4), 5 mM EDTA, 120 mM NaCl, and protease 
inhibitors (Complete Protease inhibitor Cocktail tablet, Roche). Cell 
lysis was obtained by sonication and the cytosolic fraction 
containing the metabolites was obtained upon centrifugation at 
17,000xg for 1 h at 4 °C. Subsequently, cytosols were collected for 
analysis and stored at  -80 °C until used.  
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 NMR sample preparation
NMR cell lysate samples were prepared in 5.00 mm NMR tubes 
(Bruker BioSpin srl) after the addition of 50 μl of 2H2O containing 10 
mM sodium trimethylsilyl [2,2,3,3-2H4]propionate (TMSP) to 450 μl 
of cell lysate. The cell culture media samples were considered and 
analysed according to standard procedures for the NMR preparation 
of human plasma and serum. Frozen conditioned media samples 
were thawed at room temperature and shaken before use. An 
aliquot (300 μl) of a phosphate sodium buffer (70 mM Na2HPO4; 
20% v/v 2H2O; 0.025% v/v NaN3; 0.8% w/v TMSP; pH 7.4) were 
added to 300 μl of each medium sample and the mixture was 
homogenized by vortexing for 30 seconds (s). The mixture was 
transferred into a 5.00 mm NMR tubes (Bruker BioSpin srl) for 
analysis. 
2.3.3 NMR experiments 
In order to study the possible metabolomic changes induced by 
GlaB treatment 1H NMR spectra were acquired on both cell lysates 
and conditioned media verifying their feasibility and reproducibility. 
NMR spectra were recorded with a Bruker 900 MHz spectrometer 
equipped with CP TCI 1H/13C/15N probe. The 1H NMR spectra of cell 
lysates were acquired with the Carr-Purcell-Meiboom-Gill (CPMG) 
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sequence using a monodimensional spin–echo sequence with water 
presaturation (cpmgpr, Bruker). 256 scans over a spectral region of 
18 kHz were collected into 110 K points, giving an acquisition time 
of 3.07 s. The spectra were recorded with the CPMG pulse sequence 
(Carr and Purcell, 1954) to impose a T2 filter that allows selective 
observation of small molecular weight components. The total T2 
delay was set to 290 ms. The T2 filtering in the CPMG pulse 
sequence, which contains trains of -(τ-180°-τ)- blocks repeated n= 
256 times, was achieved with a total spin-echo delay (2nτ) of 80 ms. 
The acquisition of each spectrum required about 32 min. The raw 
data were multiplied by a 1 Hz exponential line broadening before 
Fourier transformation into 131 K points. The 1H NMR spectra of 
conditioned media were acquired with a 1D nuclear Overhauser 
enhancement spectroscopy (NOESY)-presaturation pulse sequence 
(noesygppr1d, Bruker) with irradiation at the water frequency 
during the recycle and mixing time delays and a spoil gradient. A 
total of 64 scans with 110 K data points were collected using a 
spectral width of 17942 Hz, an acquisition time of 3.07 s, a 
relaxation delay of 4 s, and a mixing time of 100 ms. The NOESY 
spectra generally give the best overview over all types of molecules 
in biofluids. Transformed spectra were automatically corrected for 
phase and baseline distortions and calibrated (chemical shift was 
referenced to the proton of TMSP at δ 0.0 ppm) using TopSpin 3.5 
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(Bruker Biospin srl). We performed this type of experiments on 
various replicates (from five to seven) identifying the metabolomic 
fingerprints of both human MB DAOY and glioma murine GL261 
cells and of those ones of the same cell lines treated with GlaB. 
2.3.4 Spectral Analysis 
Each spectrum in the region 10.00 – 0.2 ppm was segmented into 
0.02 ppm chemical shift bins, and the corresponding spectral areas 
were integrated using the AMIX software (Bruker).  
 DAOY spectra
The area of each bin was normalized to the total spectral area, 
calculated with exclusion for the cell lysates of the regions 1.09 – 
1.23, 1.85 – 1.97, 3.25 – 3.43, 3.63 – 3.71, 4.01 – 4.02 (which 
correspond to EDTA and Tris peaks, and the most intense peaks of 
the protease and phosphatase inhibitors used for sample 
preparation) and the water region (4.45 – 5.67 ppm). 
 GL261 spectra
The area of each bin was normalized to the total spectral area, 
calculated with exclusion for the cell lysates of the regions 2.55 – 
2.57, 2.69 – 2.72, 3.6 – 3.65, 3.20 – 3.236, 3.67 – 3.72, 3.75 – 3.78, 
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3.79 – 3.82, 3.86 – 3.9, 7.65 – 7.70, 8.05 – 8.13 (which correspond to 
EDTA and Tris peaks, and the most intense peaks of the protease 
inhibitors used for sample preparation) and the water region (4.4 – 
5.9 ppm); for the conditioned media exclusion regarded the water 
region 4.6 – 4.8 ppm.  
2.3.5 Metabolite statistical analysis 
The multivariate and univariate statistical techniques were applied 
on the obtained buckets using R 3.0.2 in house scripts. 
Unsupervised PCA was used to obtain a preliminary outlook of the 
data (visualization in a reduced space, clusters detection, screening 
for out-layers). From the PCA score plot (PC1, PC2), a perfect 
discrimination between the two different groups tested (the treated 
and the untreated samples) was clearly visible indicating a strong 
differences on the cell metabolic profiles. The global accuracy for 
classification was assessed by means of a leave-one-out cross-
validation scheme (LOOCV).  
Around 30 metabolites, whose peaks in the spectra were well 
defined and resolved, were assigned and their levels analysed. The 
assignment procedure was made up using a NMR spectra library of 
pure organic compounds, public databases (such as Human 
Metabolome Database-HMBD) storing reference NMR spectra of 
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metabolites, spiking NMR experiment and using data available in 
literature. The relative concentrations of the various metabolites 
were calculated by integrating the corresponding signals in the 
spectra with an in house deconvolution script. The Wilcoxon test 
was used for the determination of the meaningful metabolites: a p-
value of 0.05 was considered statistically significant. The 
concentration changes of the metabolites are also expressed as the 
Log2(FC). 
 
 
2.3.6 Supplementary figures 
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Figure S1. Univariate analysis of the relative integrals of characteristic 
metabolites inside the DAOY cells. The box plot shows the comparison of relative 
intensities of characteristic endo-metabolites between the untreated (CTR, orange 
box) and treated (GlaB, purple box) samples of DAOY cell line. (p<0.05, Wilcoxon 
test was used). 
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Figure S2. Univariate analysis of the relative integrals of characteristic 
metabolites outside the GL261 cells. The box plot shows the comparison of 
relative intensities of characteristic exo-metabolites between the untreated (CTR, 
cyan box) and treated (GlaB, red box) samples of GL261 cell line. (p<0.05, Wilcoxon 
test was used). 
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Conclusions 
NMR spectroscopy represents a versatile technique that is 
employed in diverse scientific areas, including life science, material 
science and medicine. It has proved to be a multifaceted tool both 
for monitoring the progression of olefin metathesis reaction, and for 
detecting variation in metabolic phenotype of cancer cell culture 
after drug treatment. In particular, in part A it has been described 
the detection of a ruthenium-carbene-resorc[4]arene complex 
produced, as a key intermediate, during an olefin metathesis 
reaction carried out on a resorc[4]arene bicyclic olefin (namely, 2a) 
with [Ru(=CHPh)Cl2(PCy3)2] Grubbs first-generation (G1ST) catalyst. 
Although the olefin metathesis reaction on the chair stereoisomer 
1a was carried out with the Grubbs second-generation catalyst 
(G2ST), for the investigation of mechanistic pathway involved in the 
dimer 3a formation from 2a the G1ST was used. It is well known that 
G2ST initiated much slower than G1ST, despite the much greater σ-
donating ability of SIMes versus PCy3. Instead, the origin of the 
higher rate of activity of second generation complexes was found to 
be due to the preference of second generation alkylidenes for 
alkene over phosphine. The complex was identified by high-
resolution (600 MHz) 1H, 31P NMR and DOSY spectroscopy, in a non-
invasive fashion. The singlet at 19.98 ppm (1H NMR), attributed to 
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the alkylidene proton in the G1ST catalyst and that at 53.37 ppm (31P 
NMR), attributed to the phosphorus atom coordinated with the 
metal, were selected as probes for a kinetic analysis. They proved to 
decrease at the expense of the singlets at 19.26 (1H NMR) and 52.68 
ppm (31P NMR), diagnostic for the formation of the ruthenium-
carbene-resorc[4]arene complex 3a[Ru]. Such resorc[4]arene 
activated olefin proved to behave as key propagating species 
leading to oligomers according to a ROMP pathway. Moreover, the 
high instability of G1ST complex in CDCl3, due to the residual acidity 
of the solvent, induces a fast degradation of the catalyst; a good 
stability was instead found in benzene-d6 solutions, even if the 
reaction is faster in CDCl3. Thank to this higher stability and to the 
slowness of the reaction, a quantitative analysis was performed, 
thus highlighting that, beside highly strained and unstrained olefins, 
macrocycles themselves could be appropriate substrates for a 
“macrocyclization” reaction, according to a ROM-CM mechanism, 
and the size of the macrocycles can be modulated by using 
appropriate substrate/catalyst ratios (2a/G1ST = 4:1 and 2a/G1ST = 
1:4, respectively). Such structures would have the advantage to 
share supramolecular properties (e.g., molecular recognition of 
appropriate guests, propensity to self-assembly) with the intrinsic 
ability to yield suitable materials for biomedical applications 
Conclusions 
219 
 
(namely, drug delivery, tissue engineering and regenerative 
medicine). 
The data presented in part B highlight the potential of 1H NMR 
based profiling of drug response in cancer cells. Following other 
methods of functionally annotated profiling, the importance of 
metabolomics is that it describes the actual functional state of the 
cells. In the present work, we performed NMR-based metabolomic 
analysis on human MB DAOY and murine glioma GL261 cell lines 
before and after GlaB administration. A reliable sample protocol 
preparation was developed for each cell line in order to perform a 
trustworthy metabolomics NMR analysis. The procedures can be 
recapitulated in the following main steps: (i) growth of the cell 
culture; (ii) cell washing; (iii) cell scraping; (iv) quenching with 
protease and phosphatase inhibitors; (v) cell lysis by sonication; and 
(vi) centrifugation. In order to reduce the bias in the interpretation, 
from five to seven replicates (for both cell lysates and the 
corresponding conditioned media) were, consequently, analysed by 
high resolution 1H NMR (900 MHz) spectroscopy. After the 
resonance assignment of major metabolites (≈ 30 metabolites), the 
untargeted and unbias multivariate data analytical approach (PCA) 
on the 1D 1H NMR spectra revealed that both the cell lysates and 
the conditioned media were completely differentiated from those 
treated with GlaB along the first principal component (PC1). The 
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LOOCV method established a discrimination accuracy of the model 
of 100%. Moreover, we identified for both DAOY and GL261 cell 
lines characteristic metabolites contributing significantly to 
distinguishing the metabolic profiles between the treated and the 
untreated group. Although these are an ongoing studies at their 
initial stage of advancement, some promising results, summarized 
below, have been obtained so far: the exo- and endo-metabolomic 
phenotype of both the DAOY and GL261 cell line resulted to be 
completely changed after 24 h and 48 h of GlaB administration, 
respectively; GlaB administration in DAOY cells seems to promote 
changes in mitochondrial morphology, respiration and function; 
GL261 cells after GlaB treatment strongly increased the intake of 
glucose and the excretion of lactate. These data are not in 
agreement with the known GLI-mediated extracellular lactate 
concentration increment. It suggests the presence of a different 
mechanism of action in no HH/GLI-dependent manner; the levels of 
most metabolites decreased in both DAOY and GL261 cells after 24 
h and 48 h incubation time, consistently with possible apoptosis 
phenomenon. In order to better evaluate the changes induced 
before apoptotic events, these data need to be combined with 
molecular and biological analyses performed on the same cells and 
the NMR metabolic profiling needs to be performed at different 
time points of treatment with GlaB (6 h and 12 h for DAOY cells; 12 
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h and 24 h for GL261 cells). Altogether, our results demonstrate that 
the metabolome characterisation of tumor cell lines 
(“oncometabolomics”) provides important information about the 
metabolic changes accompanying cancer progression and response 
to different environmental conditions (like drugs), which help 
identify and characterise new therapeutic agents and diagnostic 
biomarkers.
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